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II. Zusammenfassung 
Jedes Jahr erhalten etwa 500 000 Deutsche die Diagnose Krebs und die Anzahl der Krebspa-
tienten wird laut Prognosen in den nächsten Jahren steigen. Die therapeutischen Möglichkei-
ten sind abhängig von der Krebsart und der Konstitution des Patienten/ der Patientin wie 
auch die Überlebenschancen. Falls möglich, wird der Tumor chirurgisch entfernt, bestrahlt 
und/ oder mit Chemotherapie behandelt. Jedoch sind insbesondere die Entfernung und Be-
strahlung nicht für alle malignen Tumore möglich, besonders Metastasen stellen eine Heraus-
forderung dar. Außerdem führen Bestrahlung und Chemotherapie häufig zu Nebenwirkungen, 
die die Therapieoptionen weiter einschränken können. Durch eine gezieltere Verabreichung 
des Wirkstoffs können unerwünschte Arzneimittelwirkungen abgemildert und eine Erhöhung 
der Dosis am Tumor erreicht werden. Dafür eignen sich Wirkstofftransportsysteme wie meso-
poröse Silikananopartikel (MSN), die in dieser Arbeit als Transporter evaluiert wurden. Die 
hier verwendeten MSN bestanden aus einem dendritischen Siliciumoxidgeflecht mit integrier-
tem Fluoreszenzfarbstoff. In die daraus resultierenden Poren konnten verschiedene Wirkstof-
fe eingebracht werden und diese wurden anschließend mit einem pH- und Redox-sensitiven 
Verschlusssystem ausgestattet, das aus Ferrocen und β-Cyclodextrin bestand. Dann wurden 
die Biokompatibilität sowie die zelluläre Aufnahme anhand von Zellkulturversuchen und die in 
vivo Biodistribution mit dem HET-CAM Model untersucht. Insgesamt war die Biokompatibilität 
sehr hoch und eine zeitabhängige zelluläre Aufnahme in Endosomen und Lysosomen wurde 
festgestellt. In vivo wurden die MSN hauptsächlich in der Leber und den Nieren detektiert, 
gleichzeitig auch wenige MSN in einem Tumor, der in die CAM eingewachsen war. Weiterhin 
konnte die zelluläre Aufnahme durch die Konjugation eines Epidermal Growth Factor Recep-
tor (EGFR)-Antikörpers an den unbeladenen Wirkstofftransporter beschleunigt werden. Als 
Zweites wurden die Wirkstoffbeladung und -freisetzung untersucht, indem das Chemothera-
peutikum Doxorubicin, das über toxische und fluoreszierende Eigenschaften verfügt, in die 
MSN inkorporiert wurde. Es konnte eine effiziente Beladung durchgeführt und eine retardierte 
Freisetzung in zwei Krebszelllinien beobachtet werden. Als besonders herausfordernd stellte 
sich die Beladung der MSN mit siRNA und die Freisetzung dieser dar, da eine Wirkung der 
siRNA nicht festgestellt werden konnte. Die Porengröße der MSN wurde vergrößert und ver-
schiedene Beladungsprotokolle wurden verwendet, jedoch ohne eine Wirkung der siRNA 
nachweisen zu können. Schließlich wurden die mit siRNA beladenen MSN mit einem lipid-
basierten Transfektionsreagenz verschlossen, was zu einer starken Erhöhung der zellulären 
Nanopartikelaufnahme führte, nicht jedoch zu einer Wirkung der siRNA auf die mRNA- und 
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Proteinexpression. Dies konnte auch nicht durch die Konjugation eines EGFR-Antikörpers an 
siRNA-beladene und mit Ferrocen und β-Cyclodextrin verschlossene MSN erreicht werden. 
Insgesamt zeigten die MSN mit dem primär verwendeten Verschlusssystem vielversprechen-
de Eigenschaften bezüglich Biokompatibilität und Wirkstofftransport von Doxorubicin, jedoch 
konnte ein effizienter siRNA-Transport nicht umgesetzt werden. Somit stellen große und ge-
ladene Moleküle eine Herausforderung für den Wirkstofftransport mittels MSN dar. Gleich-
wohl sind MSN als Wirkstofftransportsystem niedermolekularer Wirkstoffe hervorragend für 
eine zielgerichtete Therapie von Kopf- und Halsplattenepithelkarzinomen geeignet. 
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III. Abstract 
More than half a million Germans are newly diagnosed with cancer every year, and prognosis 
revealed increasing numbers in the future. The therapeutic options are dependent on the 
cancer type and the patients’ overall health condition; the same applies to survival rates. If 
possible, solid tumors are surgically removed, irradiated, or treated with chemotherapy. How-
ever, not all malignant tumors – especially metastases – can be reached with irradiation or 
surgical intervention and side-effects often limit the therapeutic intervention. Targeted therapy 
can reduce side-effects and increase the dose at the tumor site. This can be achieved by 
drug delivery vehicles such as mesoporous silica nanoparticles (MSNs) that were evaluated 
as drug nanocarrier in this work. MSNs consist of a dendritic silica network that generates 
pores that can be loaded with different drugs and should be sealed. First, MSNs were 
equipped with a pH- and redox-sensitive gatekeeper system consisting of ferrocene and β-
cyclodextrin. The biocompatibility, cellular uptake, and biodistribution of the sealed MSNs 
were analyzed in vitro in several cancer cell lines and in vivo using the CAM assay, respec-
tively. The overall biocompatibility was remarkably good; the MSNs were taken up time-
dependently by cancer cells and localized in the endolysosomal system. The MSNs were 
found mainly in the liver and kidneys of chicken embryos but also in the tumor which grew 
within the CAM. The addition of an epidermal growth factor receptor (EGFR)-antibody to the 
MSNs accelerated nanoparticle uptake. Second, the drug loading and release were examined 
with the chemotherapeutic drug doxorubicin because of its toxic and fluorescent characteris-
tics. Efficient drug loading was achieved, and a retarded release of doxorubicin was observed 
in two cancer cell lines. Third, siRNA loading and release were studied which was highly chal-
lenging. The MSN pore size had to be adjusted, and different loading protocols were tested 
without success. Eventually, siRNA was loaded to the MSNs and a lipid-based transfection 
agent was added to seal the pores. Although MSN uptake increased tremendously, no siRNA 
release could be detected by determining mRNA and protein expression, respectively. When 
an EGFR-antibody was added to the siRNA-loaded MSNs, also no siRNA efficacy was no-
ticed. 
Overall, the MSN-based drug delivery system showed promising characteristics regarding 
biocompatibility and transport of the small molecule drug doxorubicin, but efficient siRNA 
transport was not achieved. Thus, the transport of large and charged molecules by MSNs is 
challenging. Nevertheless, MSNs are suited as drug delivery vehicles for small molecule 
drugs in head and neck cancer therapy. 
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1 Introduction 
This chapter gives an overview of the current state of research on drug delivery systems for 
cancer therapy with a focus on mesoporous silica nanoparticles (MSNs), siRNA delivery with 
MSNs and active targeting of MSNs. Some parts and three figures (Figures 5, 6, and 8) of 
this introductory chapter were adopted from the review “Mesoporous silica nanoparticles as 
drug delivery vehicles in cancer” written by me and Juergen Brieger and published in Nano-
materials 2017, 7, 189 under a Creative Commons Attribution (CC BY) license [1]. These 
parts were indicated according to the standard bibliographic rules.  
1.1 General introduction 
Every year more than 500 000 people are newly diagnosed with malignant neoplasms in 
Germany, and because of an aging demographic, the number of cancer patients will increase 
in the following years [2]. The treatment of cancer is highly dependent on the kind of malig-
nancy, for example, some solid tumors can be surgically removed, others are irradiated, and 
in most cases, chemotherapeutics are administered, too. Still, therapy of tumors at anatomi-
cal critical sites is challenging. For example, the surgical removal of head and neck squa-
mous cell carcinoma (HNSCC) would often greatly constrain the patient’s quality of life and 
therefore, radio- and chemotherapy are mainly applied. However, the unfavorable effects of 
those therapies include resistances, metastasis and second primary tumors. Furthermore, 
adverse effects diminish the patient’s quality of life and provoke numerous adjuvant drugs to 
be taken that themselves induce side-effects. Some of the most severe chemotherapeutic 
side-effects are neuropathy, neutropenia, nephrotoxicity, and cardiotoxicity, but also milder 
side-effects such as hair loss and nausea greatly affect the patient. For that reason, new 
therapeutic strategies are needed that specifically target the malignant tumors and spare 
healthy tissues as good as possible. On one side, the advantages of specific gene expression 
regulation by RNA interference can be exploited as a new therapeutic option in cancer thera-
py and will be described in 1.2. On the other side, nanoparticles (NPs) and especially MSNs 
will be thoroughly introduced and characterized in 1.3. Also, the model drug doxorubicin 
(Dox) (1.4) and the chorioallantoic membrane model (1.5) as in vivo model will be briefly de-
scribed. 
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1.2 RNA interference 
The phenomenon of post-translational silencing of gene expression after the introduction of 
double-stranded RNA (dsRNA) was first identified in Caenorhabditis elegans by Fire et al. in 
1998 and termed RNA interference (RNAi) [3]. RNAi can reduce gene expression with high 
efficiency [4], and therefore was extensively studied and improved during the last 15 years 
[5]. Since Elbashir et al. found that 21-nucleotide siRNA duplexes specifically suppress genes 
in mammalian cells [4], the tool of RNAi is broadly being used to study gene function in 
mammalian cells and is being exploited to develop new cancer therapies. Along these lines, a 
multitude of siRNAs targeting abundant proteins became commercially available. 
1.2.1 The mechanism of RNA interference 
The multistep process of RNAi is depicted in Figure 1 and occurs in the cytoplasm. First, 
dsRNA is cleaved into siRNA segments of about 20 nucleotides (approx. 7.5 nm long and 
2 nm in diameter) by the enzyme Dicer (not shown here) [6]. Second, the siRNA is incorpo-
rated into an enzyme called RNA-inducing silencing complex (RISC). After ATP-dependent 
activation of RISC, one strand of the siRNA remains in the RISC which exploits this strand to 
bind to single-stranded mRNA molecules with a complementary sequence. Finally, this target 
mRNA is cleaved by the RISC’s nuclease activity at a single site in 21 or 22 nucleotides-long 
siRNAs – the cleaving site of the target mRNA is 11 or 12 nucleotides downstream of the first 
nucleotide that is complementary to the siRNA – resulting in mRNA degradation followed by a 
reduction in gene expression [7]. The siRNA sequence must be carefully designed to mini-
mize off-target effects, and to optimize the degradation of the target mRNA. Also, a mix of 
several siRNAs targeting one gene can be applied to enhance gene suppression. Since siR-
NAs can be designed with high specificity, they became interesting as a new therapeutic tool 
for cancer therapy, e.g. to circumvent chemoresistance [8]. 
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Figure 1: The mechanism of RNA interference technology used for gene silencing 
Double-stranded 21- 23 nucleotide segments (siRNA) are incorporated into the RNA-
inducing silencing complex (RISC). This enzyme is ATP-dependently activated and unwinds 
the siRNA duplex. Next, the single-stranded antisense strand guides the RISC to the target 
mRNA which has a complementary composition. Finally, the target mRNA is cleaved by the 
RISC, thus the target gene expression is reduced. Graphic adapted from [9] and [10]. 
1.2.2 Application of RNA interference in therapy 
The application of siRNA in a physiological environment faces several hurdles: siRNAs are 
degraded by endogenous nucleases in plasma and tissues and are rapidly cleared by the 
mononuclear phagocytic system (MPS) or renal filtration, respectively [5]. Moreover, siRNAs 
are negatively charged, thus they are not able to penetrate the cellular membrane directly. 
For this reason, siRNAs can be taken up only by endocytosis or pinocytosis. Yet, this also 
causes the necessity of endosomal escape before degradation in the endolysosomal system. 
Different approaches were utilized to stabilize the siRNA and to circumvent these hurdles: 
siRNAs were chemically modified, conjugated to biomolecules or incorporated into organic 
and inorganic NPs, respectively [5,11]. Recently, chemical modifications of siRNA and siRNA 
conjugation to biomolecules were extensively reviewed by Chernikov et al. [11]. For example, 
methylation of the 2’-OH of the ribose entity enhances nuclease resistance in vitro and in vivo 
[12,13] while consecutive 2’O-methyl groups inhibit RNAi [14]. Moreover, ribose 2’F analogs 
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can increase the nuclease resistance, too, while only a slight decrease in RNAi was observed 
[15,16]. These and other modifications increase the in vivo stability of the siRNA but do not 
enable cellular penetration. For this reason, siRNA was conjugated to various biomolecules 
such as antibodies [17], aptamers [18], peptides [19], folate [20], and carbohydrates [21] as 
ligands for membrane receptors, or molecules that facilitate membrane penetration by natural 
mechanisms, e.g. cholesterol [22]. Also, siRNA was modified with neutral phosphotriester 
groups in the siRNA’s phosphate backbone that enabled membrane penetration. Afterward, 
cytoplasmic thioesterases restored the native siRNA form, and RNAi was induced [23]. In 
most cases, cleavable linkers were applied so that RISC formation was not obstructed by the 
biomolecules. These linkers can contain pH- or photosensitive bonds [24,25], or consist of 
disulfide bonds that are cleaved in the cytoplasm by glutathione, respectively [26,27]. Yet, the 
application of siRNA bioconjugates in the clinic is still limited due to low bioavailability, incon-
venient pharmacokinetics, and high production costs [11]. So far, only one siRNA-based drug 
was approved by the FDA and the EMA, namely Patisiran [28]. The drug was developed by 
Alnylam Pharmaceuticals and is used for the treatment of hereditary transthyretin polyneu-
ropathy [29]. It significantly reduces the symptoms of the disease compared to placebo, but it 
also exhibits proinflammatory side-effects caused by the cationic lipid that complexes the 
siRNA. For that reason, Patisiran must be combined with antihistamines, corticosteroids, and 
acetaminophen [30]. Several siRNA-based cancer therapeutics were and are evaluated in 
clinical trials [31] but were not approved yet. Another possibility to deliver siRNAs to the target 
tissue is to use NPs as delivery vehicles. This approach is consequential because of “the en-
hanced permeability and retention (EPR) effect of solid tumors: Due to a leaky vasculature 
and the lack of lymphatic drainage small structures such as NPs can accumulate in the tumor 
[32].” [1] For example, several organic siRNA drug delivery systems for cancer therapy were 
already tested in clinical trials: TKM-080301 is a stable nucleic acid lipid particle formulation 
with siRNA that targets polo-like kinase 1, a cell proliferation promoting protein. The siRNA is 
incorporated into the aqueous core of a liposome consisting of cationic lipids (1,2-
dilinoleyloxy-N,N-dimethyl-3-aminopropane), release promoting lipids (1,2-distear-oyl-sn-
glycero-3-phosphocholine), and cholesterol for stabilization. The surface was modified with 
polyethylene glycosylated lipids which facilitate crossing barriers and stabilizes the formula-
tion, too [33]. In a first phase I/II clinical trial (NCT02191878) of TKM-080301, the drug was 
generally well-tolerated and showed preliminary antitumor efficacy [34,35]. Moreover, the 
pharmacodynamics and antitumor activity were analyzed in a subsequent trial 
(NCT01262235) [36]. Half of the patients (4/8) who received at least two treatment cycles (0.6 
or 0.75 mg/ kg/ week TKM-080301) exhibited an improvement of the stable disease, but seri-
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ous adverse effects were musculoskeletal pain, ECG T-wave inversion and infusion reaction 
[37]. Still, the drug was generally well tolerated for up to 18 cycles, and in patients with refrac-
tory adrenocortical cancer, the siRNA showed antitumor activity. The siRNA formulation 
siG12D-LODER (by Silenseed Ltd) is also already evaluated in clinical trials for pancreatic 
cancer treatment. The target of the siRNA is G12D-mutated KRAS, and the siRNA is trans-
ported by a biodegradable poly lactic-co-glycolic acid (PLGA) matrix which has a small cylin-
drical rod shape. This local drug eluter (LODER, 0.8 mm x 5.5 mm ± 1 mm) enables sus-
tained siRNA release directly into the tumor tissue. In a phase I/IIa clinical trial 
(NCT01188785) the safety, tolerability and antitumor effects of siG12D-LODER were studied 
in non-operable Locally Advanced Pancreatic Cancer (LAPC) patients [38]. Different doses of 
siG12D-LODER were administered directly in the tumor tissue by a standard endoscope ul-
trasound biopsy procedure, and the patients were also treated with concomitant chemothera-
py such as Gemcitabine or FOLFIRINOX (Leucovorin, Fluorouracil, Irinotecan, Oxaliplatin). 
The drug siG12D-LODER was regarded as safe and well-tolerated. Two patients even 
demonstrated partial response, and most patients had stable disease [39]. In a current 
phase II study (NCT01676259), 2.8 mg (eight 0.35 mg siG12D-LODERs) are administered in 
a 12-week cycle to patients combined with chemotherapy (Gemcitabine + nab-Paclitaxel) and 
the progression-free survival will be evaluated compared to chemotherapy alone [40]. Still, 
siG12D-LODER must be directly administered to the tumor and therefore is not suited for the 
treatment of metastasis. The drug Atu027 was developed to reduce tumor growth and meta-
static spreading. This synthetically synthesized siRNA targets protein kinase N3 (PKN3), 
which is part of the phosphoinositide 3-kinase signaling cascade in highly vascularized tissue. 
A reduction of PKN3 stabilizes vessel integrity, amends inflammation in the tumor environ-
ment, and decreases metastasis [41]. The siRNA-lipoplex Atu027 consists of PKN3 targeting 
siRNA, the cationic lipid AtuFECT01 to complex the siRNA, a neutral helper lipid and a 
PEGylated lipid to protect from clearance by the immune system [42]. In a phase I clinical 
trial, Atu027 was examined in patients with advanced refractory solid tumors to determine 
safety, tolerability, pharmacokinetics, pharmacodynamics and anticancer activity 
(NCT00938574) [43]. Overall, Atu027 was well-tolerated and stabilized the disease in circa 
half of the treated patients and even reduced metastatic lesions in some patients. For that 
reason, a phase I/II clinical trial was initiated (NCT01808638) in patients with advanced or 
metastatic pancreatic carcinoma. In this trial, Atu027 was administered together with gem-
citabine which exhibited good tolerability. Patients who received higher doses of Atu027 ex-
hibited a longer progression-free survival and overall survival [33]. Although the described 
siRNA delivery systems showed promising results in the performed clinical trials, the applied 
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lipids and polymers might still exhibit toxicity and immune response in higher concentrations. 
Therefore, the use of inorganic materials such as silica to deliver siRNA is widely studied [44] 
and will be described in the following paragraphs. 
1.3 MSNs as drug delivery vehicles 
“Research in nanomedicine prospered over the last decades and yielded several prerequi-
sites for drug delivery systems. NPs should have a high loading capacity and the cargo 
should be protected until it reaches the side of action. Moreover, NPs should be taken up 
predominantly and efficiently by cancer cells and evade the MPS. Once drug carriers are in-
corporated by the cells, endosomal escape and drug release are crucial. Good tumor accu-
mulation and deep tumor penetration are also favorable. Importantly, NPs need good bio-
compatibility which is dependent on the used material but also influenced by degradation and 
excretion. 
Over the past decades a plethora of different NPs for drug delivery, organic and inorganic, 
were developed. Organic NPs are represented for example by liposomes, polymer micelles, 
dendrimers, and PLGA-based NPs. In fact, some liposomal formulations are already ap-
proved by the US Food and Drug Administration (FDA), e.g. liposomal Dox (Doxil®/Caelyx™) 
for treatment of Kaposi’s sarcoma, ovarian cancer and multiple myeloma [45]. Yet, the ad-
vantage of liposomes compared to the free drug is mostly limited to a longer half-life and re-
duced toxicity [46]. Furthermore, several polymeric and micelle based vehicles for cancer 
therapy were or are in clinical trials, respectively, among others as described above (1.2.2) 
[45]. 
Drug delivery systems can also be based on inorganic materials, e.g. gold NPs, metal oxide 
such as iron oxide particles, carbon nanotubes, quantum dots and MSNs [47–51]. Particular-
ly, iron oxide NPs are already approved for glioblastoma therapy in Europe and as contrast 
enhancers for magnetic resonance imaging [45]. So far, no clinical trials were performed with 
MSNs but an early phase I study (NCT02106598) is conducted with targeted silica NPs [SiO2-
NPs] for image-guided operative sentinel lymph node mapping [52]. However, MSNs exhibit 
several superior features in comparison to other inorganic NPs: MSNs possess a unique 
structure with a tunable pore and particle size, resulting in a high specific surface area which 
can be easily functionalized, and most importantly are highly biocompatible. Silica is classi-
fied as “generally recognized as safe” (GRAS) by the FDA and is used in cosmetics and as a 
food additive [53]. The MSNs’ porous structure allows a high drug loading capacity and a 
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time-dependent drug release, but the cargo can also be absorbed to the particle’s surface. 
The pores are usually sealed by a gatekeeper system which is often also used for additional 
functionalization and improvement of pharmacodynamical characteristics.” [1] Overall, SiO2-
NPs were increasingly studied from the beginning of the 21st century and most studies on 
SiO2-NPs and MSNs were published in the last two years. 
1.3.1 MSN synthesis and characterization 
“First, MSN synthesis will be discussed briefly with regard to NP diameter and pore size. 
Then, the influence of the characteristics is described regarding drug delivery vehicles. 
1.3.1.1 MSN synthesis 
Several different approaches are used for MSN synthesis resulting in a variety of engineered 
particle and pore sizes. For instance, MSNs are synthesized based on a modified Stöber syn-
thesis, using e.g. tetraethyl orthosilicate (TEOS) as the precursor for silica condensation and 
different additives as templates such as surfactants like cetyltrimethylammonium bromide 
(CTAB), polymers, micelle forming agents or other dopants [54,55]. In brief, surfactants are 
stirred in a mixture of water and alcohol under basic conditions and TEOS or other silicates 
are added under agitation. Concentrations and compositions of silica sources, template-
agents and stirring conditions determine particle size, pore size, and shape. When the surfac-
tant concentration is above the critical micelle concentration, CTAB self-aggregates into mi-
celles and the silica precursor condensates at the surface. A silica structure is formed around 
the surface of the micelles. Then, the surfactants have to be completely removed to obtain 
biocompatible [MSNs] which are usually further modified [56].” [1] An exemplary transmission 
electron microscopy (TEM) image is shown in Figure 2 which depicts the dendritic silica net-
work that generates the porous structure of MSNs. 
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Figure 2: Representative TEM image of a mesoporous silica nanoparticle 
The spherical NP consists of a dendritic silica network that generates a porous structure. 
Here, cetyltrimethylammonium chloride (CTAC) was used as a surfactant and TEOS as a 
silica source. Image provided by Sven Kurch. 
“Another approach was first introduced by Zhao et al. who used triblock copolymers as tem-
plating agents for well-ordered hexagonal mesoporous silica structures with up to 30 nm 
pores [57]. The common pore size of MSNs ranges between 2 and 5 nm but larger pore sizes 
of 23 nm can be generated e.g. by adding swelling agents such as trimethyl benzene [58]. 
Also, hollow-structured MSNs were examined as drug carriers by Wu et al. who employed a 
stability difference-based selective bond breakage strategy. In brief, this strategy relies on the 
fact that a Si-C bond is weaker than a Si-O bond and can be degraded by hydrothermal 
treatment. By applying different temperatures, pore sizes were increased gradually up to 
24 nm [59]. A greater variation can be found in the particle diameter which is also dependent 
on surface modifications. While some [SiO2-NPs] are 100- 120 nm in diameter others are 
larger than 200 nm, yet pore sizes are similar (2.5 nm or 3.0 nm, respectively) [60–62]. How-
ever, the denoted particle diameter is also dependent on surface modifications such as coat-
ings and the suspension medium. A more detailed description of MSN synthesis strategies 
can be found here [56]. 
1.3.1.2 Influence of MSN characteristics on biological systems 
The influence of NP characteristics including size, shape, surface area and chemistry on bio-
logical systems play an important role for efficient drug delivery and was extensively reviewed 
by A. Albanese, P.S. Tang, and W.C.W. Chan [63]. MSNs exhibit a high specific surface area 
of up to 1000 m2/ g which is decreased by surface modifications such as amination or coating 
[64,65]. Accordingly, large-pore NPs (10 nm) exhibit a smaller specific surface area [66]. Yet, 
a large surface area increases loading efficiency for small molecule drugs and siRNA. For 
example, a nearly 1000 fold higher amount of Dox could be loaded in MSNs compared to the 
FDA-approved liposomal formulation Doxil® [67]. MSNs uniformity is important for quality 
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assurance and can be determined by dynamic light scattering [DLS]. Analyzing the Brownian 
motion reveals the polydispersity index (PDI) as an indication for the colloidal dispersion size 
range and a low PDI is favorable [68]. Also, particle shape and size are analyzed with TEM. 
The NP characteristics such as shape, size and charge have an influence on particle uptake. 
Cellular entry is also dependent on the applied targeting strategy. In general, several possible 
endocytic pathways for cellular NP uptake were proposed [as shown in Figure 3], namely 
caveolae or clathrin-dependent endocytosis, caveolae or clathrin-independent endocytosis 
and micropinocytosis [69]. The most prominent cellular entry strategy is [clathrin-dependent] 
receptor-mediated endocytosis of targeted NPs. After the MSNs’ ligands bound the corre-
sponding receptors on the cellular membrane, the endocytic process is initiated and particles 
are incorporated in endosomes [70]. Yet, untargeted MSNs can also interact with the plasma 
membrane through their surface modifications by non-specific binding forces, and then are 
endocytosed or penetrate the cellular membrane [71].” [1] 
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Figure 3: A simplified illustration of the cellular nanoparticle uptake in nonphagocytic 
cells 
The NPs are taken up via different routes of endocytosis and are trafficked through the cell. 
Here, macropinocytosis is presented as only one route through macropinosomes which form 
after incorporation of NPs by invagination of the cellular membrane. A similar mechanism is 
caveolae-dependent endocytosis of NPs. The small membrane invaginations contain 
caveolins and can incorporate small NPs which are then trafficked further  to endosomes and 
sometimes to the endoplasmic reticulum (ER). The most prominent NP uptake route is 
clathrin-dependent endocytosis, also called receptor-mediated endocytosis. NPs with 
targeting ligands bind to the extracellular receptors and are taken up by clathrin -coated pits. 
In the next step, the vesicles are processed to endosomes and further to late endosomes, 
and NP degradation is mediated by lysosomes. Moreover, the lysosomes are processed to 
the Golgi apparatus (GA). However, NPs can also be transported through the cell by 
transcytotic vesicles. Graphic adapted from E. Fröhlich [69]. 
“Regarding the NP shape, the best cellular uptake was achieved by rods, followed by 
spheres, cylinders, and cubes when particles were larger than 100 nm [63,72]. Yet, spherical 
MSNs of 50 nm showed notable better incorporation by HeLa cells than 110, 170 or 280 nm 
particles, respectively [73]. The membrane-wrapping process and ligand-receptor interactions 
influence the uptake efficiency of different particle sizes. A smaller NP of 50 nm [can] induce 
membrane-wrapping by binding a sufficient number of receptors. While larger NPs interact 
with a higher number of receptors and the uptake is limited by the receptors’ redistribution on 
the cellular membrane through diffusion to compensate for local receptor shortage [63,71]. 
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Since endosomes exhibit an acidic pH and pH decreases along the endocytic pathway from 
late endosomes to lysosomes [74], this acidic environment is used for a controlled release 
strategy, which is reviewed later. The surface charge also influences NP uptake. Positively 
charged particles have been found to be taken up faster than neutral or negatively charged 
particles by human cancer cells [70]. The cellular membrane has a slightly negative charge 
and favors the binding of positively charged NPs by electrostatic interaction. Yet, in a physio-
logical environment, NPs are coated by a protein corona consisting of serum proteins, opso-
nins, and ions which changes the in vitro determined parameters such as size and charge 
and thereby also influences cellular uptake and toxicity [71]. The absorbed proteins facilitate 
clearance by the MPS and agglomeration, but this can be prevented by coating the NPs with 
poly(ethylene glycol) (PEG) resulting also in longer blood-circulation times [58,75]. So, MSN 
size and shape have a great influence on the NPs’ in vitro and in vivo behavior. Yet, surface 
modifications have an even greater impact on the drug delivery vehicle’s properties and will 
be discussed next. 
1.3.2 Modifications to control cellular uptake, drug release and endosomal es-
cape 
MSN surface modifications are necessary for several purposes: targeting moieties are sup-
posed to direct the drug carrier to the desired destination, different capping systems ensure 
controlled drug release at the site of action and endosomal escape is not only crucial for effi-
cacy but can also be influenced by certain alterations. The […] [MSNs] can be modified with 
various functional molecules [inside the pores and on the surface]. These alterations will be 
discussed in the following sections. 
1.3.2.1 Passive and active targeting of MSNs 
Scientists imagine a site-directed cancer therapy to lower toxic side-effects, enhance efficacy 
and reduce required drug doses. In general, three different strategies are exploited for this 
purpose, namely passive targeting, active targeting, and magnetic-field directed targeting.” [1] 
Next, passive and active targeting will be introduced in detail. 
1.3.2.1.1 Passive targeting 
“As mentioned above, NPs accumulate favorably in solid tumor tissue due to the EPR effect, 
which is considered as passive targeting [(see Figure 4)]. Generally, tumors exceeding about 
one cubic millimeter in size require oxygen and nutrient supply to proliferate further [76]. 
Therefore, they rapidly form a highly abnormal vasculature by angiogenesis. The blood ves-
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sels are lined by a single, thin layer of flattened endothelial cells, the basement membranes 
have fenestrations varying in size, and little or no pericytes cover the vessels [77]. Hence, 
macromolecules larger than 40 kDa, which is the threshold of renal clearance, can leave the 
blood vessels and accumulate in the adjacent tumor tissue but not in normal tissue. Also, 
solid tumors commonly lack effective lymphatic drainage, so accumulated macromolecules or 
NPs remain longer in the tumor tissue without being cleared by the immune system [78]. To 
achieve efficient passive targeting, so far the focus laid on prolonging circulation time which is 
dependent on renal clearance and MPS escape. Phagocytic cells such as monocytes and 
macrophages are mainly located in the liver, spleen, bone marrow and lymph nodes [79]. 
Hence, NPs also tend to accumulate in these organs.” [1] 
 
Figure 4: The enhanced permeability and retention effect of solid tumors  
The fenestrations in the endothelial layer allow NPs to leave the bloodstream and to 
accumulate in vascularized tumors. Also, the lymphatic drainage is reduced in the tumor 
environment thus, NPs are not cleared by the immune system. 
“For efficient passive targeting several NP characteristics [must] be considered such as parti-
cle size, morphology and surface modifications. To avoid renal clearance, particles have to 
be at least 10 nm in diameter and a size of 100- 200 nm seems to be optimal to also evade 
the MPS [80]. Besides, the NP shape also plays a role in passive targeting based on the EPR 
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effect and was examined by Huang et al. in vivo. Using short-rod and long-rod MSNs the 
main accumulation was found in the liver, spleen, and lung, which is no surprise considering 
the high blood flow rate of these organs. Yet, short-rod MSNs tended to preferably accumu-
late in the liver with a fast clearance rate while long-rod MSNs were distributed in the spleen 
with relatively slow clearance [81]. However, this study was performed without tumors and 
therefore no passive targeting was shown. Lu and colleagues could demonstrate enhanced 
tumor accumulation of MSNs in comparison to normal tissue in vivo while MSNs also exhibit-
ed good biocompatibility [82]. 
Surface modifications also have a major influence on NP tumor accumulation. As mentioned 
above, PEG is used to minimize opsonization and thereby evade the MPS. However, it has 
been implicated that PEGylation reduces cellular NP uptake in cancer cells but also in mac-
rophages [75,83,84]. Nevertheless, Zhu and colleagues reported improved uptake of 
PEGylated hollow MSNs in comparison to naked particles in cervical cancer cells and mouse 
embryonic fibroblasts [85]. Another considerable aspect with regard to passive targeting is 
the elevated interstitial fluid pressure in solid tumors which can be 10 to 40 fold higher com-
pared to normal tissue [86]. This can create pressure gradients and heterogeneous flow in 
the interstitium which influences the distribution of NPs and can lead to reduced particle con-
centrations in the tumor. Nonetheless, larger tumors and metastases often have necrotic tis-
sue or highly hypovascular areas in the center because angiogenesis was slower than tumor 
growth. For this reason, NPs can barely reach these regions by passive targeting. 
Moreover, based on the data collected and analyzed by Wilhelm and colleagues [77] only 
0.4 % ± 0.2 % of the administered untargeted MSN dose (7 data sets) could be found in the 
tumor tissue. However, 0.8 % ± 0.5 % of injected targeted MSNs (6 data sets) were found in 
tumors supporting the advantage of active targeting which will be discussed in the following 
paragraphs. 
1.3.2.1.2 Active targeting 
In order to enhance drug delivery with nanocarriers and drug efficacy, active targeting is con-
ducted to membrane receptors predominantly expressed in tumors, in vascular structures or 
in the nuclear membrane. In the case of leukemic diseases, NP targeting is inevitable be-
cause the EPR effect does not apply. So, different targeting moieties can be added to the 
MSNs’ surface such as small molecules, short peptides, aptamers, and whole antibodies or 
antibody fragments. Usually, the MSNs are then taken up by receptor-mediated endocytosis. 
An overview of the described targeting ligands is given in Figure 5. 
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Figure 5: Ligands for active tumor targeting 
MSNs can be coated with PEG to prolong the circulation time. Small molecules such as folic 
acid are often used for active targeting. Different peptides with the RGD motif or proteins 
such as transferrin were also employed for tumor targeting. Moreover, aptamers or 
antibodies are utilized to target membrane-receptors which are commonly overexpressed in 
cancer cells. Adopted from [1]. 
A prominently used tumor cell target is the folate receptor which is overexpressed in many 
tumors in comparison to healthy tissue [87]. Qi et al. targeted laryngeal carcinoma with folic 
acid-modified MSNs. They successfully delivered commonly used chemotherapeutic drugs 
(paclitaxel, cisplatin, 5-fluorouracil) and siRNA targeting ABCG2, a drug efflux pump involved 
in multidrug-resistance, to CD133+ positive laryngeal cancer cells in vitro and in vivo [88]. 
Before, the group showed a greater reduction in laryngeal tumor size in a mouse model by 
using cisplatin-loaded and folate-conjugated MSNs compared to untargeted MSNs [61]. 
Zhang and colleagues also utilized folate as targeting ligand on MSNs to improve the radio-
enhancer effect of valproic acid in glioblastoma cells [89]. Moreover, PEG-conjugated folate 
was applied by Cheng et al. as targeting ligand on pH-sensitive polydopamine coated MSNs 
in vitro and in vivo. Dox delivery via folate-targeted MSNs had improved efficacy compared to 
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the free drug and untargeted MSNs with Dox in a xenograft tumor model. Also, distinctly 
higher tumor accumulation of folate-targeted MSNs in comparison to untargeted NPs was 
observed [90]. 
Using another concept, the glycoprotein transferrin was applied as targeting-ligand and re-
dox-responsive gatekeeper by Chen et al. who could show the same toxicity of the free drug 
Dox and Dox in transferrin-targeted-MSNs in hepatocellular carcinoma cells [91]. Further-
more, Chen and colleagues exploited the fucose-binding lectin UEA1 for colorectal adenocar-
cinoma, adenoma, and polyposis coli targeting and detection. Fluorescently labeled and 
UEA1 carrying MSNs were successfully tested in a mouse colon cancer model as a contrast 
agent to visualize malignant lesions in the colon [92]. 
Not only proteins can be utilized for targeting but also short peptides. For instance, Sweeney 
and co-workers attached a bladder-cancer specific peptide named Cyc6 to Gd2O3-MSNs and 
thereby improved the detection of tumor boundaries in magnetic resonance imaging (MRI) 
scans in a mouse bladder cancer model [93]. The arginine-glycine-aspartic acid (RGD) motif 
is a prominent peptide sequence targeting integrin αvβ3 which is overexpressed in certain 
tumors [94,95]. Therefore, peptides including the RGD motif have been used for targeting 
MSNs to tumors in vivo by Pan et al. who showed good tumor accumulation and efficacy of 
Dox-loaded MSNs. Even better tumor accumulation and reduction in tumor size were found 
when the cell-penetrating and nuclear-targeting peptide TAT was also coupled to the MSNs 
besides RGD. In addition, bare MSN accumulation in the liver and spleen was distinctly 
greater than RGD/TAT-MSN accumulation in those organs while untargeted MSNs were 
found only in small concentrations in the tumor tissue [96]. A similar approach was conducted 
by Ashley and colleagues who used the peptide SP-94 and a nuclear localization signal 
(NLS) for cancer cell and nuclear targeting, respectively. The MSNs were loaded with siRNA 
and different chemotherapeutic drugs, and were then coated with a lipid bilayer which con-
veyed the targeting moieties, a fusogenic peptide for endosomal escape and PEG. Dox-
loaded and targeted MSNs significantly decreased cellular viability of hepatocellular carcino-
ma cells in comparison to hepatocytes which were barely affected [67]. 
Apart from small molecules and peptides, aptamers can be used for tumor cell targeting. Ap-
tamers are synthetic single-stranded DNA or RNA oligonucleotides that show high affinity and 
specificity toward different targets. They are polyanionic and larger than small peptides but 
smaller than antibodies [97]. An aptamer binding to epithelial cell adhesion molecule (Ep-
CAM) was employed by Babaei and colleagues for hepatocellular carcinoma targeting in vitro 
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and in vivo. They encapsulated 5-Fluorouracil in MSNs with citrate-modified gold NPs as 
gatekeepers which were PEGylated and conjugated with the EpCAM aptamer. Targeted NPs 
showed a greater reduction of cellular viability than untargeted NPs. Moreover, in vivo, the 
system was tested as a theranostic device, and profoundly better tumor accumulation was 
observed after Rhodamine-6G-loaded MSN injection in in vivo imaging [98]. Another receptor 
for aptamer targeting is nucleolin which is expressed on cancer cells. Tang et al. developed a 
photoresponsive drug delivery system based on graphene oxide wrapped MSNs for light-
mediated drug release and a conjugated nucleolin-targeting aptamer. However, in vitro, no 
difference between targeted and untargeted Dox-loaded MSNs on the cellular viability of 
breast cancer cells was recognized [99]. 
Finally, whole antibodies or antibody fragments are used for tumor targeting of drug delivery 
vehicles. For instance, antibodies already approved for cancer therapy are utilized for this 
purpose including cetuximab (targeting […] [epidermal growth factor (EGF)] receptor), 
trastuzumab (targeting HER2/neu receptor), and bevacizumab (targeting […] [vascular endo-
thelial growth factor (VEGF)] receptor) or related antibodies with similar targets. The group of 
Jeffery Brinker developed a drug nanocarrier named “protocell” which consists of an MSN 
core for drug loading and a lipid bilayer as gatekeeper and platform for surface modifications. 
They availed an epidermal growth factor receptor (EGFR)-antibody for targeting leukemic 
cells efficiently in vitro and in vivo [100].” [1] The EGFR belongs to the family of ErbB/HER 
protein kinases which are transmembrane growth factor receptors consisting of a glycosylat-
ed extracellular domain for ligand binding (e.g. EGF), a single transmembrane region, and a 
cytoplasmic domain with kinase activity. In the case of ligand binding, the EGFR dimerizes, 
and autophosphorylation initiates a signaling cascade that stimulates e.g. cell proliferation 
and inhibits apoptosis in normal and malignant tissues. For that reason, the EGFR has been 
linked with cancer development and progression [101]. In about 70- 90 % of HNSCC, the 
EGFR expression is upregulated, and therefore the EGFR became a target in HNSCC thera-
py [102,103]. In the past years, several EGFR inhibitors were approved for cancer therapy. 
On the one side, several tyrosine kinase inhibitors were approved which are small molecule 
drugs that inhibit the cytoplasmic kinase activity of the EGFR. On the other side, biologicals 
were developed. The most prominent biological is Cetuximab (Erbitux®, Merck KGaA), a 
chimeric monoclonal IgG1 antibody that binds the extracellular domain of EGFR with high 
affinity and thereby inhibits the receptor function [104]. Another EGFR targeting antibody is 
Panitumumab (Vectibix®, Amgen) which is a fully human monoclonal IgG2a antibody. So, 
Introduction  17 
EGFR targeting antibodies can execute dual functions – as targeting moiety and inhibitors – 
and therefore are valuable tools for drug delivery systems. 
“Moreover, Zhou and colleagues conjugated Rituximab to MSNs and evaluated the drug de-
livery vehicle in vitro and in vivo [105]. Rituximab is a chimeric monoclonal antibody targeting 
the CD20 antigen on B cells and is approved amongst others for B-cell non-Hodgkin lym-
phoma therapy [106]. In a murine xenograft lymphoma model, a pronounced effect on tumor 
volume reduction was observed for Rituximab-targeted Dox-loaded MSNs, while the mice 
constitution remained better in comparison to mice treated with free Dox [105]. Furthermore, 
for tumor vasculature targeting, the anti-CD105 antibody (TRC105) has been employed by 
Chen et al. in a murine breast cancer model. Tumor uptake of antibody-conjugated MSNs 
was significantly larger compared to untargeted NPs but still, liver accumulation 24 hours af-
ter injection was witnessed [107]. The same group also used a TRC105 antibody fragment 
(Fab) to target dual-labeled MSNs for in vivo targeted positron emission tomography (PET) 
imaging/ near-infrared fluorescent dye (NIRF) imaging of the tumor vasculature in a mouse 
model [108]. 
In conclusion, several strategies are available for NP targeting and some have already been 
employed successfully in murine models. However, high accumulation in organs such as liv-
er, spleen, lungs, and kidneys still raises a problem for application in cancer therapy and reg-
ulatory approval. 
1.3.2.2 Systems for controlled drug release 
A plethora of different approaches have been used to control MSN drug release and are re-
viewed in detail by Mekaru, Lu and Tamanoi [109]. The various gatekeeper systems are cat-
egorized by internal and external stimuli responses and an overview of the here described 
examples is shown in Figure 6. Internal stimuli include decreasing pH, reducing environment 
and enzymes. As mentioned before, NPs are often engulfed via endocytosis, so a system 
responding to low pH is frequently applied using different concepts. Besides, the tumor mi-
croenvironment exhibits a low pH due to hypoxia [110] and therefore, drug release can be 
facilitated at the target site. Examples for low pH activated capping systems include pH-
sensitive nanovalves such as pseudorotaxane encircled by β-cyclodextrin (β-CD) [111], tan-
nic acid [112], polymer and lipid coatings as applied by Popat et al. and Durfee et al., respec-
tively [100,113]. Another pH-sensitive system consisted of a block copolymer containing posi-
tively charged artificial amino acids and oleic acid blocks, which acted simultaneously as 
capping and endosomal release agents [66]. Upon protonation, the pore blocking agents 
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were removed or degraded and the cargo could be released. Furthermore, J. Liu et al. devel-
oped a cascade pH-responsive system using the weak acidic pH of the tumor microenviron-
ment and the acidic endolysosomal pH. First, β-CD was conjugated to hollow MSNs with a 
boronic-acid-catechol ester bond for sealing the pores which was degraded in the endosomes 
or lysosomes at pH 4.5 to 6.5. Second, PEG was grafted to adamantine via a weak pH-
sensitive benzoic-imine bond which was degraded at pH 6.8 and PEGylated adamantine re-
acted with the sealed NPs via host-guest interactions. Therefore, PEG was released in the 
tumor microenvironment facilitating NP uptake and more efficient drug delivery [114]. Another 
dual-responsive drug carrier was developed by X. Liu and co-workers who induced drug re-
lease at high temperature and low pH. The polymer poly[(N-isopropylacrylamide)-co-
(methacrylic acid)] was grafted onto MSNs to seal the pores and control the diffusion of the 
cargo in and out of the pore channels depending on temperature and pH [61]. 
MSN drug release can also be modulated by a redox-sensitive system. As intracellular gluta-
thione concentration can be up to 10 mM, disulfide bonds linking the capping system to the 
MSNs are reduced upon entering the cytoplasm and cargo can be released [115]. For exam-
ple, Kim et al. used β-cyclodextrin directly linked to the MSNs with a disulfide bond to seal the 
pores and efficient Dox toxicity in lung adenocarcinoma cells was shown [116]. Also, poly-
mers cross-linked by cystamine were utilized to close the MSNs’ pores and the polymeric 
network was degraded in a reducing environment [117]. Besides, Wu et al. sealed their hol-
low structured MSNs with poly-(β-amino-esters) via a disulfide-linker which was also reduced 
intracellularly [59]. Furthermore, a redox- and pH-sensitive dual response system was devel-
oped by Y. Li and colleagues who utilized ammonium salt to seal the MSNs’ pores. The am-
monium salt was connected via an amide and a disulfide linker to the MSNs. Hence, the di-
sulfide bond was reduced glutathione-dependently and the amide bond was degraded at low 
pH upon cellular uptake [118]. 
Using a biomolecule activated system, Mondragón et al. encapsulated camptothecin in MSNs 
with a protease cleavable ε-poly-ι-lysine, and in human cervix epithelial carcinoma cells viabil-
ity was reduced after camptothecin-loaded NP incubation [119]. The same group also [uti-
lized] […] several hydrolyzed starch products as saccharides for enzyme-responsive drug 
release [120]. 
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Figure 6: Mesoporous silica nanoparticle gatekeeper systems to control drug release 
Drug release can be regulated by internal stimuli such as pH decrease or reduction by 
glutathione or by external stimuli.  PH-sensitive systems respond to acidic pH in the tumor 
microenvironment and in the endolysosomal system. Several examples are presented here 
such as pseudorotaxan encircled by β-cyclodextrin, tannic acid, polymer and lipid coatings. 
Several capping structures are linked to the MSNs via disulfide bonds which are reduced by 
glutathione intracellularly. Then the pore blocking agents such as β -cyclodextrin, cystamine, 
poly-(β-aminoesters) and ammonium salt are released, and the drugs can escape the NP. 
External stimuli such as light and magnetism are utilized to control drug release, too. 
Photolabile coumarin encircled by β-cyclodextrin is cleaved from the MSNs by light or a 
magnetic field stimulates iron oxide NPs to release the encapsulated drugs. Adopted from 
[1]. 
Apart from internal stimuli also external stimuli such as light or magnetic fields are utilized to 
control gatekeepers. These systems can generate more precise and local drug release, 
hence reducing toxicity towards normal cells. With regard to light-activated drug release, the 
best wavelengths for adequate tissue penetration are within the biological spectra, typically 
800- 1100 nm [109]. In an in vitro model, Guardado-Alvarez et al. used two-photon excitation 
at 800 nm to cleave the NPs’ cap which consisted of photolabile coumarin-molecules bound 
to the NP surface and non-covalently conjugated β-cyclodextrin molecules [121]. Moreover, 
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Croissant and colleagues also used two-photon light to control drug release via a photo-
transducer from mesoporous silica nanoimpellers in human cancer cells [122]. However, tis-
sue penetration of light is still limited, so using a magnetic field for external stimulated cargo 
release is more advantageous even though a magnetic component is necessary. Therefore, a 
magnetic iron oxide core is coated with mesoporous silica or MSNs are capped with iron ox-
ide NPs [123,124]. The iron oxide core has superparamagnetic properties and can be heated 
up by an oscillating magnetic field which in turn can be used to open a nanovalve and for ex-
ample release Dox [124]. Several superparamagnetic iron oxide NPs (SPION) are already 
FDA-approved imaging agents (Endorem®/ umirem®) and iron oxide NPs (Nanotherm®) are 
also approved in the European Union for glioblastoma therapy [45].” [1] 
In this work, a combination of a pH-sensitive and redox-sensitive gatekeeper system for pore 
sealing was developed and applied. The amino-functionalized MSNs were conjugated to fer-
rocenecarboxaldehyde (ferrocene) via a pH-labile imine bond at pH 7.6 and methyl-β-
cyclodextrin (β-CD) or amino-functionalized β-cyclodextrin (NH2-β-CD) was added to encircle 
the ferrocene stalk and seal the pore as illustrated in Figure 7. The cyclic oligosaccharide β-
CD consists of seven glucopyranosyl units linked by α-(1,4) bonds and has a hydrophobic 
center that can interact with other hydrophobic molecules, and β-CD can also increase the 
solubility of hydrophobic drugs in aqueous solutions [125]. The β-CD has a cylindrical shape: 
The dimensions are 0.79 ± 0.01 nm from top to bottom, 0.60- 0.65 nm internal diameter, and 
1.54 ± 0.04 nm external diameter, respectively [126]. So, the organic moiety of ferrocene in-
teracts with β-CD by hydrophobic-hydrophobic interaction and several ferrocene/ β-CD moie-
ties seal one pore. Upon cellular entry of the MSNs, the iron can be oxidized (Fe2+ → Fe3+) by 
intracellular oxidizing agent e.g. reactive oxygen species (ROS), so the hydrophobic (NH2)-β-
CD interaction is diminished and (NH2)-β-CD leaves the ferrocene stalk [127]. Furthermore, 
upon protonation, the imine bond is cleaved in an acidic environment (pH≤ 5.2) and thereby 
the pore is opened and the cargo can be released [128]. 
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Figure 7: Mesoporous silica nanoparticle conjugation with the gatekeeper system ap-
plied in this project 
(A) Ferrocenecarboxaldehyde is conjugated to the amino-functionalized MSNs by an imine 
bond. The imine bond is labile in an acidic environment. (B) The hydrophobic core of NH 2-β-
CD interacts hydrophobically with the organic moieties of the ferrocene and thereby the 
pores are sealed. The NH2-β-CD can be further modified at the amino group e.g. the addition 
of a linker is possible to conjugate a targeting antibody.  
1.3.2.3 Endosomal escape of MSNs and their cargo 
“Once MSNs entered the cancer cells by endocytosis, an endosomal escape of the NPs or 
the delivered drug is mandatory for efficacy. The endosomal pH ranges from 6.0- 6.5, but 
along the endocytic pathway acidity increases and late endosomes and lysosomes exhibit a 
pH from 4.5 to 5.5 [74]. Thus, the MSNs’ cargo could be degraded or inactivated by lysoso-
mal enzymes. To avoid this, several concepts are applied to enable drug release in the cell, 
based on different theories (Figure 8). For example, endosomal escape can be achieved by 
the so-called ‘proton sponge effect’, which relies on an increase of proton concentration dur-
ing hydrolysis. This leads to an increase in membrane potential and an influx of counter-ions 
resulting in osmotic swelling and bursting of the endosome [129]. Hence, the cargo is re-
leased to the cytosol and can take full effect. For instance, the MSN system utilized by Wu et 
al. released siRNA and Dox into the cytoplasm after the coating with poly-(β-aminoesters) 
=
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induced endosome bursting [59]. In the same way, cationic polyethyleneimine (PEI) coating 
can trigger the proton sponge effect which was applied by Finlay and colleagues to deliver 
TWIST1 siRNA to xenograft tumors and reduce tumor burden [130]. 
 
Figure 8: Endosomal escape mechanisms 
After MSNs were taken up by endocytosis, an endosomal escape is mandatory for drug 
efficacy. Coating with cationic polymers such as polyethyleneimine or poly -(β-aminoesters) 
induces the proton sponge effect. The proton concentration increases during hydrolysis 
which leads to an increase in membrane potential and influx of counter -ions such as chloride 
ions. Finally, osmotic swelling by water inflow bursts the endosome , and the MSNs with its 
cargo are delivered into the cytosol. Also, fusogenic peptides such as KALA or zwitterionic 
co-lipids such as dioleoyl-phosphatidylethanolamine (DOPE) can destabilize the endosomal 
membrane resulting in MSN release. Adopted from [1]. 
Other methods use fusion lipids, cationic polymers or peptides to destabilize the endosomal 
membrane by proton absorption and acidification [131]. One example is the zwitterionic co-
Introduction  23 
lipid dioleoylphosphatidylethanolamine (DOPE) which was also utilized in combination with a 
polymer to coat MSNs and improve drug release [132,133]. Moreover, Ashely et al. employed 
a fusogenic peptide to enhance the endosomal escape of protocells in hepatocellular carci-
noma [67]. Fusogenic peptides referred to as KALA were conjugated to PEI-coated MSNs by 
X. Li and colleagues and were used to deliver VEGF targeting siRNA in a xenograft tumor 
model. The siRNA-loaded MSNs with KALA peptides inhibited tumor proliferation significantly 
compared to control particles without siRNA or control siRNA, respectively [134]. However, 
many so far developed MSN systems relied on the proton sponge effect for endosomal es-
cape. Aside from endocytosis, other mechanisms for NP uptake are possible, thus endoso-
mal escape is not always necessary for drug efficacy. 
Overall, surface modifications play an important role for efficient drug transport via MSNs, 
MSN targeting, and drug release. However, the ‘perfect’ system does not exist and is unlikely 
to be invented due to the heterogeneity of cancer. 
1.3.3 Biocompatibility of MSNs 
A major advantage of MSNs is their high biocompatibility in vivo. Several studies examined 
biodistribution, toxicity, and excretion of MSNs. The FDA classified silica as ‘Generally Rec-
ognized as Safe’ and silica is used as a food additive and in cosmetics [53]. In general, silica 
particles are degraded into water-soluble orthosilicic acid (Si(OH)4) which is also absorbed by 
humans to form silica as a trace element [135]. Many in vitro studies showed no toxicity for up 
to 100 µg mL-1 MSNs in cell culture [90,100,105,135]. Sometimes even higher concentrations 
were tested without significant toxicity [91,136]. It is generally recognized that crystalline 
[SiO2-NPs] can cause reactive oxygen species (ROS) formation which compromises cellular 
viability [137]. Yet, MSNs seem to induce ROS formation only in high concentrations. For ex-
ample, MSN concentrations of 1 mg mL-1 and higher exhibited ROS in colon carcinoma cells 
while 200 µg mL-1 did not induce ROS [138]. Furthermore, a relatively small MSN concentra-
tion did not promote ROS formation in hepatocellular carcinoma cells [139]. Elle and col-
leagues covalently coated MSNs with antioxidants to reduce ROS formation and rutin de-
creased ROS formation dose-dependently in a keratinocyte cell line and dose-independently 
in colon carcinoma cells [62]. However, ROS formation after MSN application has been rarely 
examined due to the overall good biocompatibility. 
One of the first in vivo studies was conducted by Park and colleagues who examined biodis-
tribution of silica for four weeks. A relatively low dose of 20 mg kg-1 MSNs (126 nm diameter) 
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was administered intravenously into mice and the bodyweight increased in the same manner 
as in the control group. The NPs predominantly accumulated in [mononuclear phagocytic 
system] (MPS)-related organs such as the liver and spleen. Yet, after one week, MSNs were 
mostly cleared from the analyzed organs (liver, spleen, heart, kidney, brain, and lung) and 
almost completely vanished after four weeks. Moreover, the histopathological analysis indi-
cated no significant toxicity compared to controls, even though apparently macrophages in 
the liver (Kupffer cells) were swollen one day after MSN injection. The authors assumed that 
MSNs were degraded and then excreted via the kidneys [135]. Furthermore, Q. He and co-
workers thoroughly studied NP excretion and biodistribution in vivo. On that account, MSNs 
and PEGylated MSNs of several sizes (80 nm, 120 nm, 200 nm, and 360 nm) were analyzed. 
Fluorescently labeled MSNs were evaluated in different organs with fluorescence intensity 
measurements of homogenized samples at several time points after injection of 20 mg kg-1 
NPs. Most NPs accumulated in the spleen and liver, 30 minutes after injection also in the 
lungs, and low accumulation was detected in the heart and kidneys. PEGylation reduced the 
accumulation of larger particles in the lung and overall in the spleen 30 minutes after injec-
tion. However, after one month, smaller particles were only observed in the liver and spleen 
in low concentrations while 200 nm particles were also detected in even lower concentrations 
in the heart, lung, and kidneys. Regarding 360 nm MSNs, the lowest concentrations were 
found after one month, whereas PEGylated MSNs were still visible in all examined organs. 
Besides, the NP concentration of larger particles in the liver and spleen decreased over time. 
Blood clearance of MSNs was slower for PEGylated particles, and after eight hours, particles 
were barely detectable, yet the smallest MSNs had the longest blood circulation time. With 
regard to excretion, MSNs and PEGylated MSNs were mainly already excreted after 
30 minutes and smaller particles mostly within five days. However, after one month, larger 
particles were still detectable in urine. Histopathological evaluation showed no significant tis-
sue toxicity and [no] inflammation one month after injection for all particle sizes compared to 
controls [140]. In a study conducted by the group of F. Tamanoi biodistribution, biocompatibil-
ity, and drug-delivery efficiency of MSNs were analyzed in a xenograft tumor model. First, 
they determined a maximally tolerated dose of 50 mg kg-1 spherical MSNs (100- 130 nm) after 
intravenous injection and monitoring for ten days. Then, MSNs were administered intraperito-
neally with the same concentration in 18 doses over two months for long-term toxicity profil-
ing. No unusual responses or behaviors compared to controls were observed and all meas-
ured hematologic factors were within normal ranges, proposing that the treatment did not in-
duce an inflammatory response. However, all experiments were conducted in nude mice 
which lacked a thymus and therefore a possible T-cell response. Good biocompatibility could 
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also be […] [because] more than 90 % of the administered silicon concentration was excreted 
via feces and urine within four days. Moreover, in a xenograft breast cancer tumor model 
MSNs were mainly found in tumor, lung, and kidneys 24 hours after tail-vein injection, while 
48 hours after injection the spleen exhibited increased silicon concentration. Targeting with 
folic acid increased the tumor accumulation of NPs. Furthermore, camptothecin-loaded MSNs 
reduced tumor size faster and greater after in total 18 intraperitoneal injections over nine 
weeks. Also, hematology profiling suggested reduced toxicity of camptothecin-loaded MSNs 
compared to the free drug [82]. In a more recent study, J. Liu et al. evaluated 120 nm hollow 
MSNs with a pH-dependent gatekeeper system in a xenograft hepatocellular carcinoma 
model. The untargeted but PEGylated MSNs were loaded with Dox and inhibited tumor prolif-
eration over a time period of 21 days. At the same time, the mice’s weight increased while 
mice treated with the free drug lost weight. The same tendency was observed in survival 
analysis where mice treated with free Dox all died shortly after the treatment stopped. How-
ever, half of the mice treated with PEGylated MSNs survived more than one month after the 
last injection until the end of the experiment. In a biodistribution study after a single injection, 
most of the particles accumulated in liver, spleen, and lung whereas PEGylated MSNs exhib-
ited less accumulation. During the first week after injection, naked particle concentrations 
increased in the liver and spleen while PEGylated MSNs also increased in lung tissue. Only 
low concentrations of nanocarriers were detected in heart and kidney tissues. Yet after one 
month, MSN concentrations were decreased as expected [114]. Zhou and colleagues utilized 
a relatively high concentration of 100 mg kg-1 Rituximab-conjugated MSNs for toxicity and 
distribution analysis in vivo. After seven MSN doses during three weeks, the bodyweight in-
creased correspondingly to control mice and histological analysis indicated no significant 
pathological lesions or damages in the major organs. Still, experiments were conducted in 
immunodeficient nude mice and therefore a lack of pathological damages is not surprising 
[105]. 
In brief, MSNs exhibited remarkable good biocompatibility in many in vivo studies so far while 
tested particle concentrations increased over time. Still, the accumulation of NPs in MPS-
related organs presents a challenge but this seemed to have no major impact on the animals’ 
constitution and inflammatory responses remained mild. However, most studies were per-
formed in immunodeficient mice decreasing the chances for a severe immune response. So, 
more studies in rodents with an intact immune system are necessary to fully evaluate the tox-
ic profile of MSNs before clinical trials. Nevertheless, the first early phase I clinical trial involv-
ing targeted SiO2-NPs for image-guided operative sentinel lymph node mapping is realized 
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[52]. In conclusion, MSNs are promising drug delivery vehicles for cancer therapy from a bio-
compatibility perspective.” [1] 
1.4 The chemotherapeutic drug doxorubicin 
The antibiotic doxorubicin (Dox) is one commonly used chemotherapeutic drug for the treat-
ment of various metastatic solid tumors often in combination with other cytostatic drugs. Dox 
is an anthracycline, a 14-hydroxylated form of daunorubicin, and intercalates with the DNA. 
Thereby the DNA is irreversibly damaged, and topoisomerase IIb (TopoIIb) is inhibited. Nor-
mally, the enzyme TopoIIb prepares the DNA for transcription by unwinding supercoils in the 
DNA. Therefore, DNA and RNA synthesis are inhibited, DNA repair mechanisms are induced, 
and apoptotic and necrotic cell deaths occur [141,142]. Moreover, Dox also increases 
ceramide levels which can lead to growth arrest, apoptosis, or senescence, respectively. Dox 
can be oxidized to a semiquinone radical by NAD(P)H-oxidoreductases. The semiquinone 
radicals react with oxygen thus, ROS are formed and cause DNA damage, but also induce 
cardiotoxicity [142]. For that reason, the therapeutic application of Dox is limited, and targeted 
therapy is favorable. For example, a PEGylated liposomal formulation of Dox (Doxil®) en-
hances blood circulation time, tumor accumulation, reduces adverse effects, and has an in-
creased efficacy compared to Dox [46,143]. Moreover, Dox is frequently used as a model 
drug to evaluate drug delivery systems because the toxicity of Dox can be exploited in cell 
culture experiments to study drug release. Also, Dox is soluble in water, has a red color, and 
exhibits fluorescence. The fluorescence (λex= 480 nm, λem= 560- 590 nm) enables the quanti-
fication of small Dox concentration and quantification of the loading efficiency. The red color 
gives a visual proof if drug loading was successful and the fluorescence can be exploited in 
vitro with different techniques such as flow cytometry and confocal laser scanning microscopy 
(CLSM). Moreover, effective doses of Dox usually are below 0.5 µM dependent on the used 
cell line [142]. So, results can be obtained dose-dependently in short time e.g. by measuring 
the metabolic activity of cells or determining the number of dead cells by DNA staining with 
subsequent flow cytometry analysis. The DNA damage repair upon Dox treatment can al-
ready be detected after two hours incubation with staining of γH2AX foci (own observation). 
Because of these characteristics, Dox is often exploited as a model drug for new drug deliv-
ery systems. 
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Figure 9: Doxorubicin intercalates with the DNA 
(A) Mediated by formaldehyde a covalent bond between Dox with guanine is formed (shown 
in red). Also, hydrogen bonds occur with the guanine on the opposing DNA strand [144]. (B) 
When Dox intercalates with the DNA, Dox parts the flanking base pairs with the sugar moiety 
sitting in the minor groove. Adopted from [142] with permission under CC BY NC SA license. 
1.4.1 γH2AX as marker for DNA damage 
After DNA damage by e.g. Dox, several mechanisms in the cell are induced to repair the DNA 
damage or, in case of severe DNA damage, induce apoptosis. Normally, the DNA is wrapped 
around histone complexes and forms nucleosomes to pack the whole DNA in the nucleus. 
The histone complex consists of two copies each of histone proteins H2A, H2B, H3 and H4 
[145]. Besides forming nucleosomes, these histone variants have specialized biological func-
tions, e.g. the histone H2A variant H2AX plays a role in maintaining genomic stability [146]. 
Upon DNA damage, a highly conserved serine residue located 4 amino acids from the COOH 
terminus (Ser139) is rapidly phosphorylated [147]. This phosphorylation of H2AX is mediated 
by a rapid kinase-based signaling pathway upon DNA double-strand breaks. The main me-
diators in this pathway are the Phosphatidylinositol-3 kinase-like family of kinases (PIKK) and 
among these ataxia telangiectasia mutated (ATM), ATM- and Rad3-related (ATR), ATM-
related kinase (ATX) and DNA dependent protein kinase (DNA-PK) were identified as signal 
transducer after DNA damage to generate phosphorylated H2AX (γH2AX) foci [148]. Next, 
γH2AX foci recruit repair/ signaling proteins to the DNA damage site. The γH2AX foci can be 
detected by immunofluorescence staining and are utilized to evaluate DNA damage in vitro. 
 
A B
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1.5 The chorioallantoic membrane model as in vivo model 
Chicken embryos and especially the chorioallantoic membrane (CAM) are exploited as in vivo 
models to examine angiogenesis, tumor growth and metastasis, wound healing, tissue grafts, 
drug delivery and toxicology [149]. In comparison to other in vivo models (rodents, guinea 
pigs, hamster, sheep, etc.), cultivation of chick embryos is simple and cheap, and importantly, 
no approval by an ethics committee is necessary as long as experiments are terminated be-
fore incubation day 14 (until then no experience of pain [150]) or before hatching. The exact 
incubation times are dependent on the local regulations. The embryonic development lasts 21 
days after the start of incubation at 37.5 °C. After incubation for about three and a half days, 
the allantois of the chicken embryo appears as an evagination from the ventral wall of the 
endodermal hindgut. The allantois pushes out of the embryonic body into the extraembryonic 
coelom and its proximal part (allantoic stalk) lies in parallel and caudal to the yolk sac while 
the distal portion enlarges when it grows clear of the embryo (allantoic vesicle). The allantoic 
vesicle rapidly grows from days 4- 10 of incubation, and meanwhile the mesodermal layer of 
the allantois and the chorion fuse to form the CAM. In between the chorionic epithelium, a 
large blood capillary network is established which is connected to the embryonic circulation. 
The surface of the vascular network increases tremendously within eight days to fulfill its res-
piratory function by exchanging oxygen and carbon dioxide. Also, the CAM acts as a reser-
voir for waste products such as urea and urea acid and mobilizes calcium from the shell for 
bone mineralization. In general, the CAM model offers an immunodeficient environment, 
however, a nonspecific inflammatory reaction can occur after 15 days incubation. Another 
limitation is the low number of analytic tools that are compatible with chicken embryonic tis-
sue such as antibodies, cytokines, and primers. 
As mentioned above, the CAM model allows a toxicological evaluation of new drugs or drug 
delivery systems such as MSNs. Tumors can be grown on the CAM to study tumor vasculari-
zation and metastasis. Moreover, the biodistribution of fluorescently labeled NPs or other re-
agents can be analyzed by fluorescence microscopy. So, the CAM is a valued in vivo model. 
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Figure 10: The chorioallantoic membrane on incubation days 3 and 7 
Only a few blood vessels exist after opening the fertilized egg  on day 3. The vascular 
network already extended greatly until day 7 when a tumor was placed on the CAM (marked 
with an arrow) and a thin thread circled the tumor area. The embryo can be seen in the 
middle. 
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2 Aims of study 
In this work, MSNs were evaluated as drug delivery vehicles to improve HNSCC therapy. For 
this reason, the MSNs were examined step by step in vitro and in vivo. First, the MSNs were 
characterized, and NPs with different sizes and pore sizes were investigated. Second, the 
MSNs were sealed by a gatekeeper system, and the biocompatibility in vitro and in vivo, the 
cellular uptake in vitro, and the in vivo biodistribution were examined. Third, the drug loading 
and release were studied with the model drug Dox in vitro. Fourth, siRNA loading and release 
were tested and optimized in vitro. Fifth, an EGFR-targeting antibody was conjugated to the 
MSNs for active targeting, and the influence on cellular uptake was evaluated in vitro. Finally, 
EGFR-targeted and siRNA-carrying MSNs were analyzed in vitro. 
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3 Materials and Methods 
3.1 Materials 
All used devices, consumables, reagents, kits and software are listed below. 
3.1.1 Devices 
Table 1: Devices 
Device Manufacturer 
Autoklav tuttnauer Systec 5050 ELV Tuttauer, Breda (Netherlands) 
Bank top centrifuge: 
Fisherbrand Mini-Centrifuge 
 
Fisher Scientific GmbH, Schwerte 
Biofreezer: HERAfreeze™ Kendro Laboratory Products, Hanau 
Biometra® Minigel-Twin Biometra GmbH, Göttingen 
Biometra® Standard Power Pack P 25 Biometra GmbH, Göttingen 
Biometra® Tpersonal 48 Thermocycler Biometra GmbH, Göttingen 
BLAUBRAND®-counting chamber (Neubauer) BRAND GmbH + Co KG, Wertheim 
Blotter: 
Trans-Blot® Turbo™ Transfer System 
 
Bio-Rad Laboratories GmbH, Munich 
Centrifuges: 
Biofuge fresco  
Multifuge 1L-R  
Universal 16 R 
 
Heraeus, Kendro Laboratory Products, Hanau  
Heraeus, Kendro Laboratory Products, Hanau  
Hettich Zentrifugen, Tuttlingen 
CoolCell® Cell Freezing Container CryoShop, Munich 
Confocal Laser Scanning Microscope: 
TCS SP-8 
 
Leica Microsystems, Wetzlar 
Darkreader™ 195 M Transilluminator Clare Chemical Research, Inc., Dolores, 
CO (USA) 
Dishwasher: 
Spülmaschine Professional G7883CD 
 
Miele, Gütersloh 
Drying oven: 
Heraeus Function line 
Kendro Laboratory Products GmbH, Langen-
selbold 
Flow cytometer: 
LSR II 
 
BD Bioscience, Heidelberg 
Fluorescence microscope: 
Eclipse TE2000-U 
 
Nikon GmbH, Düsseldorf 
Fluoroskan Ascent™ Mircoplate Fluorometer Thermo Fisher Scientific GmbH, Waltham, 
MA (USA) 
Freezers: 
Liebherr GP 1466 Premium  
Bosch Economic computer control  
 
Liebherr Holding GmbH, Biberach 
Robert Bosch Hausgeräte GmbH, Munich 
Fridges:  
Bosch cooler  
Liebherr Profi Line 
 
Robert Bosch Hausgeräte GmbH, Munich  
Liebherr Holding GmbH, Biberach 
ChemiDoc™ MP Imaging System Bio-Rad Laboratories GmbH, Munich 
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Gel chamber (PAGE): 
Minigel-Twin G42 
 
Biometra GmbH, Göttingen 
HIDEX Sense beta plus HIDEX, Turku (Finland) 
Incubators: 
Cell culture:  
Heracell 150i CO2 Incubators 
Fertilized chicken eggs:  
Brutmaschine Typ 3000 Digital 
 
 
Thermo Fisher Scientific, Waltham, MA (USA) 
Brutmaschinen-Janeschitz GmbH, Hammel-
burg 
Light microscope:  
invers TMS (5x/10x/20x/40x) 
Leitz 307-148.002 
 
Nikon GmbH, Düsseldorf  
Leitz Messtechnik GmbH, Wetzlar 
Liquid nitrogen tank CRYO-400 Chart Ind., Burnsville (USA) 
Luminoskan Ascent Thermo Fisher Scientific, Waltham, MA (USA) 
Magnetic stirrer:  
IKA MAG® REO 
 
IKA® -Werke GmbH & CO. KG, Staufen 
Multipette® plus Eppendorf AG, Hamburg 
Multichannel pipette: 
Finnpipette® 50-300µL 
 
Thermo Fisher Scientific, Waltham, MA (USA) 
Multiskan Ascent Microplate Reader Thermo Fisher Scientific, Waltham, MA (USA) 
Nano Drop 2000 Spectrophotometer Thermo Fisher Scientific, Waltham, MA (USA) 
pH-Meter:  
Hydrus 300 
 
Fisher Scientific UK Ltd, Loughborough (Eng-
land) 
Pipetts:  
1000 µL, 100 µL, 10 µL, 2.5 µL 
Transferpette® S: 1000 µL, 200 µL, 20 µL 
 
Eppendorf AG, Hamburg 
BRAND GmbH + Co KG, Wertheim 
Pipettus® 
Pipetboy 
Hirschmann Laborgeräte, Eberstadt 
Integra Biosciences GmbH, Biebertal 
Rotary Microtome Leica RM2165 Leica Biosystems 
Safety cabinet:  
Herasafe Safety cabinets 
 
Heraeus, Kendro Laboratory Products, Hanau 
Scales: 
Kern Waage ABT 120-5DM  
Kern PCB 8000-1 prescision scale 
Kern PCB 250-3 
 
Kern & Sohn GmbH, Balingen-Frommern 
Scotsman® AF80 Ice Flaker Hubbard Systems, Ipswich (UK) 
Shaker: 
Rocky® 3D 
Tilt Shaker WS10 
 
 
Edmund Bühler GmbH, Bodelshausen 
Smartphone Camera: Samsung Galaxy A3 2016 Samsung Electronics, Seoul (South Korea) 
Ultrasonic homogenizer: 
Sonoplus mini20/HD 2070 
 
BANDELIN electronic GmbH & Co. KG, Berlin 
Ultrasonic bath: 
EMAG Ultraschallreiniger Emmi-40 HC 
 
EMAG AG, Moerfelden-Walldorf 
StepOnePlus™ Real-Time PCR System Life Technologies GmbH, Darmstadt 
Thermomixer comfort Eppendorf AG, Hamburg 
Tissue embedding center Leica EG1140H Leica Biosystems, Nussloch 
Vortex: 
Top-Mix 11118 Fisherbrand® 
 
Fisher Scientific GmbH, Schwerte  
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VV3  
Vortex Mixer CLASSIC 
VWR International, Radnor (USA)  
VELP® Scientifica, Usmate (Italy) 
Water bath (shaking): 
GFL® 1083 
 
GFL Gesellschaft für Labortechnik mbH, 
Burgwedel 
 
3.1.2 Consumables 
Table 2: Consumables 
Consumable Manufacturer 
5 mL Polystyrene round-bottom tube FALCON® Corning Inc., Corning, NY (USA) 
µ-slide 8 well, IbiTreat ibidi GmbH, Munich 
Advanced TC Dish, sterile, 60 x 15 mm Greiner Bio-One GmbH, Frickenhausen 
BD Falcon™ cell scraper BD Bioscience, Bedford (England) 
Blotting Paper MN440B Macherey-Nagel GmbH & Co. KG, Düren 
Cell culture flasks, PS, red filter screw cap, clear, 
CELLSTAR® TC 
50 mL, 25 cm2 
250 mL, 75 cm2 
550 mL, 175 cm2 
Greiner Bio-One GmbH, Frickenhausen 
 
Cell culture plates: 
cell culture microplate, 96-well, PS, F-bottom, 
µClear®, black/ clear, CELLSTAR®  
cell culture multiwell plate, 12 well, PS, clear 
CELLSTAR®  
Nunc™ Multidish 6 Nuclon™ Delta SI  
 
Greiner Bio-One GmbH, Frickenhausen 
 
 
 
Thermo Fisher Scientific, Waltham, MA 
(USA) 
Centrifuge tubes: 
Safe-lock tubes: 0.5 mL, 1.5 mL, 2.0 mL 
Falcon CELLSTAR® 15 mL, 50 mL 
 
Eppendorf AG, Hamburg 
Greiner Bio-One GmbH, Frickenhausen 
Cover glass #1 9 mm x 9 mm Electron Microscopy Sciences, Hatfield, PA 
(USA) 
Cryotube Cryo. S™ Greiner Bio-One GmbH, Frickenhausen 
Disposable weighing dishes neoLab Migge Laborbedarf-Vertriebs GmbH,  
Heidelberg 
Gloves:  
Sempercare® premium  
Sempercare® nitrile skin2 
ABENA classic, Nitrile, powder-free 
 
Semperit Technische Produkte Gesellschaft  
mbH., Wien (Austria) 
Abena GmbH, Aabenraa (Denmark) 
Immobilon®-P Transfer Membranes, Pore size 
0.45 µm 
Merck-Millipore Ltd., Tullagreen (Ireland) 
Leukofix®, 2.5 cm x 9.8 m (micropore bandage) BSNmedical GmbH, Hamburg 
Microplate 96 well, PS, U-Bottom, clear Greiner Bio-One GmbH, Frickenhausen 
MicroAmp™ Optical Adhesive Film Life Technologies, Carlsbad, CA (USA) 
Needles: 
BD Microlance™ 3 Nr. 2, 0.8 x 40 mm, 
21 G x 1 ½”  
 
BD Bioscience, Bedford (England) 
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Disposable hypodermic needle, 0.45 x 25 mm, 
26 G x 1” Gr.18 
B.Braun, Melsungen 
Parafilm „M“™ Laboratory Film Pechiney, Chicago (USA) 
PCR-Plates:  
Micro-Amp® Fast Optical 96-Well Reaction Plate 
 
Life Technologies, Carlsbad, CA (USA) 
Petri dishes: 
CELLSTAR® Cell Culture Dishes (94 mm),  
Cellview cell culture dish, PS, 35/10 mm, vents, 
Advanced TC  
 
Greiner Bio-One GmbH, Frickenhausen 
Pipettes:  
CELLSTAR® 2 mL, 5 mL, 10 mL, 25 mL 
 
Greiner Bio-One GmbH, Frickenhausen 
Pipette tips: 
10 µL, 20 µL, 200 µL, 1000 µL 
Finntip® 5- 300 µL 
MµltiFlex Round Tips 1- 200 µL 
 
Kisker Biotech GmbH & Co. KG, Steinfurt 
Thermo Fisher Scientific, Waltham, MA 
(USA) 
Sorenson™ BioScience, Inc., Salt Lake City, 
UT (USA) 
Pipette tips with filter: 
10 µL/ super slim 
ART® 100 E Molecular Bio Products 100 µL bar-
rier 
TipOne 101-1000 µL filter tips 
 
Nerbe plus GmbH, Winsen (Luhe) 
Fisher Scientific GmbH, Schwerte 
 
Starlab, Ahrensburg 
Pipette tips for Multipette®: 
Combitips advanced 0.5 mL, 5 mL 
 
Eppendorf AG, Hamburg 
Quali-PCR-Tube-Strips 0.2 mL Kisker Biotech GmbH & Co. KG, Steinfurt  
Sterile filter Millex (0.22 µm) Millipore Corporation, Billerica, MA (USA) 
Syringe: 
BD Discardit™ II Syringe 5 mL, 10 mL 
 
BD Bioscience, Bedford (England) 
Thermo Scientific PageRuler Prestained Protein 
Ladder 
Thermo Scientific, Rockford, IL (USA) 
Western Lightning® Plus ECL PerkinElmer, Waltham, MA (USA) 
White tissue embedding cassettes Kartell Labware, Noviglio (Italy) 
Zeba™ Spin Desalting Columns, 7K MWCO, 
0.5 mL 
Thermo Scientific, Rockford, IL (USA) 
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3.1.3 Reagents and solutions 
Table 3: Reagents for experiments 
Reagent Manufacturer 
0.9 % Sodium chloride Fresenius Kabi, Bad Homburg 
3A-Amino-3A-deoxy-(2AS,3AS)-β-cyclodextrin TCI Deutschland GmbH, Eschborn 
Bovine serum albumin Fraction V (BSA) PanReac AppliChem, Darmstadt 
BupH™ Phosphate Buffered Saline Packs Thermo Fisher Scientific, Waltham, MA (USA) 
cOmplete™ Protease inhibitor Cocktail Hoffmann- La Roche AG, Basel (Switzerland) 
DPEC-treated water Carl Roth, Karlsruhe 
Dimethylsulfoxide (DMSO) Carl Roth, Karlsruhe 
Doxorubicin*HCl (Dox) Sigma-Aldrich, St. Louis, MO (USA) 
Ethanol PanReac AppliChem, Darmstadt 
Ethylenediaminetetraacetic acid (EDTA) Carl Roth, Karlsruhe 
Ferrocenecarboxaldehyde Sigma-Aldrich, St. Louis, MO (USA) 
Glycine Carl Roth, Karlsruhe 
Isopropanol Aug. Hedinger GmbH & Co. KG, Stuttgart 
Lipofectamine™ RNAiMAX transfection reagent 
(Lipo) 
Invitrogen™, Thermo Fisher Scientific, Waltham, 
MA (USA) 
Matrigel® Basement Membrane Matrix, Phenol 
Red-free 
Corning Inc. Corning, NY (USA) 
Methanol Honeywell Riedel- de Haën®, Seelze 
Methyl-β-cyclodextrin Sigma-Aldrich, St. Louis, MO (USA) 
Para formaldehyde (PFA) Carl Roth, Karlsruhe 
PEG12-SPDP crosslinker Thermo Scientific, Rockford, IL (USA) 
PhosSTOP™ Hoffmann- La Roche AG, Basel (Switzerland) 
Roti®-Plast (Paraffin) Carl Roth, Karlsruhe 
Sodium chloride Carl Roth, Karlsruhe 
Sodiumdodecyl sulfate (SDS), ultrapure Carl Roth, Karlsruhe 
TaqMan™ Universal PCR Master Mix Thermo Scientific, Rockford, IL (USA) 
Terralin® liquid Schülke & Mayr GmbH, Norderstedt 
Thermo Scientific PageRuler Prestained Protein 
Ladder 
Thermo Scientific, Rockford, IL (USA) 
Traut’s reagent (2-Iminothiolane*HCl) Thermo Scientific, Rockford, IL (USA) 
Tris(hydroxymethyl)aminomethane (Tris) Carl Roth, Karlsruhe 
TritonX100 Sigma-Aldrich, St. Louis, MO (USA) 
Trypan blue solution (0.4 %) Sigma-Aldrich, St. Louis, MO (USA) 
Tween20 Carl Roth, Karlsruhe 
Type F Immersion Liquid ne
23 = 1.5180 Leica Microsystems, Wetzlar 
Vectashield® Antifade Mounting Medium Vector Laboratories, Burlingame, CA (USA) 
Vectashield® Hardset™ Antifade Mounting Me-
dium with DAPI 
Vector Laboratories, Burlingame, CA (USA) 
White leghorn eggs (fertilized) LSL, Dieburg 
Xylene PanReac AppliChem, Darmstadt 
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Table 4: Cell culture reagents 
Reagent Manufacturer 
Accutase® Sigma-Aldrich, St. Louis, MO (USA) 
Bovine Calf Serum (FCS) VWR Seradigm, Radnor, PA (USA) 
Dulbecco's Modified Eagle's Medium (DMEM)- 
Nutrient Mixture F12 (Ham) medium 
(DMEM/F12) 
Gibco™ by Thermo Fisher Scientific, Waltham, 
MA (USA) 
DMEM High Glucose Gibco™ by Thermo Fisher Scientific, Waltham, 
MA (USA) 
DMEM/F12 without phenol red Gibco™ by Thermo Fisher Scientific, Waltham, 
MA (USA) 
Dulbecco’s phosphate-buffered saline (PBS) Sigma-Aldrich, St. Louis, MO (USA) 
Non-Essential Amino Acids (100x) (NEAA) Gibco™ by Thermo Fisher Scientific, Waltham, 
MA (USA) 
10 000 units Penicillin/ 10 mg Streptomycin per 
mL (Pen/Strep) 
Sigma-Aldrich, St. Louis, MO (USA) 
Trypsin/ EDTA (T/E) Sigma-Aldrich, St. Louis, MO (USA) 
 
Table 5: Cell culture media 
DMEM/HamF12 + 5 %FCS + 
2 % Pen/Strep 
DMEM/HamF12 + 10 % FCS + 
1 % NEAA + 2 % Pen/Strep 
DMEM High Glucose + 10 % FCS 
+ 2 % Pen/Strep 
DMEM/HamF12 500 mL DMEM/HamF12 500 mL DMEM High Glucose 500 mL 
FCS 25 mL FCS 50 mL FCS 50 mL 
Pen/Strep 10 mL NEAA (100x) 5.5 mL Pen/Strep 10 mL 
  Pen/Strep 10 mL   
 
Table 6: Fluorescent dyes 
Dye Excitation Emission Manufacturer 
alamarBlue™ Cell Viability Rea-
gent 
530- 560 nm 590 nm Invitrogen™ by Thermo Fisher 
Scientific, Waltham, MA (USA) 
AlexaFluor® 555-Phalloidin 555 nm 565 nm Invitrogen™ by Thermo Fisher 
Scientific, Waltham, MA (USA) 
4',6-diamidino-2-phenylindole 
dihydrochloride (DAPI) 
360 nm 460 nm Invitrogen™ by Thermo Fisher 
Scientific, Waltham, MA (USA) 
eBioscience™ Fixable Viability 
Dye eFlour™ 506 
405 nm 506 nm Invitrogen™ by Thermo Fisher 
Scientific, Waltham, MA (USA) 
eBioscience™ Fixable Viability 
Dye eFlour™ 780 
633 nm 780 nm Invitrogen™ by Thermo Fisher 
Scientific, Waltham, MA (USA) 
Fluorescein 490 nm 525 nm - 
Sulfo-Cyanine5  
N-hydroxysuccinimide ester 
649 nm 666 nm Lumiprobe GmbH, Hanover 
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Table 7: Solutions for (immuno)fluorescence staining 
PBS + 0.3 % TritonX100 5 %BSA in PBS + 
0.3 %TritonX100 
0.5 %BSA in PBS + 0.3 % Tri-
tonX100 
PBS 500 mL Albumin Frac-
tion V 
2.5 g 5 % BSA in PBS + 0.3 % 
TritonX100 
5 mL 
TritonX100 1.5 mL PBS + 0.3 % 
TritonX100 
Ad 50 mL PBS + 0.3 % TritonX100 45 mL 
10x Tris-buffered saline 
(TBS) pH 7.6 
5 % Tween20 TBST 400 mM NaCl 
Tris 302.85 g Tween20 25 mL 10x TBS 200 mL 
NaCl 430.50 g H2O 475 mL 5 % Tween® 20 20 mL 
H2O Ad 5 L   NaCl 29.56 g 
Adjust pH to 7.60 with con-
centrated hydrochloric acid 
  H2O Ad 2 L 
 
Table 8: Antibodies 
Antibody Species Manufacturer 
Anti-β-Actin monoclonal antibody, 
clone AC-15 
Mouse, IgG1 Sigma-Aldrich, St. Louis, MO (USA) 
Anti-phospho-Histone H2A.X (Ser139), 
clone JBW301 
mouse IgG1 EMD Millipore Cooperation, Temecula, 
CA (USA) 
Anti-EEA1 C45B10 mAb rabbit Cell Signaling Technology, Inc., Danvers, 
MA (USA) 
Anti-EGFR monoclonal antibody 
(199.12) 
mouse/ 
IgG2a 
Thermo Fisher Scientific, Rockford, IL 
(USA) 
Anti-EGF Receptor (D38B1) XP® mAb rabbit Cell Signaling Technology, Inc., Danvers, 
MA (USA) 
Anti-LAMP1 (D2D11) XP® mAb rabbit Cell Signaling Technology, Inc., Danvers, 
MA (USA) 
IgG2a isotype control antibody mouse Thermo Fisher Scientific, Rockford, IL 
(USA) 
Anti-mouse IgG, HRP-linked antibody horse Cell Signaling Technology, Inc., Danvers, 
MA (USA) 
Anti-rabbit IgG, HRP-linked antibody goat Cell Signaling Technology, Inc., Danvers, 
MA (USA) 
Goat anti-mouse AlexaFlour®488 anti-
body (H+L) 
goat Molecular Probes by Thermo Fisher Sci-
entific, Waltham, MA (USA) 
Goat anti-rabbit AlexaFlour®488 anti-
body (H+L) 
goat Molecular Probes by Thermo Fisher Sci-
entific, Waltham, MA (USA) 
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Table 9: Solutions for antibody conjugation 
PBS (pH 7.2) Coupling buffer pH-Adjusted coupling buffer 
BupH™ Phosphate 
Buffered Saline Packs 
2 EDTA 1.4612 g Coupling buffer 50 mL 
Water for injection 1000 mL PBS (pH 7.2) Ad 500 mL pH adjusted to 8.0 with 1 M 
NaOH, sterile filtration sterile filtration  pH adjusted with 1 M 
NaOH to 7.2, sterile filtra-
tion 
 
Table 10: siRNAs used for experiments 
siRNA Catalogue # Sequence (5’ → 3’) Manufacturer 
Silencer® GFP 
(eGFP) siRNA 
AM4626 Unknown Ambion®; Thermo 
Fisher Scientific, 
Waltham, MA (USA) 
Silencer® FAM™ 
GAPDH siRNA 
AM4650 Unknown Ambion®; Thermo 
Fisher Scientific, 
Waltham, MA (USA) 
Silencer® Select 
siRNA hnRNP K 
S6739 GAGCUUCGAUCAAAAAUUGAtt Ambion®; Thermo 
Fisher Scientific, 
Waltham, MA (USA) 
Silencer® Select 
Negative Control 
siRNA #2 
4390846 Unknown Ambion®; Thermo 
Fisher Scientific, 
Waltham, MA (USA) 
 
Table 11: Primer for real-time polymerase chain reaction (qPCR) 
Primer target Context Sequence  Dye Manufacturer 
eGFP AACCGCATCGAGCTGAAGGGCATCG FAM-NFQ Applied Biosystems by 
Thermo Fisher Scien-
tific, Waltham, MA 
(USA) 
GAPDH GACTCATGACCACAGTCCATGCCAT FAM-NFQ Applied Biosystems by 
Thermo Fisher Scien-
tific, Waltham, MA 
(USA) 
hnRNP K GACGAGGCGGCCGGGGTGGTAGCAG FAM-NFQ Applied Biosystems by 
Thermo Fisher Scien-
tific, Waltham, MA 
(USA) 
RPLPO (large 
ribosomal 
protein) 
Unknown VIC-
TAMARA 
Applied Biosystems by 
Thermo Fisher Scien-
tific, Waltham, MA 
(USA) 
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Table 12: Buffers and solutions for protein expression analysis  
Lysis buffer 5x Electrophoresis (EPho) 
buffer  
Transfer buffer 
SDS 69 mM Tris 250 mM Tris 25 mM 
2 M Tris/HCl pH 
6.8-7.5 
50 mM Glycine 1.9 M Glycine 150 mM 
Glycerol 1.6 M Solved in desalted H2O Methanol 10 % (V/V) 
Solved in desalted H2O 1x Electrophoresis buffer SDS 0.037 % 
cOmplete™ 1 tablet/ 
40 mL 
5x EPho buffer 100 mL Solved in desalted H2O 
PhosSTOP™ 1 tablet/ 
10 mL 
10 % SDS 5 mL 
Desalted H2O Ad 500 mL 
10x Tris Buffered Saline (pH 
7.6) 
1x TBS-T20 25 mM Glycine, pH 2.0 
Tris 200 mM 10x TBS 100 mL Glycine 25 mM 
NaCl 1.37 M Tween20 0.01 % Solved in desalted H2O, pH 
adjusted with conc. HCl 
Solved in desalted H2O, pH 
adjusted with HCl 
Desalted H2O Ad 1000 mL 1 % SDS in desalted H2O 
SDS 35 mM 
 
Table 13: Kits used in experiments 
Kit Manufacturer 
innuPrep RNA isolation Analytik Jena AG, Jena 
DC™ Protein Assay Bio-Rad Laboratories GmbH, Munich 
TaqMan™ Universal PCR Master Mix Thermo Fisher Scientific, Waltham, MA (USA) 
TGX Stain-Free™ Fast Cast™ Acrylamide 
Solutions 
Bio-Rad Laboratories GmbH, Munich 
Western Lightning™ Plus Enhanced Chemi-
luminescence Substrate for Western Blotting 
PerkinElmer, Waltham, MA (USA) 
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3.1.4 Software 
Table 14: Software for experimental analysis, literature management and graphic de-
sign 
Software Manufacturer 
ACD/ChemSketch (Freeware) 2018.2.1 Advanced Chemistry Development, Inc, Toronto 
(Canada) 
Ascent Software 2.6 Thermo Electron Corporation, Dreieich 
BD FACS Diva Software BD Bioscience, Heidelberg 
Cytobank.org Cytobank, Inc., Santa Clara, CA (USA) 
Fiji (Image J) https://imagej.net/Fiji Open-Source [151] 
GraphPad Prism 5 (Version 5.04) GraphPad Software, Inc., La Jolla, CA (USA) 
ImageLab Bio-Rad Laboratories GmbH, Munich 
Inkscape Free Software Foundation, Inc., Boston, MA (USA) 
Mendeley Elsevier, Amsterdam (Netherlands) 
Microsoft Office 2010, Office 365 Microsoft Corporation, Redmond, WA (USA) 
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3.2 Methods 
3.2.1 Cell culture 
The cells and used solutions for cell culture were always handled with care in a safety cabinet 
and kept sterile. The cell culture media were prepared according to Table 5 and stored at 
4 °C. 
3.2.1.1 Cell lines 
The used cell lines are summarized in Table 15. All cell lines were regularly tested for myco-
plasma contamination and only used when no contamination was detected. 
Table 15: Cell lines used in this work 
Cell line Origin Cell culture medium 
Passaging 
ratio 
Source 
Cal-33 Tongue squa-
mous cell carci-
noma [152] 
DMEM/F12 + 10 % 
FCS + 2 % Pen/Strep 
1:3 Deutsche Samm-
lung von Mikroor-
ganismen und 
Zellkulturen 
HNSCCUM-02T base of tongue 
squamous cell 
carcinoma [153] 
DMEM/F12 + 5 % 
FCS + 2 % Pen/Strep 
1:5 University medical 
center Mainz, 
Johannes Guten-
berg-University, 
Mainz, Germany  
HuH7 Hepatocellular 
carcinoma[154] 
DMEM/F12 + 5 % 
FCS + 2 % Pen/Strep 
1:4 RIKEN BioRe-
source Center 
HuH7-GFP Hepatocellular 
carcinoma with 
stable eGFP ex-
pression [155] 
DMEM/F12 + 5 % 
FCS + 2 % Pen/Strep 
1:4 Institute of Phar-
maceutical Biolo-
gy, Goethe-
University, Frank-
furt/Main 
NIH-3T3 Mouse embryonic 
fibroblasts[156] 
DMEM High Glucose + 
10 % FCS + 2 % 
Pen/Strep 
1:3 ATCC 
RPMI2650 nasal septum 
squamous cell 
carcinoma (pleu-
ral effusion) [157] 
DMEM/F12 + 10 % 
FCS + 1 % NEAA + 2 % 
Pen/Strep 
1:10 every 
two weeks 
Deutsche Samm-
lung von Mikroor-
ganismen und 
Zellkulturen 
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3.2.1.2 Passaging of cells 
The cells were passaged regularly, usually twice per week, except RMPI2650 cells (see Ta-
ble 15). For passaging of cells, the medium was discarded, the cells were washed twice care-
fully with PBS, an appropriate amount of Trypsin/EDTA in PBS (T/E) or Accutase® (for 
RPMI2650) was added and the cells were incubated at 37 °C until the cells detached. The 
reaction was stopped by adding the cell line’s medium (preheated to 37 °C) and the cells were 
suspended with a pipette. Then, the cells were centrifuged (1500 rpm, 5 min, 20 °C, Multifuge 
1L-R), the supernatant was discarded, and the cell pellet was suspended in fresh medium. 
Finally, the cells were transferred in the above-mentioned ratios to cell culture flasks (see 
Table 15) and the medium was added as needed. The cells were incubated in an incubator at 
37 °C and 5 % (V/V) CO2. 
3.2.1.3 Counting of cells 
Different numbers of cells were needed for different experiments. Therefore, the cells were 
counted before seeding with the following protocol: A 20 µL aliquot of suspended cells was 
diluted with 20 µL 0.4 % Trypan blue solution to distinguish between living (clear) and dead 
(blue) cells and transferred to a counting chamber (BLAUBRAND® counting chamber). The 
cells were counted manually under a microscope with 100-fold magnification, usually, at least 
100 cells or four squares were counted, respectively. The number of cells in solution was de-
termined by Equation 1: 
Equation 1  
# cells =  
counted cells
# counted squares
× 2 (dilution factor) × 10 000 (chamber factor)
× mL of total cell suspension 
The cells were centrifuged (1500 rpm, 5 min, 20 °C, Multifuge 1L-R) and suspended at 
1 000 000 cells per mL and diluted with the respective medium as needed. 
3.2.1.4 Freezing and storage of cells 
The cells were removed from cell culture flasks as mentioned above (3.2.1.2). In the next 
step, the pelleted cells were suspended at about 1 000 000 cells per mL in 10 % DMSO in 
FCS and an aliquot of 1 mL was added to a cryotube. The cryotubes were first frozen in a 
freezing box (-1 °C per min) for 48 hours in a -80 °C freezer, then transferred and stored in 
liquid nitrogen (-196 °C). 
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3.2.1.5 Taking cells into culture 
The cells’ respective medium was preheated to 37 °C and 10 mL were added to a centrifuga-
tion tube. The cells were thawed by holding the cryotube in a water bath (37 °C) until almost 
the whole suspension was thawed. Then, a few drops of medium were added to the cells and 
the cells were transferred to the centrifugation tube containing the medium. The cells were 
centrifuged (1 500 rpm, 5 min, 20 °C, Multifuge 1L-R) and the pellet was suspended in medi-
um. The cells were seeded in a cell culture flask and incubated in the incubator at 37 °C and 
5 % (V/V) CO2. 
3.2.1.6 Preparation of 3D-cell cultures as tumor models 
The 3D-cell cultures were prepared with the technical assistance of Simone Mendler, and the 
cell lines HuH7 or HuH7-GFP were used for the preparation of 3D-cultures as tumor models. 
5 000 000 cells were needed for one tumor model. First, the cells were transferred to a 1.5 mL 
centrifuge tube and generated a cellular pellet by centrifugation (1 400 rpm, 10 min, 20 °C, 
Hettich Universal 16R). Second, the supernatants were carefully removed, the cells were 
quickly suspended in 25 µL Matrigel® Basement Membrane Matrix and pipetted into 6-well 
plates. After 30 minutes incubation in the incubator (37 °C, 5 % (V/V) CO2), the tumor model 
stiffed, medium was added to the wells and the 3D-cultures were incubated overnight. 
3.2.1.7 RNA interference 
Transfection of cells with Lipofectamine™ RNAiMAX was performed as control experiments. 
The amount of siRNA and Lipofectamine™ RNAiMAX reagent used was dependent on the 
cell line and the transfected number of cells as presented in Table 16. 
First, plain DMEM/HamF12 (without FCS and without Pen/Strep) was pipetted into a centri-
fuge tube, then the respective siRNA or nsRNA was added, the solution was vortexed and 
briefly spun down. The Lipofectamine™ RNAiMAX reagent was added and the tube was vor-
texed and spun down again. Controls containing no RNA, but Lipofectamine™ RNAiMAX 
reagent or just DMEM/HamF12 medium were prepared dependent on the experiment, re-
spectively. The transfection formulations were incubated at room temperature (RT) for at 
least 20 minutes or until the cells were prepared. The preparation and counting of cells was 
conducted based on the standard protocol (3.2.1.2, 3.2.1.3), but cells were suspended and 
seeded in DMEM/HamF12 + 5 % FCS (HNSCCUM-02T, HuH7-GFP) or DMEM/HamF12 + 
10 % FCS + 1 % NEAA (RPMI2650). The transfection formulation was pipetted in the middle 
of the well and the cells were added. After all samples were prepared, the plate was briefly 
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swayed and incubated in an incubator for 24 hours. Then, the medium was removed, the 
cells were washed once with PBS and the normal cell culture medium was added at a suffi-
cient volume. The cells were further incubated dependent on the performed experiment. Fi-
nally, cells were prepared for RNA isolation or stained and fixed for flow cytometry analysis. 
Table 16: RNA interference sample preparation 
Cell line # cells seeded  V 
(DMEM/HamF12) 
n (siRNA/ nsRNA) V (Lipofec-
tamine™ 
RNAiMAX) 
HNSCCUM
-02T 
200 000 cells in 
6-well plate 
500 µL 15 pmol Silencer® Se-
lect siRNA hnRNP K 
2.4 µL 
HNSCCUM
-02T 
200 000 cells in 
6-well plate 
500 µL 100 pmol Silencer® 
FAM™ GAPDH siRNA 
4 µL 
HNSCCUM
-02T 
200 000 cells in 
6-well plate 
500 µL 100 pmol Silencer® 
Select Negative Control 
siRNA #2 
4 µL 
RPMI2650 400 000 cells in 
6-well plate 
500 µL 37.5 pmol Silencer® 
Select siRNA hnRNP K 
6 µL 
RPMI2650 400 000 cells in 
6-well plate 
500 µL 100 pmol Silencer® 
FAM™ GAPDH siRNA 
4 µL 
RPMI2650 400 000 cells in 
6-well plate 
500 µL 100 pmol Silencer® 
Select Negative Control 
siRNA #2 
4 µL 
HuH7-GFP 100 000 cells in 
12-well plate 
250 µL 25 pmol Silencer® GFP 
(eGFP) siRNA 
2 µL 
HuH7-GFP 200 000 cells in 
6-well plate 
500 µL 50 pmol Silencer® GFP 
(eGFP) siRNA 
4 µL 
 
3.2.2 MSN preparation 
3.2.2.1 MSN synthesis and characterization 
All used NPs were synthesized and characterized by Sven Kurch. The MSNs were stored in 
ethanol at 4 °C and sonicated and vortexed before removing aliquots. The provided MSN dis-
persions are listed in Table 17 and characterized in chapter 4.1. All MSNs (except SK-214) 
were labeled with the fluorescence dye Cyanine5 (Cy5, excitation maximum 649 nm, emis-
sion maximum 666 nm). 
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Table 17: Used MSN dispersions 
Mesoporous silica nanoparticles Stock concentration 
AS-21-OT+12 4.5 mg/ mL  
SK-214 2.23 mg/ mL 
SK-267 SK2 
2.2 mg/ mL 
6.2 mg/ mL 
SK-267 2 G 3.8 mg/ mL 
Sk-267-SK4 
13.2 mg/ mL 
5.0 mg/ mL 
SK-268 SK3 4.1 mg/ mL 
SK-268 3 C 1.4 mg/ mL 
SK-275 SK1 6.5 mg/ mL 
 
3.2.2.1.1 MSN synthesis, amino functionalization and characterization  
The MSN synthesis was conducted as described in [158] and different stirrers and stirring 
rates were employed to generate different particle and pore sizes. Tetraethyl orthosilicate 
was used as silica source and cetyltrimethylammonium chloride (CTAC) was used as surfac-
tant. Also, the fluorescent dye Cyanine 5 was encapsulated during the MSN synthesis and 
amino functionalization was performed with (3-aminopropyl)-trimethoxysilane (APTMS). The 
MSNs were stored in ethanol under light protection at 4 °C until further usage and sonicated 
and vortexed before aliquots were removed.  
The MSNs were characterized by TEM, dynamic light scattering, thermogravimetric analysis 
and nitrogen sorption measurements as described in [158]. 
3.2.2.2 Nanoparticle capping 
The required mass of MSNs was added to PBS and centrifuged (10 000 g, 5 min, RT). Sub-
sequently, the supernatants were carefully removed, and the NPs were washed with PBS by 
sonicating and vortexing, followed by centrifugation (10 000 g, 5 min, RT). The supernatants 
were again carefully removed, an appropriate amount of PBS was added to the MSNs and 
the NPs were sonicated and vortexed until in dispersion. For sealing 0.44 µg ferrocenecar-
boxaldehyde (ferrocene) and 2.74 µg methyl-β-cyclodextrin (β-CD) or 3A-Amino-3A-deoxy-
(2AS,3AS)-β-cyclodextrin (NH2-β-CD) per µg MSN were added, respectively, vortexed and 
incubated for six hours at 4 °C. The sealed MSNs are termed “Cy5-MSNs”. Then, the Cy5-
MSNs were washed by centrifugation (10 000 G, 5 min, RT), the supernatants were carefully 
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removed, and the pellet was dispersed in PBS by sonication and vortexing. This washing step 
was repeated once and finally, the Cy5-MSNs were dispersed in PBS at 1 mg/ mL by soni-
cation and vortexing. 
3.2.2.3 Preparation of doxorubicin-loaded nanoparticles 
The steps of the Dox loading protocol are presented in Figure 11. First, the MSNs (SK-267) 
were washed with double-distilled water (ddH2O) and centrifuged (10 000 g, 5 min, RT). The 
supernatants were carefully removed and 5 nmol (2 mg/ mL = 3.45 mM Dox stock solution) or 
2.15 nmol (5 mg/ mL= 8.6 mM Dox stock solution) Dox per µg MSN in ddH2O were added for 
Dox-loaded MSN (Dox-MSNs) and ddH2O was added for control MSNs. The particles were 
shortly sonicated and vortexed until dispersed, and incubated overnight at 4 °C. For sealing, 
0.44 µg ferrocene and 2.74 µg NH2-β-CD per µg MSN were added, vortexed and incubated 
for six hours at 4 °C. The samples were centrifuged, and the supernatants were collected for 
determining the drug loading efficiency. The NP pellets were dispersed in ddH2O by soni-
cation and centrifuged again. Washing was repeated at least five times and all supernatants 
were collected. Finally, Dox-MSNs and Cy5-MSNs were dispersed in PBS at 1 mg/ mL. The 
Dox-MSNs and Cy5-MSNs were used for experiments within two days. 
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Figure 11: Loading of mesoporous silica nanoparticles with doxorubicin 
The MSNs were washed twice, the supernatants were removed, and the Dox solution was 
added overnight. The next day, the gatekeeper (ferrocene and NH2-β-CD) were added and 
the NPs were incubated for 6 hours. The Dox-MSNs were washed, and the supernatants 
were collected for analysis of the loading efficiency. Finally, Dox -MSNs were dispersed in 
PBS and used in experiments. 
3.2.2.3.1 Analysis of doxorubicin loading efficiency 
A standard curve of Dox in ddH2O was generated and was only used when R² ≥ 0.98. Su-
pernatants were diluted 1:100 or 1:10 or used undiluted, respectively. The absorption at 
488 nm and the fluorescence (excitation: 485/10 nm, emission: 560/40 nm) were measured 
with HIDEX Sense beta plus microplate reader and the amount of Dox left in supernatants 
was calculated after subtracting the control supernatants. The loading efficiency (LE) was 
determined by Equation 2: 
Equation 2 
LE (%) =  100 % −
∑ Dox in supernatants
total Dox used in loading
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3.2.2.3.2 Doxorubicin release in different media 
The preparation of 200 µg Dox-MSNs (SK-267 SK2, 5 mg/ mL, 2.15 nmol Dox per µg MSNs) 
was performed as described above and the loading efficiency was determined. Unloaded 
MSNs were prepared the same way as the controls. Then, 10 µg/ mL Dox-MSNs and Cy5-
MSNs were incubated in different media for 24 and 96 hours in an incubator (37 °C, 5 % CO2 
(V/V)) in duplicates, namely PBS, sterile DPEC-treated water (DPEC-H2O), DMEM without 
phenol red and DMEM without phenol red with 5 % FCS and 2 % Pen/Strep. The centrifuge 
tubes were left open for the first hour to allow the media the reaction with the gaseous envi-
ronment to imitate cell culture conditions as good as possible. After incubation, the samples 
were centrifuged (10 000 g, 5 min, 20 °C) and the supernatants were transferred to fresh 
1.5 mL centrifuge tubes. A fluorescence standard curve of Dox was generated in each medi-
um from 0.2 µM to 5 µM Dox (linear fluorescence range) in triplicates. The standard curve 
was used to calculate the Dox concentration in the supernatants when R2 ≥ 0.97. The super-
natants and the standard curve samples were measured in triplicates with HIDEX Sense beta 
plus microplate reader (excitation: 485/ 10 nm, emission: 560/ 40 nm). Next, the Dox concen-
tration was determined by the standard curves and the mean of the two samples per time 
point was normalized to the used Dox concentration (13.1 µM, 14.8 µM, and 13.4 µM). The 
experiment was performed three times. 
3.2.2.4 siRNA loading to MSNs  
During the project, different protocols for siRNA loading were tested and applied. These pro-
tocols are described in the following paragraphs. 
3.2.2.4.1 Loading of eGFP-siRNA and capping with ferrocene/ β-cyclodextrin (I) 
First, three aliquots of 80 µg MSNs (SK-267) were washed twice with DPEC-H2O and dis-
persed in 60 µL DPEC-H2O. In the next step, 400 pmol (8 µL of 50 µM stock solution) eGFP-
targeting siRNA or nsRNA were added, vortexed and incubated overnight at 4 °C, respective-
ly. One aliquot was incubated with DPEC-H2O (control). The next day, 0.44 µg ferrocene and 
2.74 µg NH2-β-CD per µg MSN were added to each aliquot for six hours. The eGFP-siRNA-
MSNs, nsRNA-MSNs and Cy5-MSNs were washed twice with DPEC-H2O and were dis-
persed in DPEC-H2O at 1 mg/ mL and stored at 4 °C until use. 
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3.2.2.4.2 Loading of FAM™-siRNA and hnRNP K siRNA and capping with ferro-
cene/ β-cyclodextrin (II) 
Three aliquots of 600 µg MSNs (SK-275) were washed twice with PBS and dispersed in 
500 µL PBS. Then, 0.44 µg ferrocene per µg MSN were added for six hours. The NPs were 
centrifuged (10 000 g, 5 min, RT), the supernatants were removed, and the MSNs were dis-
persed in 100 µL PBS. Subsequently, 1.5 pmol per µg MSN Silencer® FAM™ GAPDH siRNA 
(FAM™-siRNA), Silencer® Select siRNA hnRNP K (hnRNP K-siRNA) or Silencer® Select 
Negative Control siRNA #2 (nsRNA) were added, respectively, briefly vortexed and incubated 
overnight at 4 °C. The next day, 2.74 µg NH2-β-CD per µg MSN were added to each aliquot 
for five hours. The FAM™-siRNA-MSNs, hnRNP K-siRNA-MSNs, and nsRNA-MSNs were 
washed twice with PBS and were dispersed in PBS at 1 mg/ mL. 
3.2.2.4.3 Testing of siRNA loading to MSNs and capping with ferrocene/ β-
cyclodextrin 
The MSNs SK-275 SK1 were used to test whether ferrocene conjugation before siRNA addi-
tion affects the siRNA loading. For that reason, four aliquots of 500 µg MSNs (SK-275 SK1) 
were washed twice with PBS and dispersed in 400 µL PBS by sonication and vortexing. 
Then, different amounts of ferrocene were added according to Table 18 and NPs were incu-
bated for five hours at 4 °C. The MSN formulations were centrifuged (10 000 g, 5 min, RT), 
the supernatants removed, and PBS was added for washing. Next, the MSNs were dispersed 
in 100 µL PBS by sonication and vortexing and 500 pmol FAM™-siRNA were added accord-
ing to Table 18. The samples were briefly vortexed and incubated overnight at 4 °C. The next 
day, 2.72 µg NH2-β-CD were added, and the MSNs were incubated for five hours at 4 °C. Fi-
nally, the NP formulations were washed twice with PBS and were dispersed in PBS. To eval-
uate the success of siRNA loading, the MSNs were centrifuged (10 000 g, 5 min, RT) and the 
pellets were examined with Darkreader™ 195 M Transilluminator and a picture was taken 
with a smartphone camera. 
Table 18: Different formulations for testing siRNA loading and release  
Label Ferrocenecarboxaldehyde 
(µg/ mL) 
Silencer® FAM™ GAPDH 
siRNA (pmol) 
A 0 500 
B 54.1 500 
C 89.6 500 
Control 133.2 0 
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3.2.2.4.4 Sealing with Lipofectamine™ RNAiMAX: Test of different protocols 
Furthermore, different incubation protocols were tested for MSN sealing with Lipofectamine™ 
RNAiMAX after siRNA loading. First, six aliquots of 200 µg MSNs (SK-275 SK1) were trans-
ferred to 1.5 mL centrifuge tubes and washed twice with PBS. The supernatants were re-
moved after centrifugation (10 000 g, 5 min, RT) and the MSNs were dispersed in 100 µL 
PBS. 200 pmol FAM™-siRNA or nsRNA were added according to Table 19 and the NPs 
were vortexed and incubated at 4 °C overnight. Then, the samples were centrifuged 
(10 000 g, 5 min, RT), the supernatants were collected for further analysis and the FAM™-
siRNA-MSNs or nsRNA-MSNs were dispersed in the stated amount of PBS (see Table 19) by 
sonication and vortexing, respectively. Subsequently, Lipofectamine™ RNAiMAX was added 
and samples were incubated as indicated. The NP formulations were centrifuged, washed 
with PBS, and dispersed in 200 µL PBS. After centrifugation, the NP pellets were analyzed 
with Darkreader™ 195 M Transilluminator and a picture was taken with a smartphone cam-
era. 
Table 19: Different protocols for testing MSN sealing with Lipofectamine™ RNAiMAX 
Label RNA Incubation 
parameters 
V (PBS) V (Lipofectamine™ 
RNAiMAX) 
A1 Silencer® FAM™ GAPDH siRNA 1 h (RT) 140 µL 60 µL 
B1 Silencer® FAM™ GAPDH siRNA 1 h (RT) 120 µL 80 µL 
A3 Silencer® FAM™ GAPDH siRNA 3 h (4 °C) 140 µL 60µL 
B3 Silencer® FAM™ GAPDH siRNA 3 h (4 °C) 120 µL 80 µL 
ACo Silencer® Select Negative Control 
siRNA #2 
1 h (RT) 140 µL 60 µL 
BCo Silencer® Select Negative Control 
siRNA #2 
3 h (4 °C) 120 µL 80 µL 
 
3.2.2.4.5 Sealing of siRNA-MSNs with Lipofectamine™ RNAiMAX 
The required mass of MSNs (SK-275 SK1) was transferred to 1.5 mL centrifuge tubes, 
washed twice with an appropriate volume of PBS and dispersed in PBS. Next, 1 pmol 
FAM™-siRNA, eGFP-siRNA or nsRNA per µg MSN was added, respectively, and incubated 
overnight at 4 °C. The samples were centrifuged, the supernatants were removed, and the 
siRNA-loaded NPs were dispersed in PBS and Lipofectamine™ RNAiMAX according to Ta-
ble 20. After three hours incubation at 4 °C, the sealed MSNs were centrifuged again, the 
supernatants were removed, and the NPs were dispersed in PBS at 1 mg/ mL. 
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Table 20: Sealing of siRNA-loaded MSNs with Lipofectamine™ RNAiMAX 
Experiment siRNA m 
(MSNs) 
V (PBS) V (Lipofectamine™ 
RNAiMAX) 
10 µg/ mL MSNs, eGFP 
expression 
Silencer® GFP 
(eGFP) siRNA 
50 µg 40 µL 10 µL 
25 µg/ mL MSNs, eGFP 
expression 
Silencer® GFP 
(eGFP) siRNA 
150 µg 100 µL 15 µL 
10 and 25 µg/ mL MSNs, 
eGFP mRNA expression  
Silencer® GFP 
(eGFP) siRNA 
150 µg 100 µL 15 µL 
10 µg/ mL, uptake com-
parison 
Silencer® 
FAM™ GAPDH 
siRNA 
150 µg 100 µL 15 µL 
 
3.2.2.5 Antibody coupling to nanoparticles 
For active targeting, two different antibodies, namely an EGFR-antibody (0.2 mg/ mL) and an 
IgG2a-control antibody (1 mg/ mL), were coupled to capped MSN based on protocols provid-
ed by Thermo Fisher Scientific. The required solutions are stated in Table 9. First, 500 µg 
MSNs (SK-275 SK1) were sealed according to the standard protocol (3.2.2.2) with ferrocene 
and NH2-β-CD, but PBS (pH 7.2) was used for washing. The PEG12-N-succinimidyl-3-(2-
pyridyldithiol) propionate (SPDP) crosslinker (Figure 12) required available amino groups on 
one reagent, provided by NH2-β-CD of Cy5-MSNs and sulfhydryl groups on the second rea-
gent (antibodies). 
 
Figure 12: PEG12-SPDP crosslinker 
Molecular weight: 912.07 g/mol, spacer arm length: 51.1 Å. The PEG12-SPDP crosslinker 
contains an amine-reactive group, namely the N-hydroxysuccinimide ester (NHS) (on the 
left) and a sulfhydryl-reactive portion, namely a 2-pyridyldithio group (on the right). Both 
reactive groups react best at pH 7- 8. 
The antibodies (20 µg) were first incubated with 0.266 nmol Traut’s reagent (dihydrothiophen-
2(3H)-imine hydrochloride) in pH-adjusted coupling buffer (pH 8.0) for one hour at RT to en-
hance the number of sulfhydryl groups ((SH)x-antibodies) (see Figure 13). 
N
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Figure 13: Sulfhydration of antibodies with Traut’s reagent (dihydrothiophen-2(3H)-
imine hydrochloride) 
Traut’s reagent reacts with primary amines of antibodies to an amidine compound with a 
sulfhydryl group. 
In the next step, Zeba™ Spin Desalting Columns (7K MW cut-off) were equilibrated with cou-
pling buffer according to the supplier’s instructions for buffer exchange. Then, the (SH)x-
antibodies were slowly pipetted onto the columns to remove excess Traut’s reagent and the 
flow-through contained the (SH)x-antibodies which were adjusted to 150 µL with coupling 
buffer. The Cy5-MSNs were suspended in coupling buffer at 1 mg/ mL and incubated with 
1 mM PEG12-SPDP crosslinker (10 mM stock solution in DMSO) for 30 minutes at RT as 
shown in Figure 14. In the next step, the NPs were centrifuged (10 000 g, 5 min, RT) to re-
move excess linker and the pellet was suspended in 350 µL coupling buffer by sonication and 
vortexing. The (SH)x-antibodies were added to the linker-modified MSNs and incubated over-
night (18 hours) in a Thermomixer comfort with 500 rpm at 22 °C. The next day, the EGFR-
MSNs and IgG2a-MSNs were centrifuged (10 000 g, 5 min, RT), the supernatants were re-
moved, and the NPs were washed twice with 500 µL PBS (pH 7.2). Finally, EGFR-MSNs and 
IgG2a-MSNs were dispersed at 1 mg/ mL. 
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Figure 14: Antibody conjugation to nanoparticles 
First, PEG12-SPDP crosslinker was conjugated to MSN sealed with ferrocene and NH2-β-CD. 
The reactive NHS ester facilitated the reaction of the carboxy group with the amino group of 
the NH2-β-CD to a stable amide bond. Second, (SH)x-antibodies were added to the linker-
modified MSNs and incubated overnight.  The 2-pyridyldithio group enabled conjugation of 
the (SH)x-antibodies by a disulfide bond. The reaction byproduct pyridine-2-thione was 
removed by centrifugation and PBS washing.  
3.2.2.5.1 Analysis of antibody coupling efficiency 
A fluorophore-labeled anti-mouse antibody was used to estimate the amount of antibody 
which was successfully coupled to MSNs as presented in Figure 15. First, 250 µL EGFR-
MSNs, IgG2a-MSNs and Cy5-MSNs were transferred to centrifuge tubes and from these ali-
quots, 100 µL were pipetted into a 96-well microplate black with clear bottom in duplicate. 
The NPs were measured at Fluoroskan Ascent Microplate Reader with 485/ 538 and 
590/ 638 filter pairs as reference. Then, the NPs were pipetted back into their respective cen-
trifuge tubes and two 100 µL aliquots were transferred to new centrifuge tubes. 500 µL of 
goat anti-mouse AlexaFluor® 488 antibody (H+L) (AF488) in PBS (pH 7.2) (1:250, 8 ng/ µL) 
were added to each tube and incubated for one hour in a Thermomixer comfort with 300 rpm 
at 22 °C. 
 
Figure 15: Analysis of antibody-coupling efficiency 
EGFR-MSNs, IgG2a-MSNs, and Cy5-MSNs were incubated with goat anti-mouse 
AlexaFluor® 488 antibody (AF488 anti-mouse Ab). After washing, the AF488 fluorescence 
was measured and the coupling efficiency was determined.  
Next, the samples were centrifuged (10 000 g, 5 min, RT) and the supernatants were collect-
ed. The NPs were dispersed in PBS (pH 7.2) by sonication and vortexing, centrifuged 
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(10 000 g, 5 min, RT), and the supernatants were collected. This washing step was repeated 
once and finally, the EGFR-MSNs, IgG2a-MSNs, and Cy5-MSNs were dispersed in 100 µL 
PBS (pH 7.2). A standard curve ranging from 0.0 to 8.0 ng/ µL AF488 was generated using 
triplicates for each concentration. The NP samples were added to the 96-well microplate 
black with a clear bottom to the same wells as before and the supernatants were added in 
triplicates or duplicates (100 µL per well). The fluorescence of the standard curve and the 
samples was measured at Fluoroskan Ascent Microplate Reader (485/ 538 and 590/ 638 filter 
pairs) and the analysis was conducted with Microsoft Excel. First, the mean blank value was 
subtracted from each value and a linear standard curve cutting 0 was generated to determine 
the slope m. The standard curve was only used if R2 ≥ 0.99. As shown in Equation 3, the 
difference between the fluorescence of AF488 before [Flu(AF488)0] and after the incubation 
[Flu(AF488)1h] was calculated and used to determine the mass of secondary antibody per 
sample [m(AF488)S] by taking the sample’s volume (VS) into account. The m(AF488)S was 
divided by the fluorescence measured with the 590/ 638 filter pair representing the amount of 
Cy5-MSNs [Flu(Cy5)1h] to identify the Coupling Factor (CF) as depicted in Equation 4. Finally, 
the mean for each group was determined and all mean CFs were normalized to the mean CF 
of control MSNs (Cy5-MSNs). The mean values (blank-subtracted) of the supernatants were 
utilized to calculate m(AF488)S in the supernatants according to Equation 3 and the total 
mass of AF488 in the sample and the supernatants was compared to the applied AF488 
mass evaluating the success of the antibody coupling analysis. The average AF488 recovery 
rates were 59 ± 4 %, 62 ± 3 % and 69 ± 2 %, respectively. 
Equation 3 
m(AF488)S =
Flu(AF488)1h − Flu(AF488)0
𝑚
× VS 
Equation 4 
CF =
m(AF488)S
Flu(Cy5)1h
  
3.2.3 Toxicity analysis (alamarBlue™ assay) 
In general, the toxicity was determined by means of a reduction in metabolic activity with the 
alamarBlue™ assay. Alamar Blue, also called resazurin (7-Hydroxy-3H-phenoxazin-3-one-
10-oxide), is a weak fluorescent blue dye that is reduced to highly fluorescent pink resorufin 
(7-Hydroxy-3H-phenoxazin-3-one) by the metabolic product nicotinamide adenine dinucleo-
tide (NADH/H+) as shown in Figure 16 and thereby reflects the number of viable cells [159]. 
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For the standard protocol, at least triplicates were used per treatment or control solution, re-
spectively. A dead control was prepared by treating cells with cold Terralin® for ten minutes. 
The treatment solutions and Terralin® were replaced by 10 % alamarBlue™ in cell culture 
medium at stated time points. The fluorescence was measured with Fluoroskan Ascent Mi-
croplate Reader (538/ 600 nm filter pair) before and after three hours incubation in the incu-
bator. The difference between both measurements was normalized to the mean PBS control 
generating the relative metabolic activity (in %). 
 
Figure 16: Reduction of resazurin by NADH/H+ to resorufin as indicator of metabolic 
activity 
Graphic by Yikrazuul, Own Work, Public domain https://commons.wikimedia.org/w 
/index.php?curid=2774179, [Accessed: 26-June-2019]. 
3.2.3.1 IC50 of doxorubicin in HNSCCUM-02T and RPMI2650  
The Dox concentration of half-maximal reduction in metabolic activity (IC50) was determined 
in HNSCCUM-02T and RPMI2650 cells after 24 and 48 hours incubation. 
The HNSCCUM-02T (5 000 cells per well) and RPMI2650 (20 000 cells per well) cells were 
seeded in 96-well cell culture microplates (black with clear bottom) and let adhere overnight. 
The Dox stock solution (2 mg/ mL, 3.45 mM) was diluted in PBS to working solutions of dif-
ferent concentrations (2 µM, 5 µM, 10 µM, 20 µM, 50 µM, 100 µM, 200 µM, 500 µM Dox in 
PBS). Then, the working solutions were diluted in the respective cell culture medium to final 
Dox concentrations (0.1 µM, 0.25 µM, 0.5 µM, 1 µM, 2.5 µM, 5 µM, 10 µM, 25 µM) and the 
cells were treated in triplicates for 24 and 48 hours. PBS was used as control. The alamar-
Blue® assay was conducted according to the standard protocol (3.2.3). 
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The analysis of IC50 was performed with GraphPad Prism via a non-linear fit regression [log 
c(Dox) vs. normalized response (variable slope)]. 
3.2.3.2 Biocompatibility examination of unloaded nanoparticles  
The cells were seeded in a 96-well cell culture microplate (black with clear bottom) at 5 000 
cells per well (HNSCCUM-02T, NIH-3T3), 10 000 cells per well (HuH7) or 20 000 cells per 
well (Cal-33, RPMI2650) and let adhere for two days. The stock dispersions SK-214 
(HNSCCUM-02T, Cal-33, RPMI2650), SK-268 3C (NIH-3T3) or SK-267 2G (HuH7) of capped 
MSNs (1 mg/ mL, 3.2.2.2) were pre-diluted in PBS and then diluted in the respective cell cul-
ture medium to 5, 10, 25, 50 or 100 µg/ mL Cy5-MSNs. The cells were treated with these 
dispersions for 24 hours and PBS was used as control. Finally, the alamarBlue® assay was 
performed according to the standard protocol (3.2.3). 
3.2.3.3 Doxorubicin-loaded nanoparticles 
Different cell lines were incubated with free Dox, Dox-MSNs and Cy5-MSNs, respectively, 
and the influence of FCS on Dox release was studied, too. The Dox-MSNs were prepared as 
described in 3.2.2.3 with 5 nmol Dox per µg MSN for the Dox release evaluation, and with 
2.15 nmol per µg MSN for examining the influence of FCS on Dox release. 
The cells were seeded in a 96-well cell culture microplate (black with clear bottom) at 5 000 
cells (HNSCCUM-02T) or 20 000 cells (RPMI2650) per well and let adhere for two days. In 
the next step, the cells were treated with PBS as control, 1 and 2 µM free Dox, 10 µg/ mL 
Dox-MSNs, or Cy5-MSNs, respectively, in cell culture medium for 24 and 96 hours. The ala-
marBlue™ assay was performed and cells were incubated further for 72 hours in cell culture 
medium without treatment solutions, respectively, and metabolic activity was measured again 
with the alamarBlue™ assay. 
Furthermore, the influence of FCS on Dox and Dox-MSNs’ toxicity was examined in 
HNSCCUM-02T cells. The cancer cells were seeded at 10 000 cells per well in a 96-well cell 
culture microplate (black with clear bottom) and let adhere overnight. The treatment solutions 
were prepared in DMEM/F12 + 5 % FCS + 2 % Pen/Strep or DMEM/F12, respectively, and 
cells were treated for 24 and 96 hours with 2 µM free Dox, 10 µg/ mL Dox-MSNs, or 
10 µg/ mL Cy5-MSNs while PBS was applied as control. The alamarBlue™ assay was per-
formed and the cells were incubated further for 72 hours in cell culture medium without treat-
ment solutions, respectively, and metabolic activity was measured with the alamarBlue™ as-
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say again. The experiment was repeated three times with the Dox-MSNs and Cy5-MSNs 
prepared for studying Dox release in different media (3.2.2.3.2). 
3.2.4 Flow cytometry 
Flow cytometry allows analyzing high amounts of cells in a short time and the principle is 
shown in Figure 17. In brief, single cells flow through a cuvette flow cell and bypass different 
lasers which are detected at certain angles. The forward scatter (FSC) is detected in a 180° 
angle and provides information about the cell’s size while the sideward scatter (SCC) is de-
tected at a 90° angle and characterizes the cells’ granularity. Furthermore, fluorescent dyes 
can be identified simultaneously by different lasers and distinctive filters even enhance the 
number of dyes which can be detected in one measurement. The viable and dead cells can 
be distinguished by incubating the cells with a fluorescent dye which only penetrates cells 
with a damaged cellular membrane, e.g. eBioscience™ Fixable Viability Dye eFlour™ 780 
(FVD780). Also, fluorescently labeled NPs can be detected when associated with a cell. 
However, it is not possible to differentiate between the NPs inside the cells and attached to 
the cells. 
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Figure 17: Flow cytometry analysis of nanoparticle treated cells 
The cells flow through a cuvette flow cell separately  and are excited by different lasers. The 
forward scatter (FSC) correlates to the cell’s size and the sideward scatter (SSC) which is 
detected at a 90° angle, correlates to the cells ’ granularity. By using different laser lines and 
different filter sets, a high number of different fluorescent dyes can be recorded  
simultaneously. Before analysis, the cells were incubated with a fixable viability dye (FVD) to 
distinguish viable and dead cells. The dye accumulates only in cells with a permeable 
membrane and stains the DNA in the nucleus; hence only dead cells are fluorescently 
labeled. The MSNs were labeled with the fluorescent dye Cy5 and could be detected with a 
635 nm laser line, too. 
3.2.4.1 General protocol for sample preparation for flow cytometry analysis 
The used cell line, cell number and treatment characteristics (NP or drug concentrations, in-
cubation time) are specified in the following chapters. A general protocol was used to obtain 
samples for flow cytometry analysis. First, supernatants were collected to centrifuge tubes 
and stored on ice, cells were washed with PBS which was added to the respective centrifuge 
tube, and cells were detached with Accutase®. After visible detachment of the cells, the sam-
ples were thoroughly dispersed by pipetting and transferred to the respective supernatants. 
Then, the samples were centrifuged (350 g, 5 min, 4 °C) and the supernatants were discard-
ed. The cell pellets were dispersed in PBS and transferred into a 96-well plate with a round 
bottom. Next, the plate was centrifuged (350 g, 5 min, 4 °C), the supernatants were carefully 
removed with a multichannel pipette, and the cellular pellets were dispersed in 20 µL of 
FVD780 (if not stated otherwise) in PBS (1:200). The samples were stained for 30 minutes at 
4 °C, then PBS was added, and the samples were centrifuged (350 g, 5 min, 4 °C) again. In 
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the next step, the supernatants were carefully removed, the cellular pellet was dispersed in 
1 % PFA in PBS, and incubated for 30 minutes at RT under light protection. After centrifuga-
tion (350 g, 5 min, 4 °C), the samples were washed twice with PBS and stored in PBS at 4 °C 
until flow cytometry analysis. 
3.2.4.2 Nanoparticle uptake 
For NP uptake analysis, the MSNs (SK-268 SK3) were sealed overnight in accordance with 
3.2.2.2 but with two different gatekeeper solutions: 0.34 mg/ mL ferrocene with 2 mg/ mL me-
thyl-β-cyclodextrin in PBS (Cap 1) and 0.34 mg/ mL ferrocene with 2 mg/ mL 3A-Amino-3A-
deoxy-(2AS,3AS)-β-cyclodextrin:methyl-β-cyclodextrin 1:5 in PBS (Cap 2). In total 106.5 µg 
ferrocene were used for 1 mg MSNs. 
3.2.4.2.1 Sample preparation 
The HNSCCUM-02T cells were seeded at 100 000 cells per well in 12-well plates and let ad-
here overnight. Then, HNSCCUM-02T cells were incubated without MSNs (PBS), 10 µg/ mL 
Cap 1 sealed, or Cap 2 sealed Cy5-MSNs for 24 and 48 hours in triplicates, respectively. The 
samples were prepared following the general protocol (3.2.4.1). Yet, dead cells were stained 
with eBioscience™ Fixable Viability Dye eFlour™ 506 (FVD506). 
3.2.4.2.2 Flow cytometry analysis 
The samples were transferred to 5 mL polystyrene round-bottom tubes and at least 10 000 
events were analyzed with LSR II flow cytometer at a high flow rate. The settings are pre-
sented in Table 21. 
Table 21: Flow cytometer settings for nanoparticle uptake analysis 
 Channel Laser (nm) Voltage 
Size FSC 488 160 
Granularity SCC 488 231 
FVD506 AmCyan 405 357 
Cy5-MSNs APC 635 736 
 
The gating and analysis were performed with cytobank.org. First, the whole cell population 
was gated in a dot plot (Figure 18A) to remove debris and then single cells were identified by 
gating the cell population in a dot plot by size (Figure 18B). Next, a histogram of the single 
cells in the AmCyan channel was used to distinguish between viable (unstained) and dead 
(stained) cells as shown in Figure 18C. The amount of Cy5-MSNs taken up by or attached to 
the cells was determined by the mean fluorescence intensity of a histogram of viable cells in 
the APC channel. The means for each treatment and time point were calculated in each ex-
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periment and used to obtain the means and standard deviations for each treatment and time 
point. The experiment was repeated three times. 
 
Figure 18: Representative gating of Cap1-sealed MSNs (24 hours) to analyze MSN up-
take. 
(A) Cells were determined by gating SSC-A vs FSC-A channels in a dot plot. (B) Single cells 
were identified in the cell population by gating FSC-A vs FSC-H channels in a dot plot. (C) A 
histogram of single cells was generated in the AmCyan-A channel (FVD506) to separate via-
ble and dead cells. Graphics were obtained from community.cytobank.org. 
3.2.4.3 Comparison of MSN uptake after different MSN sealing 
The uptake of MSNs sealed with ferrocene and NH2-β-CD (3.2.2.2) and MSNs encapsulated 
with Lipofectamine™ RNAiMAX (3.2.2.4.5) was compared in HNSCCUM-02T cells after 24 
and 96 hours incubation, respectively. 
 
cells single cells
viable cells dead cells
A B
C
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3.2.4.3.1 Sample preparation 
The HNSCCUM-02T cells were seeded at 50 000 cells per well in 12-well cell culture plates 
and let adhere overnight. The Cy5-MSNs were prepared according to the standard protocol 
and sealed with ferrocene and NH2-β-CD (3.2.2.2). Lipo-FAM™-siRNA-MSNs and Lipo-MSNs 
were prepared according to 3.2.2.4.5. Subsequently, the cells were treated with 10 µg/ mL 
Cy5-MSNs; Lipo-FAM™-siRNA-MSNs, Cy5-MSNs, or 10 µL PBS in triplicates, respectively. 
After 24 and 96 hours incubation, samples were prepared for flow cytometry analysis accord-
ing to the general protocol (3.2.4.1). 
3.2.4.3.2 Flow cytometry analysis 
The samples were transferred to 5 mL polystyrene round-bottom tubes and at least 10 000 
events were analyzed with LSR II flow cytometer at a high flow rate. The settings are shown 
in Table 22. 
Table 22: Flow cytometer settings for uptake comparison of Cy5-MSNs, Lipo-FAM-
siRNA-MSNs and Lipo-MSNs 
 Channel Laser (nm) Voltage 
Size FSC 488 280 
Granularity SCC 488 240 
FAM GFP 488 400 
FVD780 APC-Cy7 635 500 
Cy5-MSN APC 635 550 
 
The gating and analysis were performed with cytobank.org. First, the whole cell population 
was gated in a dot plot (Figure 19A) to remove debris, and then single cells were identified by 
gating the cell population in a dot plot by size (Figure 19B). Next, a histogram of the single 
cells in the APC-Cy7 channel was used to distinguish between viable (unstained) and dead 
(stained) cells as depicted in Figure 19C. The mean fluorescence intensity of Cy5 and fluo-
rescein (FAM) was determined for viable cells only. 
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Figure 19: Representative gating of Lipo-FAM™-siRNA-MSNs after 24 hours incubation 
(A) The cell population was identified by a dot plot of SCC-A vs FSC-A. (B) Then, the cells 
were gated in a dot plot with FSC-A vs. FSC-H to determine single cells. (C) The single cells 
were separated in a histogram of the APC-Cy7-A channel (FVD780) into viable and dead 
cells. The population of viable cells was used for further analysis.  
3.2.4.4 Release of doxorubicin from Dox-MSNs 
The uptake of Dox-MSNs and the Dox release was studied in HNSCCUM-02T cells. 
3.2.4.4.1 Sample preparation 
The HNSCCUM-02T cells were seeded at 50 000 cells per well in 12-well cell culture plates 
and incubated for two days. The Dox-MSN were prepared according to the standard protocol 
(3.2.2.3) by loading 2.15 nmol Dox per µg MSNs in ddH2O. The loading efficiency ranged 
from 6 % to 31 % Dox (w/w) corresponding to 0.42 ± 0.22 nmol Dox per µg MSNs. The cells 
were treated for two hours and 24 hours with 1 µM free Dox, 10 µg/ mL Dox-MSNs (corre-
sponded to 4.2 ± 2.2 µM Dox), or Cy5-MSNs, respectively, while PBS was used as control. 
cells single cells
viable cells dead cells
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Then, the samples for flow cytometry analysis were prepared as stated in the general proto-
col (3.2.4.1). 
3.2.4.4.2 Flow cytometry analysis 
The samples were transferred to 5 mL polystyrene round-bottom tubes and at least 10 000 
events were analyzed with LSR II flow cytometer at a high flow rate. The settings are dis-
played in Table 23. 
Table 23: Settings for flow cytometry analysis of Dox release and Dox-MSN uptake 
 Channel Laser (nm) Voltage 
Size FSC 488 250 
Granularity SCC 488 250 
Doxorubicin PE 488 370 
FVD780 APC-Cy7 635 480 
Cy5-MSNs APC 635 600 
 
The gating and analysis were performed with cytobank.org. First, the whole cell population 
was gated in a dot plot (Figure 20A) to remove debris and then single cells were identified by 
gating the cell population in a dot plot by size (Figure 20B). Next, a histogram of the single 
cells in the APC-Cy7 channel was used to distinguish between viable (unstained) and dead 
(stained) cells (Figure 20C). Besides, the single cells were further gated in a dot plot (Figure 
20D) to distinguish between cells which were associated with Cy5-MSNs and with Dox (+ Cy5 
+ Dox) or without Dox signal (+ Cy5 - Dox), and cells without Cy5-MSN association with Dox 
signal (- Cy5 + Dox) and without Dox signal (- Cy5 - Dox), respectively. The experiment was 
performed three times. 
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Figure 20: Representative gating of Dox-MSN treated cells (24 hours) to evaluate MSN 
uptake and Dox release 
(A) The cells were identified by gating SSC-A vs FSC-A in a dot plot. (B) The single cells 
were determined by gating FSC-A vs FSC-H. (C) Single cells were subjected to analysis in a 
histogram of the APC-Cy7-A channel to identify viable and dead cells. (D) Viable cells were 
evaluated further in a dot plot of the PE-A (Dox) channel vs. APC-A (Cy5) channel to 
diagnose MSN uptake and Dox release. Graphics obtained from community.cytobank.org. 
3.2.4.5 eGFP expression in HuH7-GFP after eGFP-siRNA-MSN treatment 
The efficacy of eGFP-siRNA-MSNs was tested in HuH7-GFP cells. The NPs were prepared 
according to 3.2.2.4.1 and applied in different concentrations and for different time intervals. 
3.2.4.5.1 Sample preparation 
The HuH7-GFP and HuH7 cells were seeded at 50 000 cells per well in 12-well cell culture 
plates and incubated overnight. The next day, the cells were treated with DPEC-H2O, 
10 µg/ mL or 20 µg/ mL Cy5-MSNs, eGFP-siRNA-MSNs, or nsRNA-MSNs in cell culture me-
cells single cells
viable cells dead cells
+ Cy5 + Dox+ Cy5 - Dox
- Cy5 + Dox- Cy5 - Dox
A
DC
B
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dium in duplicates for 72 or 144 hours, respectively. A transfection of HuH7-GFP cells with 
eGFP-siRNA was conducted as described above (3.2.1.7) and cells were incubated for 
96 hours. Then, samples for flow cytometry analysis were prepared as mentioned before 
(3.2.4.1). 
3.2.4.5.2 Flow cytometry analysis 
The samples were transferred to 5 mL polystyrene round-bottom tubes and at least 10 000 
events were analyzed with LSR II flow cytometer at a high flow rate. The settings are shown 
in Table 24. 
Table 24: Flow cytometer settings for analysis of eGFP expression and MSN uptake  
 Channel Laser (nm) Voltage 
Size FSC 488 250 
Granularity SCC 488 250 
GFP GFP 488 383 
FVD780 APC-Cy7 635 480 
Cy5-MSNs APC 635 600 
 
The gating and analysis were performed with cytobank.org according to 3.2.4.3.2. Histograms 
(viable cells) of the GFP and the APC channel were utilized to evaluate the mean fluores-
cence intensity of those channels and thereby determine GFP knockdown and NP uptake. 
The experiment was performed once. 
3.2.4.6 eGFP expression in HuH7-GFP after Lipo-eGFP-siRNA-MSN treatment 
The efficacy of Lipo-eGFP-siRNA-MSNs was tested in HuH7-GFP cells. The NPs were pre-
pared according to 3.2.2.4.5 and applied in different concentrations. An RNA interference 
experiment (see 3.2.1.7) was performed in parallel as a positive control in all experiments. 
3.2.4.6.1 Sample preparation 
The HuH7-GFP cells were seeded at 100 000 cells per well in 12-well cell culture plates and 
let adhere overnight. In the first experiment, cells were treated with 10 µg/ mL Lipo-eGFP-
siRNA-MSNs, Lipo-nsRNA-MSNs, or 10 µL PBS in triplicates, respectively. In a second ex-
periment, cells were treated with 25 µg/ mL Lipo-eGFP-siRNA-MSNs, Lipo-nsRNA-MSNs, 
Lipo-MSNs, or 25 µL PBS in triplicates, respectively. After 96 hours incubation, the NP treat-
ed samples and the transfected samples were prepared for flow cytometry analysis as men-
tioned before (3.2.4.1). 
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3.2.4.6.2 Flow cytometry analysis 
The samples were transferred to 5 mL polystyrene round-bottom tubes and at least 10 000 
events were analyzed with LSR II flow cytometer at a high flow rate. The settings are shown 
in Table 25. 
Table 25: Flow cytometer settings for eGFP expression analysis after Lipo-eGFP-
siRNA-MSN treatment 
 Channel Laser (nm) Voltage 
Size FSC 488 300 
Granularity SCC 488 240 
GFP GFP 488 383 
FVD780 APC-Cy7 635 500 
Cy5-MSNs APC 635 650 
 
The gating and analysis were performed with cytobank.org as previously described 
(3.2.4.3.2). Histograms (viable cells) of the GFP and the APC channel were utilized to evalu-
ate the mean fluorescence intensity of those channels and thereby determine GFP knock-
down and NP uptake. Each experiment was performed once. 
3.2.4.7 Antibody-coupled nanoparticles 
The uptake and binding of EGFR-antibody and IgG2a-antibody-targeted MSNs were evaluat-
ed in HNSCCUM-02T cells and RPMI2650 cells. The preparation of antibody-coupled MSNs 
was performed according to 3.2.2.5. 
3.2.4.7.1 Sample preparation 
The HNSCCUM-02T cells (100 000 cells per well) and the RPMI2650 cells (200 000 cells per 
well) were seeded in 12-well cell culture plates and let adhere and proliferate for two days in 
an incubator. Then, 10 µL of 1 mg/ mL EGFR-MSNs, IgG2a-MSNs, Cy5-MSNs, or PBS were 
added to the medium in triplicates and cells were incubated further for one hour and 
24 hours. Samples for flow cytometry analysis were prepared according to the general proto-
col (3.2.4.1). 
3.2.4.7.2 Flow cytometry analysis 
The samples were transferred to 5 mL polystyrene round-bottom tubes and at least 10 000 
events were analyzed with LSR II flow cytometer at medium (one hour samples) or low 
(24 hours samples) flow rates. The settings are shown in Table 26. 
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Table 26: Flow cytometer settings for analysis of antibody-coupled MSN 
 Channel Laser (nm) Voltage HNSCCUM-02T Voltage RPMI2650 
Size FSC 488 280 320 
Granularity SCC 488 240 260 
Cy5-MSN APC 635 550 550 
FVD780 APC-Cy7 635 500 500 
 
The gating and analysis were performed with cytobank.org as mentioned before (3.2.4.3.2). 
The single cells were gated in a dot plot (Figure 21) to distinguish between viable cells which 
were associated with Cy5-MSNs (viable + Cy5), dead cells associated with Cy5-MSNs (dead 
+ Cy5), viable (viable - Cy5) and dead cells (dead - Cy5) without Cy5-MSN association, re-
spectively. The experiment was performed three times. 
 
Figure 21: Representative gating of HNSCCUM-02T cells incubated for one hour with 
EGFR-MSNs 
After the population of single cells was identified as described above (3.2.4.3.2), these cells 
were analyzed in a dot plot with the APC-A (Cy5) channel vs. the APC-Cy7-A (FVD780) to 
discriminate alive cells with Cy5 association (alive + Cy5), dead cells with Cy5 association 
(dead + Cy5) and dead and alive cells without Cy5 association (dead - Cy5, alive - Cy5), 
respectively. 
3.2.5 Biocompatibility of MSNs by using the CAM assay 
Chicken embryos (CE) were used to simulate an in vivo environment and analyze the bio-
compatibility and the in vivo distribution of Cy5-MSNs. All CEs were handled and supervised 
with the technical assistance of Simone Mendler. An overview of the workflow is presented in 
Figure 22. 
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First, the fertilized eggs were carefully cleaned with sterilized water, screened for any dam-
age, and intact eggs were horizontally placed in a freshly cleaned incubator at 37.5 °C. After 
three days incubation, circa 6 mL albumen were removed from each egg at the side with the 
air chamber by using a syringe (with a needle), and the hole was sealed with sticky tape. 
Then, a micropore bandage was attached horizontally to the top of the egg to prevent egg-
shells falling into the egg while the top was cut out with scissors to generate an oval hole with 
a longitudinal diameter of 2 cm and a perpendicular diameter of 1.5 cm. The egg was 
checked for fertilization, sealed with Parafilm “M”™, and further incubated for four days. The 
CEs were monitored daily for viability and dead embryos were removed. The viability was 
characterized by steady blood flow and visible heartbeat. On the seventh day of incubation, 
the hole was increased to 3.5 x 2 cm, a blood vessel was carefully cut with a scalpel, and a 
3D-culture of HuH7 or HuH7-GFP cells (preparation described in 3.2.1.6) was directly placed 
on the wound, and 20 µL Matrigel were added to the cells. Subsequently, the CEs were incu-
bated further with minimal movement to enhance tumor growth, which was monitored regular-
ly. After the tumor could grow for five days, 50 µL 0.9 % (m/V) sodium chloride solution, 
0.5 mg/ mL Cy5-MSNs, or 1.0 mg/ mL Cy5-MSNs were injected into a blood vessel. Before-
hand, the NPs (SK-275; 750 µg and 1500 µg) were sealed according to the standard protocol 
(2.2.2.2), but before usage, the dispersion medium was changed to 0.9 % (m/V) sodium chlo-
ride. In brief, the MSNs were centrifuged (10 000 g, 5 min, 20 °C), the PBS was removed, the 
appropriate volume of 0.9 % sodium chloride solution was added, and the Cy5-MSNs were 
sonicated and vortexed. The CEs were incubated for 24 hours after the injection of Cy5-
MSNs or control solution and the viability was evaluated. Furthermore, the CAM with tumor, 
heart, liver, brain, and kidneys were removed from three embryos of each treatment group, 
transferred to immunohistochemistry cassettes, and fixed in 4 % PFA overnight. Tissue sam-
ples were stored in 1 % PFA until further processing as described in 3.2.6.5. 
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Figure 22: An in vivo biocompatibility test by means of the chorioallantoic membrane 
assay 
Fertilized chicken eggs were cut open on the third day of incubation and checked for 
viability. On the seventh day of incubation, a 3D-cell culture model was placed on the CAM. 
Cy5-MSNs or 0.9 % sodium chloride solution were injected after the tumor grew for five 
days. The next day, viability was assessed, and tissue samples were removed for 
biodistribution studies.  
3.2.6 Confocal laser scanning microscopy (CLSM) 
If not otherwise stated, the images were taken with a 630-fold magnification (HC PL APO 
CS2 63x/ 1.40 Oil objective) in the sequential scan mode, with two frames average and a 
2048² resolution at a DMi8 confocal laser scanning microscope (Leica Microsystems). The 
pinhole was set at 1.0 airy units and the zoom was set to 1.0. The captured section was 
184.52² µm² and the pixel size was 90.14² nm². The used solutions for staining are depicted 
in Table 7. 
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3.2.6.1 Nanoparticle uptake 
The MSN uptake was studied in HNSCCUM-02T cells for 24 and 48 hours. 
3.2.6.1.1 Sample preparation 
The HNSCCUM-02T cells were seeded at 15 000 cells per well in µ-slide 8 well and let ad-
here overnight. The experiment was performed in parallel to 3.2.4.2 and the same prepared 
Cy5-MSNs were utilized. The cells were treated with 10 µg/ mL Cap1-Cy5-MSNs or PBS, 
respectively, and incubated for 24 and 48 hours. Then, the medium was removed, cells were 
washed with PBS (3 times, 5 min, RT), and the cells were fixed with 4 % PFA (15 min, RT). 
Next, the cells were washed again with PBS (3 times, 5 min, RT) and stored until staining 
under light protection at 4 °C. Right before staining, the cells were fixed with ice-cold acetone 
(4 min, RT), washed with PBS (3 times, 5 min, RT), and blocked with 1 % bovine serum al-
bumin Fraction V (BSA) in PBS at RT. Subsequently, samples were stained with AlexaFlu-
or® 555-Phalloidin (1:40) in 1 % BSA in PBS for 20 minutes while gently shaking. The cells 
were washed with PBS (3 times, 5 min, RT) and were embedded in Vectashield® Hardset™ 
Antifade Mounting Medium with DAPI and sealed with a glass coverslip. The samples were 
stored protected from light at 4 °C. 
3.2.6.1.2 Microscopy 
Ten microscopic images were obtained per treatment with the standard settings (3.2.6) and 
the settings stated in Table 27. Images were exported with Fiji [151]. 
Table 27: Settings for MSN uptake analysis 
Target Color Laser 
(nm) 
Laser in-
tensity (%) 
Gain (V) PMT detection 
area (nm) 
Nuclei  blue 405 3.70 714.8 408-479 
F-Actin  red 552 4.51 646.3 555-638 
Cy5-MSNs green 638 8.04 822.1 640-737 
3.2.6.2 Nanoparticle uptake and trafficking 
The NP uptake and trafficking were examined in HNSCCUM-02T cells by co-localization 
staining of Cy5-MSNs with early endosomal marker EEA1 and endosomal and lysosomal 
marker Lamp1. 
3.2.6.2.1 Sample preparation 
The HNSCCUM-02T cells were seeded at 10 000 cells per well in µ-slide 8 well and let ad-
here overnight. For each experiment 100 µg Cy5-labeled MSNs (SK-267 SK2) were sealed 
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according to the standard protocol (3.2.2.2). The cells were treated with 10 µg/ mL Cy5-MSNs 
for two, six, 24, 30, and 48 hours while PBS was used as control (zero hours). Then, the me-
dium was removed, the cells were washed with PBS (3 times, 5 min, RT), and the cells were 
fixed with 4 % PFA (15 min, RT). Next, the cells were washed again with PBS (3 times, 5 min, 
RT) and stored until staining under light protection at 4 °C. Right before staining, the cells 
were fixed with ice-cold acetone (4 min, RT), washed with PBS (3 times, 5 min, RT), and 
blocked with 5 % BSA in PBS + 0.3 % TritonX-100 (1 h, RT). The samples were stained with 
anti-LAMP1 (D2D11) XP® rabbit antibody (1:100 in PBS + 0.3 % TritonX-100, 1 h, RT) or 
EEA1 antibody (1:200 in PBS + 0.3 % TritonX-100, 1 h, RT), respectively, and washed twice 
with PBS (5 min, RT), once with TBST 400 mM NaCl (2 min, RT), and once with PBS (5 min, 
RT). Subsequently, the samples were stained with secondary goat anti-rabbit AlexaFlu-
or® 488 antibody (1:500), AlexaFluor® 555-Phalloidin (1:40) and DAPI (300 nM) in one dilu-
tion in 0.5 % BSA in PBS + 0.3 % TritonX-100 for one hour at RT. After the samples were 
washed (twice PBS 5 min, once TBST 400 mM NaCl 2 min, PBS 5 min, H2O 2 min), they 
were embedded in Vectashield® Antifade Mounting Medium and sealed with a glass co-
verslip. The samples were stored protected from light at 4 °C. 
3.2.6.2.2 Microscopy 
Ten microscopic images per time point and marker staining were taken at 40962 resolution. 
Microscope settings are depicted in Table 28 and Table 29. 
Table 28: Imaging settings for EEA1 staining 
Target Color Laser 
(nm) 
Laser in-
tensity (%) 
Gain (V) PMT detection 
area (nm) 
Nuclei  blue 405 2.79 743.7 408-479 
EEA-1  green 488 8.11 580 503-548 
F-Actin  white 552 7.17 698.7 555-638 
Cy5-MSNs red 638 8.04 650 640-737 
 
Table 29: Imaging settings for Lamp1 staining 
Target Color Laser 
(nm) 
Laser in-
tensity (%) 
Gain (V) PMT detection 
area (nm) 
Nuclei  blue 405 3.70 780 408-479 
Lamp1  green 488 2.68 632.7 503-548 
F-Actin  white 552 8.08 700 555-638 
Cy5-MSNs red 638 9.83 700 640-737 
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3.2.6.2.3 Uptake analysis 
All images were analyzed with Fiji (ImageJ). The nuclei per image were counted with the 
‘Multipoint’ tool manually. The channel displaying Cy5-MSNs was converted into a greyscale 
image to count Cy5-MSNs and the unspecific background was removed by setting the 
threshold to 0- 12 (EEA1 images) or 0- 23 (Lamp1 images), respectively. Then, the Cy5-
MSNs were counted automatically with the ‘Analyze Particles’ tool while the size was limited 
to 15-∞ pixels and the circularity was set to 0.00- 1.00. The number of Cy5-MSNs was divid-
ed by the nuclei number to determine Cy5-MSNs per cell (n=20 per time point). The experi-
ment was repeated three times. 
3.2.6.2.4 Co-localization analysis 
The co-localization analysis of Cy5-MSNs with the respective marker was conducted with 
‘JACoP’ plugin in ImageJ [160]. First, the images were split in green (EEA1 or Lamp1) and 
red (Cy5-MSNs) channels and the thresholds for each channel were set according to Table 
30. For some images the chosen threshold could not be set, in that case, the threshold was 
set one unit higher. Then, the Manders’ coefficients M1 and M2 were determined for each 
image (Equation 5 and Equation 6) to evaluate the ratio of Cy5-MSN signal with marker sig-
nal overlap to total Cy5-MSN signal (M1) [161]. The average of each Cy5-MSN and marker 
co-localization in each experiment was calculated for each time point. 
Table 30: Threshold settings for co-localization analysis 
Experiment EEA1 Lamp1 
 red green red green 
1 35 21 35 41 
2 32/33 20/21 43/44 43/44 
3 34/35 30 34/35 50 
 
Equation 5 
𝑀1 =
∑ red and green pixelsi
∑ red pixelsi
 
Equation 6 
𝑀2 =
∑ green and red pixelsi
∑ greeni  pixels
 
3.2.6.3 Detection of DNA damage 
The DNA damage after free Dox, Dox-MSN, and Cy5-MSN treatment was evaluated in 
HNSCCUM-02T and RPMI2650 cells by means of γH2AX foci staining. γH2AX foci are in-
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duced upon DNA damage and correlate to the severity of DNA damage by DNA-damaging 
agents (see 1.4.1). 
3.2.6.3.1 Sample preparation 
The HNSCCUM-02T cells (5 000 cells per well) and RPMI2650 cells (10 000 cells per well) 
were seeded each in two µ-slides 8 well and let adhere for two days. One µ-slide was treated 
for two hours, the other slide for 24 hours with 1 µM Dox, 10 µg/ mL Dox-MSNs, or Cy5-
MSNs in the respective cell culture medium, respectively, while PBS was used as control. 
The preparation of Dox-MSNs and Cy5-MSNs was conducted according to 3.2.2.3 and the 
same NPs as described in 3.2.4.4.1 were used. In the next step, the treatment solutions were 
removed, samples were washed with PBS (3 times, 5 min, RT), and cells were fixed with 4 % 
PFA (15 min, RT). The cells were washed again with PBS (3 times, 5 min, RT) and stored 
until staining under light protection at 4 °C. Right before staining, cells were fixed with ice-cold 
methanol (10 min, RT), washed with PBS (3 times, 4 min, RT), and blocked with 5 % BSA in 
PBS + 0.3 % TritonX-100 (45 min, RT, gentle shaking). Then, the samples were stained with 
phospho-Histone H2A.X (Ser139) antibody (mouse), Clone JBW301 (1:500 in 
PBS + 0.3 % TritonX-100, 1 h, RT, gentle shaking) and washed twice with PBS (4 min, RT), 
once with TBST 400 mM NaCl (2 min, RT) and once with PBS (4 min, RT). The samples were 
stained with secondary goat anti-mouse AlexaFluor® 488 antibody (1:500) and DAPI 
(450 nM) in one dilution in 0.5 % BSA in PBS + 0.3 % TritonX-100 for 45 minutes at RT under 
gentle agitation. After the samples were washed (twice PBS 5 min, once TBST 400 mM NaCl 
2 min, PBS 5 min, H2O 2 min), they were embedded in Vectashield® Antifade Mounting Me-
dium and sealed with a glass coverslip. The samples were stored protected from light at 4 °C. 
3.2.6.3.2 Microscopy 
At least three images were taken per treatment and time point for each experiment with the 
standard settings (3.2.6) and the settings presented in Table 31. 
Table 31: Imaging settings for γH2AX foci staining 
Target Color Laser 
(nm) 
Laser inten-
sity (%) 
Gain (V) 
HNSCCUM
-02T 
Gain (V) 
RPMI2650 
PMT detec-
tion area 
(nm) 
Nuclei  blue 405 5.52 700 677.4 408-496 
Doxorubicin white 488 8.12 650 650 581-623 
γH2AX foci green 488 8.12 720 720 505-535 
Cy5-MSNs red 638 7.13 600 600 640-737 
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3.2.6.3.3 Analysis 
The images were handled with Fiji and opened in multichannel mode. The color balance was 
adjusted for each channel to reduce unspecific background staining. The scale was set to 
11.0979 pixels per µm and nuclei were encircled manually as the region of interest (ROI). 
This ROI was added in the γH2AX foci channel to the ROI manager. In that way, every nu-
cleus could be analyzed separately for the ratio of γH2AX foci area per nucleus. At least 50 
nuclei were evaluated per treatment and time point. The γH2AX foci channel was transformed 
to greyscale and the threshold was set to 80- 255 to remove the unspecific background sig-
nal. Next, the ratio of γH2AX foci area per nucleus was determined with the ‘Analyze Parti-
cles’ tool. The particle size was set to 0.12- ∞  µm² for HNSSCUM-02T and 0.08- ∞  for 
RPMI2650 samples, respectively, while the circularity was set to 0.00- 1.00 and a mean was 
generated for each experiment. Finally, the mean and standard deviation of three independ-
ent experiments were determined. 
3.2.6.4 Antibody-coupled nanoparticles 
The uptake and association of antibody-coupled NPs were examined by confocal laser scan-
ning microscopy. The experiment was performed in parallel with flow cytometry analysis 
(3.2.4.7) and antibody-coupled NPs were prepared according to 3.2.2.5. 
3.2.6.4.1 Sample preparation 
The HNSCCUM-02T cells (5 000 cells per well) and RPMI2650 cells (20 000 cells per well) 
were seeded in 200 µL per well µ-slides 8 well and let adhere for two days. Then, 2 µL of 
1 mg/ mL EGFR-MSNs, IgG2a-MSNs, Cy5-MSNs, or PBS were added to one well per cell 
line. After one hour or 24 hours incubation, respectively, the supernatants were removed and 
the samples were washed with PBS (3 times, 5 min, RT). Next, the cells were fixed with 4 % 
PFA (15 min, RT), the samples were washed again with PBS (3 times, 5 min, RT), and stored 
under light protection at 4 °C. Right before staining, cells were fixed with ice-cold acetone 
(4 min, RT), washed with PBS (3 times, 5 min, RT), and blocked with 1 % BSA in PBS 
(30 min, RT, gentle shaking, light protection). Samples were incubated with AlexaFluor® 555-
Phalloidin (1:40) and DAPI (450 nM) in one dilution in 1 % BSA in PBS (45 min, RT, gentle 
shaking, light protection), washed with PBS (3 times, 5 min, RT), and washed once with H2O 
for two minutes. Finally, samples were embedded in Vectashield® Antifade Mounting Medium 
and sealed with a glass coverslip. The samples were stored protected from light at 4 °C. 
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3.2.6.4.2 Microscopy 
At least five images were taken per treatment and time point for each experiment with the 
standard settings (3.2.6) and the settings presented in Table 32. 
Table 32: Imaging settings for targeted MSNs 
Target Color Laser 
(nm) 
Laser in-
tensity (%) 
Gain (V) 
HNSCCUM-
02T 
Gain (V) 
RPMI2650 
PMT detection 
area (nm) 
Nuclei  blue 405 5.51 721.2 671.7 408-479 
F-Actin red 552 7.17 637.4 637.4 555-638 
Cy5-MSNs green 638 8.95 508.8 508.8 640-737 
 
3.2.6.5 Biodistribution of Cy5-MSNs in chicken embryonic organs 
Several organs from chicken embryos (see 3.2.5) including the CAM with tumor were exam-
ined with confocal laser scanning microscopy to evaluate the in vivo distribution of Cy5-
MSNs. The preparation of paraffin sections and the DAPI staining were conducted with the 
technical assistance of Karin Benz. 
3.2.6.5.1 Preparation of paraffin sections and DAPI staining 
The washing and dehydration of the tissues were performed at RT and under light protection. 
First, the fixed tissues were washed thrice with deionized water for 20 minutes each and then 
were incubated in 70 % (V/V) isopropanol in deionized water for one hour. Next, the samples 
were incubated in 80 % (V/V) and then 90 % (V/V) isopropanol in deionized water for one hour 
each and in 100 % isopropanol for one and a half hours. Afterward, the tissues were incubat-
ed for two hours in xylene and overnight in fresh xylene. The cassettes were transferred to 
liquid paraffin, incubated for four hours at 60 °C, transferred to fresh liquid paraffin, and incu-
bated overnight at 60 °C. The embedding of the tissues was conducted with a Leica EG 
1140H tissue embedding center. The organs were placed in a small form, liquid paraffin was 
added, and the form was placed on a cooling plate. The paraffin tissue sections were cut with 
a Leica RM2165 rotary microtome to 3- 5 µm sections and placed on microscope slides. Sub-
sequently, the tissue sections were deparaffinated with the following protocol: incubation in 
xylene for five minutes twice, incubation in 100 %, 90 %, 80 %, 70 % (V/V) isopropanol in de-
ionized water for five minutes each, and five minutes incubation in deionized water. Finally, 
the samples were embedded in Vectashield® Hardset™ Antifade Mounting Medium with 
DAPI and solidified for at least 24 hours before microscopic analysis. 
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3.2.6.5.2 Microscopy 
The analysis of the paraffin sections was performed based on the above-mentioned standard 
protocol (3.2.6), however, a 40x objective and 1x zoom was used resulting in an image size 
of 290.622 µm2 and a pixel size of 141.982 nm2. At least five images were recorded per organ 
and Cy5-MSN concentration with the settings displayed in Table 33. 
Table 33: Imaging settings for in vivo distribution analysis 
Target Color Laser (nm) Laser intensity 
(%) 
Gain (V) PMT detection 
area (nm) 
Nuclei blue 405 3.70 678.3 408-479 
Autofluorescence green 488 8.13 628.9 503-548 
Cy5-MSNs red 638 8.17 542.6 640-720 
 
The images were exported with Fiji and the color balance was adjusted to 2- 255 for each 
channel. A scale bar was added representing 10 µm. 
3.2.7 mRNA expression analysis 
The mRNA expression was analyzed to determine a change in mRNA expression after RNA 
interference experiments and siRNA-loaded NP treatment. 
3.2.7.1 Sample preparation 
The cells were seeded in 6-well plates at 100 000 cells or according to 3.2.1.7. Then, the cells 
were incubated with different NP dispersions in different concentrations (10 µg/ mL, 
25 µg/ mL, 50 µg/ mL) for various time points (24, 72  and 96 hours) and PBS was applied as 
control (the applied NPs, concentrations and incubation times are stated in the respective 
results chapter). The media were discarded, the cells were briefly washed with PBS, and de-
tached with Accutase® solution. The medium was added to disperse the cells and the sam-
ples were transferred to centrifuge tubes. After centrifugation (1 500 rpm, 5 min, RT), the su-
pernatants were discarded, the samples were washed with PBS, and centrifuged again. The 
PBS was carefully removed with a pipette and the RNA was isolated. 
3.2.7.2 RNA isolation 
The RNA isolation was conducted with innuPREPRNA Mini kit according to the manufactur-
er’s protocol. First, 400 µL Lysis solution RL were added to the cell pellet and the sample was 
incubated at RT for two minutes. Next, the sample was dissolved by pipetting and incubated 
further for three minutes. The lysed sample was added to a Spin filter D and centrifuged 
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(12 000 rpm, 2 min, RT, Biofuge fresco). Afterward, the sample was mixed with 400 µL 70 % 
(V/V) ethanol in water until the solution was clear again, transferred to a Spin filter R, and 
centrifuged (12 000 rpm, 2 min, RT). The RNA remained on the filter and first was washed 
with 500 µL washing solution high-salt by centrifugation (12 000 rpm, 1 min, RT) and second, 
was washed with 700 µL washing solution low salt by centrifugation (12 000 rpm, 1 min, RT). 
The Spin filter R was centrifuged for three minutes (12 000 rpm, RT) to remove any remaining 
ethanol. Finally, 40 µL RNAse-free water were added to the middle of the filter, the sample 
was incubated for one minute, and centrifuged (8 000 rpm, 1 min, RT) in a 1.5 mL centrifuge 
tube. The RNA concentration was measured with NanoDrop 2000 Spectrophotometer and 
the isolated RNA was stored at -80 °C. 
3.2.7.3 cDNA transcription 
Aliquots containing 1 µg isolated RNA were diluted to 50 ng/ µL with DPEC-H2O in a final 
volume of 20 µL in 0.2 mL tubes on ice. Then, the diluted RNA was incubated at 65 °C for ten 
minutes in a Biometra® T personal 48 Thermocycler. Meanwhile, an adequate volume of the 
master mix for cDNA transcription was prepared on ice according to Table 34. 30 µL of cDNA 
transcription master mix were added per sample and the cDNA was transcribed with the fol-
lowing program in the Biometra® T personal 48 Thermocycler: Two minutes incubation at 
25 °C, 30 minutes incubation at 48 °C, and five minutes incubation at 95 °C. Finally, the sam-
ples were kept at 4 °C until storing at -20 °C. 
Table 34: Master mix for cDNA transcription 
Reagent 1x master mix 
Random Primer 1 µL 
25 mM MgCl2 8 µL 
10 mM nucleotide mix  5 µL 
10x buffer Applied Biosystems with 15 mM MgCl2 5 µL 
RNasin 0.5 µL 
M-MLV 0.5 µL 
DPEC-treated water 10 µL 
Total volume 30 µL 
 
3.2.7.4 Real-time polymerase chain reaction (qPCR) 
A real-time polymerase chain reaction assay was performed to determine the mRNA expres-
sion of the desired targets. The instructions by Applied Biosystems™ for TaqMan™ Gene 
Expression Analysis were adapted to generate the following protocol: The appropriate pri-
mers were thawed on ice under light protection and spun down before use. The cDNA was 
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either directly used after transcription or thawed on ice and was mixed before use. Each 
sample was analyzed in duplicate and a calibrator cDNA generated from untreated 
HNSCCUM-02T cells or HuH7-GFP cells was utilized, respectively. First, 5 µL (100 ng) per 
sample or calibrator sample were pipetted into a MicroAmp® Fast optical 96-well Reaction 
Plate per required well while DPEC-H2O was used as the negative control. The master-mixes 
for the target gene and the reference gene, namely large ribosomal protein (RPLPO), were 
prepared on ice and contained 10 µL TaqMan™ Universal PCR Master Mix, 1 µL 20x Primer 
and 4 µL DPEC-H2O per unit. In the next step, the reaction mixture was added to each well 
(15 µL), air bubbles were removed with a needle, the plate was tightly sealed with Micro-
Amp™ Optical Adhesive Film and briefly centrifuged to collect the samples in the bottom. A 
StepOnePlus™ was used to perform real-time polymerase chain reaction with the following 
incubation parameters: two minutes at 50 °C, ten minutes at 95 °C, and 40 cycles with 95 °C 
for 15 seconds and 60 °C for one minute. The fluorescence probe was measured at the 60 °C 
incubation step once per cycle. For analysis, the threshold was adjusted to 0.135233 for 
hnRNP K, to 0.074879 for GAPDH, to 0.149301 for eGFP, and to 0.137207 for RLPLO. The 
resulting threshold cycle CT was used to evaluate gene expression with the comparative 
ΔΔCT method. Untreated HNSCCUM-02T samples or HuH7-GFP samples were utilized as 
calibrator samples and RLPLO was employed as the reference gene, respectively [162]. The 
used equations are stated in Equation 7, Equation 8 and Equation 9. 
Equation 7 
∆CT = average CT(Target) − average CT (RPLPO) 
Equation 8 
∆∆CT =  ∆CT(Sample) − ∆CT(Calibrator) 
Equation 9 
𝑟elative mRNA expression = 2−∆∆CT 
3.2.8 EGFR protein expression analysis 
The protein expression of EGFR was analyzed in different cell lines by immunoblot analysis. 
All used solutions are stated in Table 12. 
3.2.8.1 Cell lysis 
The HNSCCUM-02T cells and HuH7 cells (400 000 cells per flask) were seeded in small cell 
culture flasks and incubated for three days. The RPMI2650 cells (500 000 cells per flask) 
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were also seeded in a small cell culture flask and incubated for four days. Then, the cells 
were washed once with cold PBS, 600 µL lysis buffer were added, and the cells were lysed 
for five minutes while incubated on ice. The cells were removed with a cell scraper and trans-
ferred to 1.5 mL centrifuge tubes. Next, the samples were sonicated for 30 seconds each 
(50 %, 0.5-second pulse), centrifuged (12 000 rpm, 10 min, 12 °C), and the supernatants were 
transferred to fresh 1.5 mL centrifuge tubes. The samples were stored at -20 °C. 
3.2.8.2 Protein quantitation 
The protein content in each sample was determined with DC™ Protein Assay according to 
the standard protocol. A standard curve from 0 to 4 µg/ mL BSA in lysis buffer was generated. 
First, 5 µL of protein standards (0, 0.25, 0.5, 1.0, 2.0 and 4.0 µg/ mL) in quadruplicates and 
5 µL per sample in triplicates were pipetted into a clear 96-well plate (flat bottom). Second, 
25 µL of freshly prepared reagent A’ (1 mL reagent A + 20 µL reagent S) were added to each 
well. Third, 200 µL of reagent B were added to each well and the plate was incubated in Mul-
tiskan Ascent Microplate Reader for ten minutes, shaken for ten seconds and the absorbance 
was measured at 750 nm. The protein content was quantified by means of the standard 
curve. 
3.2.8.3 Immunoblot sample preparation 
40 µg proteins were used per sample and diluted to 42 µL with lysis buffer. Subsequently, 
0.5 µL 5 % bromophenol blue and 100 mM dithiothreitol (DTT) were added to each sample. 
Then, the samples were boiled at 95 °C for ten minutes at 500 rpm in Thermomixer comfort, 
put on ice, briefly spun down, vortexed, spun down, and vortexed again. 
3.2.8.4 SDS-polyacrylamide gel electrophoresis 
A small discontinuous SDS-polyacrylamide gel was prepared with TGX Stain-Free™ Fast 
Cast™ Acrylamide Solutions 12 % kit according to the manufacturers’ instructions. The gel 
was placed in an electrophoresis chamber and electrophoresis buffer was added. The first 
lane was loaded with Thermo Scientific PageRuler Prestained Protein Ladder and 20 µg pro-
tein of each sample were carefully pipetted into the gel pockets. The electrophoresis ran at 
10 mA until all samples entered the separating gel, the protein separation was conducted with 
20 mA until the bromophenol blue left the gel. Then, the gel was removed from the chamber, 
placed in transfer buffer, and the protein bands were recorded with ChemiDoc™ MP Imaging 
System in the Stain-free gel modus for two and a half minutes. 
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3.2.8.5 Protein transfer 
The separated proteins were transferred to a polyvinylidene fluoride (PVDF) membrane via a 
semi-dry blot in a Trans-Blot® Turbo™ Transfer System. The PVDF membrane was shortly 
activated in methanol and incubated in the transfer buffer. The blotting papers were cut into 
appropriate pieces and were also incubated in the transfer buffer for 35 minutes at RT. First, 
two blotting papers were placed in the transfer chamber, then the PVDF membrane, the gel, 
and again two blotting papers. A hand drum was used to remove any air bubbles. The protein 
transfer was performed at 0.06 A for 90 minutes. Finally, the membrane was transferred to 
TBS-T20 recorded at ChemiDoc™ MP Imaging System in the stain-free blot modus and short-
ly incubated in TBS-T20. 
3.2.8.6 Protein detection 
3.2.8.6.1 EGFR 
First, the membrane was incubated in 5 % (m/V) non-fat dry milk in TBS-T20 (1 h, gentle shak-
ing, RT) to block unspecific binding. The membrane was washed with TBS-T20 three times for 
five minutes at RT while shaking. Then, the membrane was incubated with Anti-EGF Recep-
tor (D38B1) XP® mAb (1:1 000) in 5 % (m/V) BSA in TBS-T20 overnight at 4 °C under gentle 
agitation. The next day, the membrane was washed again with TBS-T20 three times for five 
minutes at RT while shaking. The membrane was incubated with an anti-rabbit IgG, HRP-
linked antibody (1:3 000) in 5 % (m/V) non-fat dry milk in TBS-T20 (1 h, gentle shaking, RT) 
and washed again three times for five minutes with TBS-T20. Then, a freshly prepared 1:1 
mixture of Western Lightning™ Plus enhanced luminol reagent and Western Lightning™ Plus 
oxidizing reagent was pipetted onto the membrane and incubated for two minutes in the dark. 
Visualization was performed with ChemiDoc™ MP Imaging System. 
3.2.8.6.2 β-Actin 
After membrane stripping (see 3.2.8.7), the membrane was blocked with 5 % (m/V) non-fat 
dry-milk in TBS-T20 for one hour at RT and washed three times for five minutes with TBS-T20. 
Then, the membrane was incubated with an anti-β-Actin monoclonal antibody overnight at 
4 °C under gentle agitation. The next day, the membrane was washed with TBS-T20 (3 times, 
5 min, RT) and the membrane was incubated with an anti-mouse IgG, HRP-linked antibody 
(1:3 000) in 5 % (m/V) non-fat dry milk in TBS-T20 (1 h, gentle shaking, RT) and washed again 
three times for five minutes with TBS-T20. Then, a freshly prepared 1:1 mixture of Western 
Lightning™ Plus enhanced luminol reagent and Western Lightning™ Plus oxidizing reagent 
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was pipetted onto the membrane and incubated for two minutes in the dark. Visualization was 
performed with ChemiDoc™ MP Imaging System. 
3.2.8.7 Membrane stripping  
The membrane was stripped between the detection of different proteins at RT. First, the 
membrane was incubated for 30 minutes in 25 mM Glycine pH 2.0 and second, the mem-
brane was incubated for 30 minutes with 1 % (m/V) SDS in desalted water. Finally, the mem-
brane was washed three times for ten minutes with TBS-T20. 
3.2.9 Statistical analysis 
All statistical evaluations were conducted with GraphPad Prism Software (Prism 5 for Win-
dows, version 5.04). The amount of independently performed experiments (N) was stated in 
the respective method description and the respective figure caption. All the data were ana-
lyzed with explorative and descriptive statistical methods. Usually, the arithmetic mean + 
standard deviation (S.D.) or the arithmetic mean ± S.D. were calculated and expressed in the 
figure caption, respectively. The exceptions were indicated there, too. However, it was not 
possible to test for normal distribution due to small sample sizes. Generally, the data were 
analyzed with a one-way analysis of variance (ANOVA) and Dunnett’s multiple comparison 
test or a two-way ANOVA and Bonferroni multiple comparisons test when applicable, respec-
tively. The performed tests and results were mentioned in the figure caption and tabular re-
sults are presented in the appendix (8.1). 
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4 Results 
In this chapter, the results of this project are presented in the following order: First, the char-
acteristics of the Cy5-MSNs were evaluated without loaded drugs (4.1 and 4.2) and second, 
Dox was loaded to Cy5-MSNs to study drug loading and release (4.3). Third, siRNA was in-
corporated into Cy5-MSNs with different loading protocols (4.4) and finally, targeting of the 
Cy5-MSNs was performed (4.5). 
4.1 Characteristics of Cy5-MSNs 
The MSNs were synthesized and characterized by Sven Kurch, member of the group of Prof. 
Dr. Wolfgang Tremel. Spherical NPs with different sizes and pore sizes were utilized depend-
ing on the purpose, i.e. MSNs with smaller pores were used for loading of the small molecule 
drug Dox and MSNs with larger pores were used for siRNA loading (see Table 35). 
Table 35: Nanoparticle characteristics 
MSNs Diameter 
(nm) 
Pore size 
(nm) 
Pore volume 
(cm3∙g-1) 
Specific surface 
area (m2∙g-1) 
SK-214 205 ± 21 10.0 0.989 503 
SK-267  130 ± 10 8.2 1.02 522 
SK-268  180 ± 18 5.7 0.8859 622 
SK-275  164 ± 14 11.7 0.7925 448 
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Figure 23: TEM images of predominantly used mesoporous silica nanoparticles 
(A) SK-267 with a magnification of a single particle in the right corner. (B) SK-268 and (C) 
SK-275. Scale: 100 nm. Images provided by Sven Kurch. 
The porous structure, spherical shape and even size distribution of the MSNs were observed 
in TEM images (Figure 23). The respective MSN diameter was determined by dynamic light 
scattering (DLS) and ranged from 130 ± 10 nm (SK-267) to 205 ± 21 nm (SK-214). Besides, 
the pore diameter and volume were determined by nitrogen sorption analysis and calculated 
using the Barrett, Joyner und Halenda (BJH) formula [163]. The MSNs SK-268 had the 
smallest pores, and the SK-214 had the greatest diameter but both were only used for exper-
iments with unloaded MSNs. The pore size of the MSNs SK-267 was about 8 nm, and these 
MSNs were used for drug loading and release experiments with Dox. However, MSNs with 
larger pores (SK-275) were synthesized to enable loading with siRNA. Moreover, the specific 
surface area was determined according to the Brunauer Emmett-Teller (BET) formula [163] 
and is depicted in Table 35. The specific surface area is dependent on the adsorbed nitrogen 
and the applied particle mass and provides an indication for possible loading efficiency in 
case of drug adsorption to the MSNs’ porous structure. The MSNs SK-267 had a greater 
specific surface area than the MSNs SK-275. All MSNs except SK-214 were labeled with the 
fluorescent dye Cy5 which allowed monitoring of the NPs via flow cytometry and confocal 
laser scanning microscopy. 
Furthermore, the sealing of the MSNs with ferrocene and β-CD was validated by several ex-
aminations: After MSNs (SK-267) were incubated with the gatekeeper solution, the ζ-potential 
changed from -19 mV to +12 mV, suggesting successful binding of the ferrocene and β-CD 
(data obtained by Sven Kurch). The application of the gatekeeper system was further exam-
ined with DLS, thermogravimetric analysis (TGA) and nitrogen sorption analysis (conducted 
by Sven Kuch, Figure 24). The diameter of the MSNs slightly increased after ferrocene and β-
CD addition (Figure 24A) and loss of organic mass was observed in TGA for ferrocene conju-
B CA
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gated MSNs (DMSN-AF) and fully sealed MSNs (DMSN-AFC, Figure 24B). Moreover, the 
pore size and pore volume were evaluated with nitrogen absorption (Figure 24C) after MSN 
sealing. The pore size of unfunctionalized and unsealed MSNs was about 8 nm on average 
and the hysteresis regions of the sorption isotherm were shifted to lower relative pressure 
after addition of the ferrocene and the ferrocene and β-CD, respectively. Also, a decrease in 
pore volume was noticed upon ferrocene conjugation and adding β-CD further decreased the 
pore volume. Taken together, conjugation of ferrocene and β-CD sealed the MSNs’ pores 
successfully. 
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Figure 24: (A) Dynamic light scattering, (B) thermogravimetric analysis, (C) pore size 
and pore volume of MSNs (SK-267) before and after addition of ferrocene and β -CD 
(A) A small increase in particle diameter was observed after incubation of the amino-
functionalized MSNs (DMSN-A) with ferrocene and β-CD (DMSN-AFC). (B) The mass loss 
for each functionalization step of the MSNs (DMSN) was analyzed by thermogravimetric 
analysis. With an increasing amount of organic coverage by  ferrocene (ferrocene-CA) and β-
CD, the mass loss increased. The decomposition of the separate components (β -CD, 
ferrocene-CA) and their inclusion complex (ferrocene-CA + β-CD) is presented, too. DMSN-
AF = ferrocene-conjugated and amino-functionalized MSNs. Both decomposition steps were 
visible, with inflection points at 210 °C and 400 °C. (C) The pore size distribution (x-axis) and 
pore volume (right y-axis) of the MSNs (DMSN), DMSN-AF, and DMSN-AFC, respectively. 
After the MSNs were functionalized with the gatekeeper, a shift in the hysteresis region of 
the sorption isotherm to lower relative pressure was observed.  The gatekeeper ’s attachment 
diminishes pore size and pore volume slightly.  Data obtained and graphics provided by Sven 
Kurch. 
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4.2 Properties of unloaded Cy5-MSNs in vitro and in vivo 
Unloaded Cy5-MSNs were first tested for biocompatibility and cellular uptake in vitro. Second, 
Cy5-MSNs were tested in vivo by means of the CAM assay and biodistribution was analyzed. 
4.2.1 MSNs are highly biocompatible in vitro 
The biocompatibility of unloaded NPs was examined in several human squamous cell carci-
noma cell lines of the head and neck, a hepatocellular carcinoma cell line, and in mouse em-
bryonic fibroblasts. The adherent cell lines were incubated with increasing concentrations of 
Cy5-MSNs (sealed with ferrocene and β-CD) up to 100 µg/ mL for 24 hours and the metabolic 
activity was analyzed. For all malignant cell lines, no substantial decrease in metabolic activi-
ty was observed. Yet, mouse embryonic fibroblasts exhibited a decreased metabolic activity 
when incubated with 5 µg/ mL Cy5-MSNs but the metabolic activity increased with higher NP 
concentrations and was not significantly different from controls. The hepatocellular carcinoma 
cell line HuH7 showed increased metabolic activity especially for high (50 and 100 µg/ mL) 
NP concentrations. Overall, Cy5-MSNs exhibited good biocompatibility in vitro and for most 
experiments, only 10 µg/ mL Cy5-MSNs were used. 
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Figure 25: Biocompatibility of Cy5-MSNs in different cell lines after 24 hours incuba-
tion 
The cell lines were incubated with Cy5-MSNs in increasing concentrations and metabolic 
activity was measured after 24 hours incubation. No difference in metabolic activity was 
observed in HNSCCUM-02T, RPMI2650 and Cal-33 cells. N=3, one-way ANOVA, P>0.05. 
HuH7 cells displayed increased metabolic activity for higher particle concentrations. N=3, 
one-way ANOVA, P=0.0223, Dunnett’s Multiple Comparison Test: 0 µg/ mL vs. 100 µg/ mL 
P < 0.05. Mouse embryonic fibroblasts (NIH-3T3) showed decreased metabolic activity for 
5 µg/ mL of Cy5-MSNs, but an insignificant increase in metabolic activity with increasing NP 
concentrations. N=4, one-way ANOVA, P=0.2741. 
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4.2.2 MSN are taken up by cancer cells and occur in the endolysosomal sys-
tem 
Next, the uptake of Cy5-MSNs (SK-268) was studied by flow cytometry and microscopic 
analysis. MSNs were sealed with two different caps, differing in the methyl-β-CD and NH2-β-
CD composition. Cap1 contained only methyl-β-CD, and Cap 2 contained NH2-β-CD:methyl-
β-CD 1:5 while the amount of ferrocene was consistent. HNSCCUM-02T cells were incubated 
with 10 µg/ mL Cap1-Cy5-MSNs and Cap2-Cy5-MSNs for 24 and 48 hours and then were 
analyzed by flow cytometry (Figure 26). 
The viability was assessed by FVD506 staining (Figure 26A) and no effect of the Cy5-MSNs 
on viability was observed (Figure 26B). Then, only viable cells were analyzed for NP associa-
tion by histograms of the APC channel representing the Cy5-signal (Figure 26C) and a time-
dependent uptake or binding was noticed, respectively. Yet, the different β-CD compositions 
did not influence the Cy5-MSN association as depicted in Figure 26D. 
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Figure 26: Cy5-MSN uptake in HNSCCUM-02T cells after 24 and 48 hours incubation 
(A) Exemplary histogram of FVD506 staining of Cap1-Cy5-MSN treated cells after 24 hours 
incubation. Viable cells were not stained by FVD506 and occur on the left in the histogram. 
(B) Cap1-Cy5-MSNs (Cap1) and Cap2-Cy5-MSNs (Cap2) do not reduce the viability of 
HNSCCUM-02T cells after 24 and 48 hours incubation measured by flow cytometry. N=3, 
two-way ANOVA: time: n.s., treatment: n.s. (C) Representative overlaid histogram of the 
Cy5-signal of Cap1-Cy5-MSN treated HNSCCUM-02T cells. A time-dependent shift of the 
histogram to the right is noted. (D) Normalized mean fluorescence intensity (MFI) of the 
Cy5-signal to PBS controls. No difference between Cap1 and Cap2 sealed Cy5-MSN 
association is seen in HNSCCUM-02T cells after 24 and 48 hours. Yet, the Cy5-signal 
increased with time, suggesting a time-dependent association or uptake of the NPs. N=3, 
mean + S.D., two-way ANOVA: interaction: P=0.3471 (n.s.), time: P=0.0535 (n.s.), 
treatment: P=0.0002 (significant). 
If the NPs were bound to the cells or incorporated could not be distinguished by flow cytome-
try. For that reason, NP uptake was also analyzed by confocal laser scanning microscopy, 
and representative images are shown in Figure 27. Most Cy5-MSNs (green) were observed 
around the nuclei, hence NPs were rather taken up by the cells than bound to the cellular 
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membrane after 24 and 48 hours incubation. Besides, z-stacks confirmed NP localization 
inside the cells (Data not shown). 
 
Figure 27: Uptake of Cap1-Cy5-MSNs after incubation in HNSCCUM-02T cells 
F-actin (red) represents the cellular structure, Cy5-MSNs are depicted in green, and the 
nuclei in blue. After 24 and 48 hours, most Cy5-MSNs were observed inside the cells around 
the nuclei. The number of detected NPs increased over time. Representative images are 
shown. Scale: 20 µm. 
Furthermore, the kinetics of Cy5-MSN uptake and the intracellular localization were analyzed 
in more detail. HNSCCUM-02T cells were incubated with 10 µg/ mL Cy5-MSNs (Cap1 
sealed) for increasing time intervals and co-stained with the early endosome marker EEA1 
and the endosome and lysosome marker Lamp1. Overall, 20 images were analyzed per time 
point per experiment for Cy5-positive vesicles per cell. As shown in Figure 28, after two and 
six hours, only a few NPs were associated with the cells, but after 24 and 30 hours circa two 
Cy5-positive vesicles per cell were detected. Moreover, after 48 hours incubation, more than 
three Cy5-positive vesicles per cell were found on average. A linear regression of the data 
was performed and suggested a linear NP uptake in HNSCCUM-02T cells which was in ac-
cordance with flow cytometry analysis. 
F-actin Cy5-MSNs merge with nuclei
24 h
No Cy5-
MSNs
48 h
Results  91 
 
Figure 28: Cy5-MSN uptake in HNSCCUM-02T cells analyzed by CLSM imaging 
The number of Cy5-positive (Cy5+) vesicles per cell was determined for 20 images pe r time 
point and experiment. Linear regression analysis was performed and proposed a linear 
increase in Cy5-MSN uptake over time. N=3, mean ± S.D., R2=0.8542. 
Representative images of the co-localization staining of Cy5-MSNs with EEA1 (Figure 29) 
and Lamp1 (Figure 30) are shown. After two hours incubation, NPs were present at the cellu-
lar membrane, but no signal overlap with EEA1 was noticed. Commencing from six hours 
incubation time, Cy5-MSNs were primarily detected inside the cells and co-localized with 
Lamp1. This observation is supported by co-localization analysis: The signal overlap of Cy5-
MSNs with the respective marker was analyzed and the Manders coefficient M1 (Equation 5) 
was determined (Figure 31). The values for no Cy5-MSN incubation (zero hours) represent 
background staining. Only about 30 % of Cy5-MSNs co-localized with EEA1 after six hours 
incubation, hence, were associated with early endosomes. However, at the same time about 
60 % of Cy5-MSNs co-localized with Lamp1 and starting at 24 hours incubation time, almost 
all Cy5-MSNs exhibited a Lamp1 signal overlap. Therefore, Cy5-MSNs were most likely pre-
sent in endosomes and lysosomes after 24 hours incubation. Taken together, Cy5-MSNs 
were taken up by squamous cell carcinoma cells in a time-dependent manner, were found in 
endosomes and lysosomes, but did not reduce metabolic activity and therefore, were highly 
biocompatible in vitro. 
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Figure 29: Co-localization staining of Cy5-MSNs and early endosome marker EEA1 
HNSCCUM-02T cells were incubated with 10 µg/ mL Cy5-MSNs for the indicated time points, 
fixed, and stained with EEA1. In the top row, merged images (F-actin: white, nuclei: blue, 
EEA1: green and Cy5-MSNs: red) are shown. In the bottom row, merged images of EEA1 
and Cy5-MSNs (marked with arrows) are depicted. After two hours incubation, single Cy5-
MSNs were observed at the cellular membrane but without visible co-localization with EEA1. 
A time-dependent NP internalization was also seen. Sections of representative images of 
three independent experiments. Scale: 10 µm. 
 
Figure 30: Co-localization staining of Cy5-MSNs and endosome and lysosome marker 
Lamp1 
After HNSCCUM-02T cells were incubated with 10 µg/ mL for the indicated time points, 
staining of Lamp1 was conducted. Merged images (F-actin: white, nuclei: blue, EEA1: green 
and Cy5-MSNs: red) are presented in the top row. Below, merged images of Lamp1 and 
Cy5-MSNs (marked with arrows) are shown. Single Cy5-MSNs occurred at the cellular 
membrane after 2 hours incubation. Starting at 6 hours, NPs mainly co-localized with Lamp1 
(signal overlap in yellow) and a time-dependent uptake was observed. Sections of 
representative images of three independent experiments.  Scale: 10 µm. 
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Figure 31: Analysis of Cy5-MSN signal overlap with EEA1 and Lamp1 
A time-dependent increase in signal overlap was observed for  both markers but overlap with 
EEA1 remained stable after 6 hours. After 24 hours, almost all Cy5-MSNs co-localized with 
Lamp1. Hence, Cy5-MSNs were present in endosomes and lysosomes after 6 hours of 
incubation. Per experiment, 10 images were analyzed per  time point and marker. N=3, 
mean + S.D. Two-way ANOVA: Interaction: P<0.0001; Time: P<0.0001; Marker: P<0.0001 
4.2.3 MSNs are biocompatible in vivo 
Next, the biocompatibility was assessed in vivo by means of the CAM-model. Chicken em-
bryos with tumors on their CAM were injected with two different doses of Cy5-MSNs, and the 
survival rate was determined after 24 hours incubation. No significant difference between the 
control group and the Cy5-MSNs injected groups was recognized as shown in Figure 32. On 
average, 70- 80 % of chicken embryos survived the injection of NPs or sodium chloride solu-
tion, respectively. So, Cy5-MSNs also showed great biocompatibility in vivo. 
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Figure 32: Survival analysis of chicken embryos after Cy5-MSN treatment 
Cy5-MSNs were injected into the CAM of chicken embryos with tumors and survival was 
observed after 24 hours. The survival of the control group (0.9 % NaCl) and the Cy5-MSN 
injected group was not significantly different. Hence, Cy5-MSNs exhibited good in vivo 
biocompatibility. N=3- 5, one-way ANOVA: P=0.5559. 
4.2.4 MSNs are retrieved in different chicken embryonic tissues 
The biodistribution of Cy5-MSNs was also examined in vivo by means of the CAM assay. The 
chicken embryos were sacrificed 24 hours after NP injection and several organs and the CAM 
with tumor were removed, fixed, and processed for paraffin sectioning. Nuclei were stained 
with DAPI and the tissue sections were analyzed by CLSM (Figure 33). No NPs were ob-
served in control tissues (data not shown). The most Cy5-MSNs were noticed in the liver, the 
organ with the highest blood flow. Also, many Cy5-MSNs were detected in the glomeruli of 
the kidneys. Some NPs were found in the blood vessels of the CAM and even in the tumor. 
Rarely, Cy5-MSNs were seen in capillaries of the heart, but no particles were observed in the 
brain. So, the injected NPs were retrieved in different organs and the tumor. 
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Figure 33: Biodistribution of Cy5-MSNs in vivo 
1 mg/ mL Cy5-MSNs were injected into the CAM of chicken embryos and after 24  hours 
incubation, tissues were removed and processed for CLSM. The nuclei are depicted in blue, 
the tissue autofluorescence in green, and the NPs in red (also marked with arrows). The 
CAM/ tumor border is indicated by the dotted line. Representative images are shown. Some 
Cy5-MSNs were detected in the CAM and occasionally in the tumor. The most Cy5 -MSNs 
occurred in the liver and the glomeruli of the kidney. Rarely NPs were noticed in capillaries 
of the heart and no particles were found in the brain.  Scale: 50 µm. 
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4.3 Drug loading and release of Cy5-MSN 
After good biocompatibility and uptake by cells of Cy5-MSNs were confirmed, the drug load-
ing and release of Cy5-MSNs were tested with the model chemotherapeutic drug Dox in 
HNSCCUM-02T and RPMI2650 cells. 
4.3.1 HNSCC cells are sensitive to doxorubicin 
First, the sensitivity of HNSCCUM-02T and RPMI2650 cells to Dox after 24 and 48 hours was 
analyzed and the respective half-maximal reduction in metabolic activity (IC50) was deter-
mined (Figure 34, Appendix: Table 48, Table 49). A time- and concentration-dependent effect 
was observed in both cell lines. With 24 hours incubation time, the IC50 for HNSCCUM-02T 
cells was 1.57 µM and for RPMI2650 cells 0.75 µM, respectively. So, both cell lines exhibited 
high sensitivity to Dox, yet RPMI2650 cells were more sensitive than HNSCCUM-02T cells. 
Taken together, Dox was suited as a model drug and release from NPs could be studied by 
toxicity analysis in both cell lines. 
 
Figure 34: Determination of half maximal reduction in metabolic activity of doxorubicin 
in (A) HNSCCUM-02T and (B) RPMI2650 cells 
The dotted line indicates a 50 % reduction in metabolic activity. A time- and concentration-
dependent effect was observed in both cell lines. RPMI2650 cells were more sensitive to 
Dox than HNSCCUM-02T cells. N=3, mean ± S.D. IC50 (HNSCCUM-02T, 24 h)= 1.569 µM, 
R²=0.8899, IC50 (HNSCCUM-02T, 48 h)= 0.1935 µM, R²=0.9588, IC50 (RPMI2650, 24 h)= 
0.7496 µM, R²=0.9672, IC50 (RPMI2650, 48 h)= 0.1314 µM, R²=0.9772. 
4.3.2 Doxorubicin is successfully loaded to Cy5-MSNs 
Dox was loaded to Cy5-MSNs by incubation of naked MSNs with Dox solution overnight and 
then the Dox-MSNs were sealed with ferrocene and NH2-β-CD. Unloaded Cy5-MSNs were 
used as control. The amount of loaded Dox was calculated by adding the remaining Dox in 
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the supernatants and subtracting it from the initially applied Dox. However, the Dox loading 
efficiency ranged widely from 6 % to 69 % (SK-267, 5 mg/ mL Dox loading solution). The suc-
cessful loading was also confirmed visually because the NP pellet was stained red by Dox as 
depicted in Figure 35. 
 
Figure 35: Representative image of control Cy5-MSNs (left) and Dox-MSNs (right) 
The NPs were centrifuged to obtain pellets. Cy5-MSNs appeared light brown due to 
ferrocene/ NH2-β-CD capping while Dox stained Dox-MSNs in red and the capped particles 
appeared dark brown. 
4.3.3 Dox-MSNs remain stable over at least four days in different media 
The Cy5-MSNs were loaded with Dox and incubated in different media at cell culture condi-
tions for 24 and 96 hours. Then, the supernatants were analyzed for Dox with fluorescence 
measurements and compared to a standard curve generated in the respective medium. No 
release of Dox from Dox-MSNs was observed in PBS, H2O, and DMEM after 24 and 96 hours 
compared to controls (Figure 36). However, less than 6 % of loaded Dox seemed to have 
been released from Dox-MSNs in DMEM + 5 % FCS after 96 hours incubation but unloaded 
control NPs also falsely showed Dox release of about 3 %. So, Dox-MSNs remained stable 
over four days in different media and only negligible Dox release was observed. 
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Figure 36: Doxorubicin release from Dox-MSNs in different media after one day and 
four days incubation at cell culture conditions 
(A) The released concentration of Dox determined by fluorescence and (B) Dox release 
relative to loaded Dox in Dox-MSNs are shown. Cy5-MSNs were used as controls. No 
substantial release of Dox in the different media was observed. However, DMEM  + 5 % FCS 
also showed increased Dox signal in controls. N=3, mean + S.D. 
4.3.4 Dox-MSNs exhibit a retarded drug release in HNSCC cells 
After Dox-MSNs did not release Dox in different media, HNSCCUM-02T and RPMI2650 cells 
were treated with Dox-MSNs to evaluate drug release in vitro. The drug release was meas-
ured by Dox signal and viability staining in flow cytometry analysis, reduction in metabolic 
activity due to toxic effects of Dox, and DNA damage as shown by γH2AX foci staining. 
4.3.4.1 Dox-MSNs reduce the metabolic activity of HNSCC cells 
In the beginning, Cy5-MSNs were loaded with a 2 mg/ mL Dox solution, but even though 
5 nmol Dox per µg Cy5-MSN were used, only a small amount of Dox was loaded to the NPs. 
Unfortunately, the total of the loaded drug could not be determined because the whole 
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amount of used Dox was retrieved in the supernatants. Still, a retarded drug release was no-
ticed in HNSCCUM-02T and RPMI2650 cells by means of a reduction in metabolic activity as 
shown in Figure 37. Free Dox (2 µM) induced a time-dependent decrease in relative metabol-
ic activity compared to PBS treated controls. The cells were either treated with Dox-MSNs or 
Cy5-MSNs for 24, 48, or 96 hours, respectively, or the treatment solutions were removed af-
ter 24 or 48 hours and the cells were incubated further without NPs. In HNSCCUM-02T cells 
(Figure 37A), Dox-MSNs began to reduce the relative metabolic activity after 48 hours incu-
bation. Incubation for 96 hours reduced the metabolic activity to about 30 % independent of 
NP removal in between. In RPMI2650 cells (Figure 37B), free Dox had the same effect as in 
HNSCCUM-02T cells. However, Dox-MSNs reduced the metabolic activity already after 
24 hours incubation, but a retarded release was still noticed compared to free Dox. Removal 
of NPs also had no effect on the efficacy of Dox-MSNs. Hence, the Dox-MSNs which were 
taken up by the cells, released the Dox inside the cells and a decrease in metabolic activity 
was observed. 
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Figure 37: Effect of 2 µM Dox and 10 µg/ mL Dox-MSNs (loaded with 5 nmol Dox per µg 
Cy5-MSN) on (A) HNSCCUM-02T and (B) RPMI2650 cells 
The cell lines were incubated with 2 µM Dox, 10 µg/ mL Dox-MSNs, or Cy5-MSNs for the 
indicated times, respectively, and PBS was applied as a control. After 24 and 48 hours, the 
media with NPs were removed and cells were incubated further for 72 or 48  hours (until 
96 hours total incubation time). The metabolic activity was normalized to PBS controls.  Free 
Dox reduced the metabolic activity more than half after 24  hours incubation. A retarded drug 
release was noticed in both cell lines, beginning after 24 hours incubation time. After 
96 hours, no difference in metabolic activity was observed between the cells which were 
incubated the whole time with MSNs and the cells which had the NPs removed in the 
meantime. N=3, mean + S.D., (A) two-way ANOVA: interaction: P<0.0001; treatment: 
P<0.0001, time: P<0.0001; Bonferroni multiple comparisons Cy5-MSNs vs. Dox-MSNs: 24 h 
and 48 h: P>0.05; 24 h +72 h, 48 h + 48 h and 96 h: P<0.0001. (B) Two-way ANOVA: 
interaction: P=0.0415; treatment: P<0.0001; t ime: P=0.1622: Bonferroni multiple 
comparisons Cy5-MSNs vs. Dox-MSNs: 24 h: P>0.05; 48 h: P<0.01; 24 h + 72 h and 96 h: 
P<0.001; 48 h + 48 h: P<0.0001. 
4.3.4.2 Successful Dox-MSN uptake and Dox release in HNSCC cells 
Next, the loading protocol for Dox-MSNs was adjusted to increase Dox loading and to enable 
the analysis of the loading efficiency. A higher concentrated Dox solution (5 mg/ mL) was 
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used, but less total Dox (2.15 nmol per µg Cy5-MSN) was applied for loading. The capping 
protocol remained the same while more washing steps were necessary to remove excess 
Dox. The loading efficiency ranged from 6- 31 %, resulting in 4.2 ± 2.2 µM Dox when 
10 µg/ mL Dox-MSNs were used. To further examine the uptake and release of Dox-MSNs, 
HNSCCUM-02T cells were treated with 10 µg/ mL Dox-MSNs or Cy5-MSNs and incubated 
for 24 or 96 hours. Then, cells were analyzed by flow cytometry for viability, Cy5-MSN up-
take, and Dox signal as depicted in Figure 38. Cells were stained with a viability dye 
(FVD780) before analysis. 
 
Figure 38: (A) Viability, (B) nanoparticle uptake and doxorubicin signal of HNSCCUM-
02T cells after 1 µM Dox, 10 µg/ mL Dox-MSN (loaded with 2.15 nmol Dox per µg Cy5-
MSN), and Cy5-MSN treatment for 24 and 96 hours 
(A) The viability of HNSCCUM-02T cells was assessed with FVD780. After 24 hours, no 
substantial cytotoxic effects of Dox and Dox-MSNs were observed. After 96 hours 
incubation, Dox and Dox-MSNs had killed almost all cells, while Cy5-MSNs did not reduce 
the viability. N=3, mean + S.D, two-way ANOVA: interaction: P<0.0001, time: P<0.0001, 
treatment: P<0.0001. (B) Single cells in the stated gate (dead and viable cells) after 
24 hours incubation. About 90 % of all free Dox treated cells exhibited a Dox-signal. More 
than 50 % of Dox-MSN treated cells were positive for Cy5 and Dox, but also about 40  % of 
the cells contained free Dox. Fewer Cy5-MSNs were taken up than Dox-MSNs by 
HNSCCUM-02T cells after 24 hours incubation. N=3, mean + S.D, two-way ANOVA: 
interaction: P<0.0001, population: P<0.0001, treatment: P=1.0000 (n.s.). 
After 24 hours incubation, no significant reduction in viability was observed for 1 µM Dox and 
Dox-MSN treated cells compared to controls (Figure 38A). Incubation for 96 hours reduced 
viability drastically after Dox and Dox-MSN treatment, while controls showed negligible de-
crease in viability. Since the number of dead cells was comparable and small after 24 hours 
of treatment, single cells (viable and dead) were analyzed for Cy5 (MSN) and Dox signal 
(Figure 38B). A dot plot was used to characterize the cells. As expected, PBS treated control 
cells were Cy5 and Dox negative and more than 90 % of 1 µM Dox treated cells exhibited a 
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Dox signal. So, Dox was already inside the cells but had not killed the cells yet. When cells 
were treated with Dox-MSNs, two major populations were observed: About 50 % of all single 
cells were positive for Cy5 and Dox, but almost the same number of cells was Cy5 negative 
and Dox positive. There was great variability between experiments (Appendix: Figure 56), so 
both populations had a large standard deviation. Only about 30 % of cells treated with Cy5-
MSNs showed a Cy5 signal. Hence, Dox-MSN uptake was better than Cy5-MSN uptake in 
HNSCCUM-02T cells. As expected, no Dox signal was detected in Cy5-MSN treated cells. 
Overall, Dox-MSNs were detected in HNSCCUM-02T cells after 24 hours incubation while 
cells were still alive and after longer incubation time Dox caused cell death. 
4.3.4.3 Dox-MSNs induce DNA damage in HNSCC cells 
In parallel, the release of Dox was further studied by means of γH2AX foci which indicate 
DNA damage repair sites in the nucleus. HNSCCUM-02T (Figure 39) and RPMI2650 (Figure 
40) cells were treated with 1 µM Dox, 10 µg/ mL Dox-MSNs or Cy5-MSNs for two and 
24 hours, respectively. Then, cells were fixed and immunofluorescence staining for γH2AX 
foci was performed. Representative images are shown below. PBS treated control cells and 
Cy5-MSN treated cells exhibited only a small number of γH2AX foci after both treatment 
times. When cells were treated with Dox, already after two hours many γH2AX foci were ob-
served in the nuclei, but less γH2AX foci were seen in cells treated with Dox-MSNs at the 
same time point. After 24 hours incubation, the number of γH2AX foci increased in Dox treat-
ed cells and greatly increased in Dox-MSN treated cells. The γH2AX foci area per nucleus 
was analyzed for all treatment groups (at least 50 nuclei per treatment and experiment) and 
the results are presented in Figure 41. The analysis confirmed the visual observations: After 
24 hours of Dox-MSN treatment increased the amount of γH2AX foci significantly in both cell 
lines. So, a retarded release of Dox from Dox-MSNs was observed. 
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Figure 39: Detection of DNA damage by γH2AX foci staining in HNSCCUM-02T cells 
after 1 µM Dox, 10 µg/ mL Dox-MSN (loaded with 2.15 nmol Dox per µg Cy5-MSN), or 
Cy5-MSN treatment, respectively 
Nuclei are depicted in blue, Cy5-MSNs in red and γH2AX foci in green. Free Dox induced 
DNA damage after 2 hours incubation while Dox-MSNs did induce less DNA damage. After 
24 hours, the DNA damage strongly increased in these treatment groups. No DNA damage 
was seen in PBS and Cy5-MSN treated cells after 2 and 24 hours incubation. Representative 
images out of three independent experiments are shown. Scale: 20 µm. 
 
Figure 40: Detection of DNA damage by γH2AX foci staining in RPMI2650 cells after 
1 µM Dox, 10 µg/ mL Dox-MSN (loaded with 2.15 nmol Dox per µg Cy5-MSN) or Cy5-
MSN treatment, respectively 
Merged images are shown with nuclei in blue, Cy5-MSNs in red and γH2AX foci in green. 
Some DNA damage was induced by 1 µM Dox after 2 hours incubation, Dox-MSNs did 
induce less DNA damage. After 24 hours the DNA damage increased in these treatment 
groups. PBS and Cy5-MSN treated cells exhibited no DNA damage after 2 and 24 hours 
incubation. Representative images out of three independent experiments are shown. Scale: 
20 µm. 
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Figure 41: Analysis of foci area per nucleus in (A) HNSCCUM-02T and (B) RPMI2650 
cells after 2 and 24 hours incubation with 1 µM Dox, 10 µg/ mL Dox-MSNs, or Cy5-
MSNs, respectively 
After 2 hours incubation with Dox about 45 % of the nucleus area contained γH2AX foci, 
whereas in Dox-MSN treated cells only 20 % of the nuclei were covered by γH2AX foci. After 
24 hours incubation, the foci area per nucleus increased significantly for both cell lines. 
Also, γH2AX foci were barely detected in PBS and Cy5-MSN treated controls. Two-way 
ANOVA, Bonferroni multiple comparisons: Dox-MSNs 2 h vs. 24 h: (A) P<0.01; (B) P<0.05; 
n=3, mean + S.D. 
4.3.4.4 Proteins in the medium do not influence the effect of Dox-MSNs 
Also, the effect of FCS on Dox-MSN efficacy was analyzed in HNSCCUM-02T cells. Dox-
MSNs and Cy5-MSNs prepared for analysis of release in different media (see 4.3.3) were 
applied in DMEM/F12 with FCS (DMEM/F12 + FCS) or DMEM/F12 without FCS (DMEM/F12) 
for 24 and 96 hours (Figure 42), respectively. The metabolic activity was measured and nor-
malized to PBS treated cells in DMEM/F12 + FCS. Cells treated with Dox and Dox-MSNs 
exhibited a time-dependent decrease in metabolic activity independent from incubation with 
or without FCS. Yet, an overall decrease in metabolic activity was observed in cells incubated 
without FCS and after 24 hours Dox-MSN exposition, a greater reduction of metabolic activity 
was noticed compared to cells incubated with FCS. After 96 hours of incubation, Dox-MSNs 
exhibited the same effect on metabolic activity in both incubation media. Still, the difference in 
the reduction of metabolic activity by Dox-MSN treatment after 24 hours must be evaluated 
carefully due to the general influence of missing FCS on metabolic activity. Taken together, a 
retarded Dox release from Dox-MSN was observed independently from the incubation medi-
um. 
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Figure 42: Treatment of HNSCCUM-02T cells with 2 µM Dox, 10 µg/ mL Dox-MSNs or 
Cy5-MSNs in (A) medium with (DMEM/F12 + FCS) or (B) without (DMEM/F12) FCS for 24 
or 96 hours, respectively 
The metabolic activity was normalized to PBS controls incubated with FCS. A time -
dependent decrease in metabolic activity was noticed after 2  µM Dox and Dox-MSN 
treatment. Cells incubated without FCS for 24 hours had an overall slightly decreased 
metabolic activity compared to cells incubated with FCS. So, the reduced metabolic activi ty 
after 24 hours of Dox-MSN treatment in DMEM/F12 needs to be evaluated carefully. N=3, 
mean + S.D. 
Overall, the obtained data indicated that the model drug Dox was released in a retarded 
manner and intracellularly from Dox-MSNs at an effective dose. So, Cy5-MSNs were suited 
as drug carriers for small molecule drugs. 
4.4 Cy5-MSNs as siRNA nanocarriers 
After the small molecule drug Dox was successfully loaded into and released from Cy5-
MSNs, siRNA loading and release were examined. Different NPs and loading protocols were 
tested and modified. Since it is more difficult to study siRNA efficiency, distinctive model sys-
tems were used. On one side, a stable enhanced green fluorescent protein (eGFP) express-
ing hepatocarcinoma cell line, namely HuH7-GFP, was exploited as a model system to test 
siRNA-MSN efficiency, and on the other side, FAM™-labeled siRNA was used to evaluate 
different loading protocols. Also, the nucleic-acid binding protein and p53 cofactor heteroge-
neous nuclear ribonucleoprotein K (hnRNP K) was utilized as an example target for RNA in-
terference experiments. It was previously shown, that a reduction of hnRNP K expression 
sensitized HNSCC cells to irradiation, and inhibited cellular migration [164,165]. Therefore, 
hnRNP K is an interesting target for siRNA induced protein expression regulation. 
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4.4.1 Reduction of eGFP expression in stable eGFP expressing cell line 
First, the stable eGFP expressing cell line (HuH7-GFP, Figure 43A) was used as a model 
system to test eGFP knockdown by Silencer® GFP (eGFP) siRNA (eGFP-siRNA) executed 
with Lipofectamine™ RNAiMAX transfection reagent (Lipo). This eGFP knockdown by regular 
transfection was examined as a positive control (Figure 43B, C and D). HuH7-GFP cells were 
transfected with eGFP-siRNA and Silencer® Select Negative Control siRNA #2 (nsRNA) for 
24 hours, then the transfection reagents were removed, and the cells were further incubated 
for 48 (total incubation time 72 hours) or 72 hours (total incubation time 96 hours), respective-
ly. The cells were harvested, stained for viability, and analyzed by flow cytometry for viability 
and eGFP content. The transfection did not reduce the viability of the cells, only the viability 
of eGFP-siRNA treated cells was reduced by less than 20 % (controls 10 %) after 72 hours 
incubation (Figure 43B). Moreover, cells transfected with eGFP-siRNA showed a reduced 
eGFP signal compared to Lipo and nsRNA treated cells depicted by an exemplary overlaid 
histogram (Figure 43C). Two populations of HuH7-GFP cells were noticed in the histogram by 
the means of two peaks, one small population with a high eGFP expression (peak on the 
right), and one large population with a medium eGFP expression (peak in the middle). After 
eGFP knockdown by eGFP-siRNA, the peaks were shifted to the left, corresponding to de-
creased eGFP expression and the peak associated with high eGFP expression was greatly 
reduced. Overall, eGFP expression decreased by 70 % (72 hours) or 75 % (96 hours) com-
pared to untreated control cells while nsRNA did not reduce eGFP expression. 
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Figure 43: HuH7-GFP cells as a model system 
(A) Exemplary image of HuH7-GFP cells. Scale: 20 µm. (B) Viability of HuH7-GFP cells after 
eGFP-siRNA transfection measured by flow cytometry. After incubation for 72 and 96  hours 
after transfection, cells were stained with FVD780 for dead cells. Transfection with eGFP -
siRNA or nsRNA did not reduce the viability. Mean + S.D. , triplicates. (C) Exemplary overlaid 
histogram (with a logarithmic scale) of viable cells in the GFP channel 72 hours after 
transfection. Lipofectamine™ RNAiMAX (Lipo) treated cells and nsRNA transfected cells 
were used as controls. Two peaks corresponding to two populations were observed. A small 
peak on the right indicating high rates of eGFP expression and a large peak in the middle 
indicating medium rates of eGFP expression. The eGFP signal of eGFP-siRNA transfected 
cells was shifted to the left indicating a reduction in eGFP expression. (D) Transfection 
efficiency normalized to untreated control HuH7-GFP cells. EGFP-siRNA reduced the eGFP 
expression by about 70 % after 72 hours and 75 % after 96 hours incubation time. NsRNA 
transfection did not reduce the eGFP expression. N=1. 
4.4.2 No eGFP knockdown is observed after eGFP-siRNA-MSN treatment in 
HuH7-GFP cells 
The MSNs (SK-267) were loaded with eGFP-siRNA or nsRNA, respectively, and sealed with 
ferrocene and NH2-β-CD. Unloaded Cy5-MSNs were used as controls. Adherent HuH7-GFP 
cells were treated with 10 or 20 µg/ mL eGFP-siRNA-MSNs, nsRNA-MSNs, or Cy5-MSNs for 
72 or 144 hours, respectively. Then, cells were harvested, stained for viability, and analyzed 
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by flow cytometry. Treatment with eGFP-siRNA-MSNs and nsRNA-MSNs did not affect the 
viability independent of incubation time and NP concentration (Figure 44A, B), respectively. 
The NP uptake was observed by the Cy5-signal and an improved uptake by eGFP-siRNA-
MSNs and nsRNA-MSNs was noticed also dependent on the applied concentration, especial-
ly after 72 hours incubation (Figure 44C, D). Moreover, the Cy5-signal of eGFP-siRNA-MSNs 
and nsRNA-MSNs decreased over time while the signal of Cy5-MSNs remained relatively 
stable. However, eGFP expression was not reduced by eGFP-siRNA-MSNs after 72 hours 
incubation (Figure 44E), while after 144 hours, 20 µg/ mL eGFP-siRNA-MSNs slightly re-
duced eGFP expression compared to nsRNA-MSNs and Cy5-MSNs (Figure 44F). So, either 
the eGFP-siRNA amount loaded to the Cy5-MSNs or the NP amount was not enough for a 
significant knockdown of eGFP or the eGFP-siRNA was not released in time to reduce eGFP 
protein expression. 
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Figure 44: Treatment of HuH7-GFP cells with 10 and 20 µg/ mL eGFP-siRNA-MSNs, 
nsRNA-MSNs and Cy5-MSNs for (A, C, E) 72 and (B, D, F) 144 hours, respectively 
Treatment with eGFP-siRNA-MSNs, nsRNA-MSNs, and Cy5-MSNs did not affect the viability 
at (A) 72 hours and (B) 144 hours after treatment. The NP uptake was measured by Cy5-
signal and a higher Cy5-signal for eGFP-siRNA-MSNs and nsRNA-MSNs was observed (C, 
D). After (C) 72 hours a greater difference between 10 and 20 µg/ mL MSNs was seen than 
after (D) 144 hours. The Cy5-signal of eGFP-siRNA-MSNs and nsRNA-MSNs decreased 
over time while the signal of Cy5-MSNs remained relatively stable. (E) Even though eGFP-
siRNA-MSNs were taken up, they did not reduce the mean fluorescence intensity of the 
eGFP signal independent of the applied concentrations after 72 hours. (F) After 144 hours, 
20 µg/ mL eGFP-siRNA-MSNs slightly reduced the eGFP expression compared to controls 
(nsRNA-MSNs, Cy5-MSNs). An overall increase of eGFP expression from 72 to 144 hours 
after treatment was noticed. N=1. 
4.4.3 siRNA-MSNs do not reduce mRNA expression after 96 hours incubation 
As no reduction in eGFP protein expression could be detected in HuH7-GFP cells, it was 
speculated that the siRNA loading efficiency was too small because the siRNA would barely 
fit in the pores of SK-267 (pore size: 8.2 nm, siRNA: ~7 nm × 2 nm [6]). For this reason, dif-
ferent MSNs with larger pores (SK-275,11.7 nm pores) were used for siRNA loading. Moreo-
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ver, the uncapped MSNs were functionalized by amino groups and therefore were positively 
charged while the siRNA was negatively charged. Strong electrostatic binding was expected 
to lead to impaired siRNA release thus, the amino groups were saturated by ferrocene before 
siRNA loading. Higher NP concentrations were applied to compensate for the expected de-
crease in loading efficiency. Also, mRNA expression was analyzed instead of protein expres-
sion, because mRNA reduction occurs and is detectable earlier than a reduction in protein 
expression, respectively. In line with this, two different siRNA-MSNs were studied in 
HNSCCUM-02T and RPMI2650 cells. One part of MSNs was loaded with FAM™-siRNA tar-
geting GAPDH (FAM™-siRNA-MSNs) and another part of MSNs was loaded with Silenc-
er® Select siRNA hnRNP K (hnRNP K-siRNA-MSNs). Besides, nsRNA-MSNs were used as 
control. The HNSCCUM-02T and RPMI2650 cells were treated with 50 µg/ mL FAM™-
siRNA-MSNs, hnRNP K-siRNA-MSNs, nsRNA-MSNs, and PBS for 24 or 96 hours, respec-
tively. A transfection with Lipo was performed as a positive control, mRNA expression was 
normalized to calibrator samples, and analyzed with the comparative ΔΔCT method (see 
3.2.7.4). In both cell lines, FAM™-siRNA transfection greatly reduced the GAPDH mRNA 
expression (Figure 45A, B) but not the hnRNP K mRNA expression. Yet, hnRNP K-siRNA 
transfection decreased hnRNP K and GAPDH mRNA expression 96 hours after transfection 
in both cell lines. So, the positive controls confirmed that GAPDH and hnRNP K mRNA ex-
pression could be detected by quantitative real-time PCR and were still reduced 96 hours 
after transfection. When HNSCCUM-02T cells were treated with FAM™-siRNA-MSNs, no 
reduction in GAPDH mRNA expression was observed after 24 and 96 hours (Figure 45C). In 
RPMI2650 cells, the GAPDH mRNA expression was also not affected by FAM™-siRNA-
MSNs (Figure 45D). HnRNP K-siRNA-MSNs did slightly reduce the hnRNP K mRNA expres-
sion in HNSCCUM-02T cells after 24 hours compared to nsRNA-MSNs (Figure 45E), howev-
er, no difference in hnRNP K expression to PBS treated controls was seen. After 96 hours 
incubation, the hnRNP K mRNA expression did not differ between hnRNP K-siRNA-MSN and 
nsRNA-MSN treated cells. Also, in RPMI2650 cells was observed no effect of hnRNP K-
siRNA-MSNs on hnRNP K mRNA expression after both incubation times (Figure 45F). The 
experiment was only performed once, so results must be evaluated carefully. Nevertheless, 
50 µg/ mL siRNA-MSNs did not reduce mRNA expression in HNSCCUM-02T and RPMI2650 
cells after 24 and 96 hours incubation, respectively. 
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Figure 45: Analysis of hnRNP K and GAPDH mRNA expression after incubation with 
50 µg/ mL FAM™-siNRA-MSNs and hnRNP K-siRNA-MSNs in (A, C, E) HNSCCUM-02T 
and (B, D, F) RPMI2650 cells, respectively 
Transfection with Lipo and FAM™-siRNA, Lipo and hnRNP K siRNA, or Lipo and nsRNA in 
(A) HNSCCUM-02T cells and (B) RPMI2650 cells was performed as  a positive control, 
respectively. A great reduction in GAPDH mRNA expression was observed for FAM ™-siRNA 
transfected cells compared to nsRNA transfected controls after 96  hours. Yet, GAPDH 
mRNA expression was also reduced in hnRNP K siRNA transfected cells. Transfection with 
hnRNP K siRNA led to a decrease in hnRNP K mRNA expression compared to nsRNA 
transfected controls. The (C, D) GAPDH mRNA expression of FAM™-siRNA-MSN treated 
cells was not reduced after 24 and 96 hours incubation compared to nsRNA-MSN treated 
cells (dotted lines) in (C) HNSCCUM-02T cells and (D) RPMI2650 cells, respectively. 
Moreover, (E, F) hnRNP K mRNA expression did not decrease after hnRNP K-siRNA-MSN 
treatment in (E) HNSCCUM-02T cells and (F) RPMI2650 cells compared to PBS or nsRNA-
MSN treated cells (dotted lines). N=1. 
4.4.4 Less siRNA loading after MSNs are preincubated with ferrocene 
So far, siRNA loading and release could not be proven. For that reason, siRNA loading to 
Cy5-MSNs (SK-275) was examined in more detail by using FAM™-siRNA and applying dif-
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ferent protocols for sealing. It was speculated that the ferrocene preincubation might impair 
siRNA loading, thus it was examined if siRNA loading is still possible when amino groups 
were partly saturated by ferrocene (Table 36). In the next step, the FAM™-siRNA was loaded 
to the NPs overnight and NH2-β-CD was added. 
Table 36: Preincubation with ferrocene before FAM™-siRNA loading to MSNs 
Label c(ferrocene) in µg/ mL n(FAM™-siRNA) in pmol 
A 0 500 
B 54.1 500 
C 89.6 500 
Control (Co) 133.2 500 
Standard 493.5 0 
 
The FAM™-siRNA-MSNs were centrifuged, the pellets were observed at Darkreader™ 195 M 
Transilluminator, and photographically documented as shown in Figure 46. Only MSNs which 
were not preincubated with ferrocene exhibited a strong fluorescence corresponding to suc-
cessful FAM™-siRNA loading. When MSNs were preincubated with ferrocene, only weak 
FAM™-siRNA fluorescence was observed. So, preincubation with ferrocene did reduce the 
siRNA loading too much as that a facilitated release would compensate for the missing 
amount of siRNA. 
 
Figure 46: FAM™-siRNA loading to MSNs preincubated with ferrocene 
MSNs were first incubated with different amounts of ferrocene as depicted in Table 36, then 
FAM™-siRNA was added overnight, and particles were capped with the same amount of 
NH2-β-CD. After centrifugation, the pellets were examined at Darkreader™ 195 M 
Transilluminator and documented. Only MSNs without ferrocene preincubation (A) showed a 
strong fluorescence signal representing FAM™-siRNA loading. 
4.4.5 Encapsulation of MSNs with Lipofectamine™ RNAiMAX improves cellular 
uptake 
Because siRNA loading and release could not be proven so far, a new method for siRNA-
MSN preparation had to be developed. Moreover, it was speculated that the siRNA-MSNs 
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were taken up by the endolysosomal system (data shown in 4.2.2) so, the siRNA could have 
been degraded before it could exhibit its effects. For this reason, NPs were incubated with 
Lipofectamine™ RNAiMAX instead of ferrocene and NH2-β-CD after siRNA loading to im-
prove cellular uptake and siRNA release independent of the endolysosomal system. 
First, an encapsulation protocol with Lipo for siRNA-MSNs was developed. The MSNs (SK-
275, pore size 11.7 nm) were loaded with FAM™-siRNA or nsRNA as control and encapsu-
lated with different amounts of Lipo for different times and at different temperatures according 
to Table 37, respectively. 
Table 37: Lipo encapsulation parameters for Lipo-FAM™-siRNA-MSNs 
Label RNA Incubation parameters µL Lipofectamine™ 
RNAiMAX per µg MSN 
A1 FAM™-siRNA 1 h (RT) 0.3 
B1 FAM™-siRNA 1 h (RT) 0.4 
A3 FAM™-siRNA 3 h (4 °C) 0.3 
B3 FAM™-siRNA 3 h (4 °C) 0.4 
ACo nsRNA 1 h (RT) 0.3 
BCo nsRNA 3 h (4 °C) 0.4 
 
The Lipo-FAM™-siRNA-MSNs and Lipo-nsRNA-MSNs were centrifuged and the pellets were 
illuminated with Darkreader™ 195 M Transilluminator as shown in Figure 47. Lipo-FAM™-
siRNA-MSNs exhibited a high brightness while no difference in brightness was observed be-
tween the differently encapsulated Lipo-FAM™-siRNA-MSNs. Besides, Lipo-nsRNA-MSNs 
showed a reduced brightness compared to Lipo-FAM™-siRNA-MSNs. So, FAM™-siRNA was 
successfully loaded to MSNs independent of the Lipo incubation protocol and the siRNA load-
ing was remarkably higher than after ferrocene preincubation (Figure 46). 
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Figure 47: Lipo-FAM™-siRNA-MSN pellets after different loading protocols 
Different Lipo-FAM™-siRNA-MSNs were prepared according to Table 37, centrifuged, and 
illuminated with Darkreader™ 195 M Transilluminator. The labels correspond to the labels in 
Table 37. Lipo-FAM™-siRNA-MSNs exhibited a high brightness while control Lipo-nsRNA-
MSNs showed a reduced brightness. No difference in brightness was observed for different 
Lipo-FAM™-siRNA-MSNs. 
Moreover, the toxicity of Lipo incubated MSNs was studied in HNSCCUM-02T cells. The cells 
were treated with 10 µg/ mL Lipo-FAM™-siRNA-MSNs or Lipo-nsRNA-MSNs for 24 hours, 
respectively, and the metabolic activity was assessed. All Lipo-FAM™-siRNA-MSNs de-
creased the metabolic activity by about 40 % compared to H2O treated controls. The Lipo-
nsRNA-MSNs reduced metabolic activity less. The experiment was only performed once, so 
the results must be evaluated carefully. Still, it was most likely that Lipo was in fact bound to 
the NPs because transfection with Lipo also induces (minor) toxicity (data not shown). For 
most further experiments, less Lipo was used for encapsulation (0.1 µL/ µg MSN) to keep the 
toxicity as low as possible and siRNA-MSNs were incubated for three hours at 4 °C with Lipo 
to protect the siRNA. 
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Figure 48: Toxicity of differently encapsulated Lipo-siRNA/ nsRNA-MSNs in HNSCCUM-
02T cells after 24 hours incubation 
The cells were treated with 10 mg/ mL Lipo-FAM™-siRNA-MSNs or Lipo-nsRNA-MSNs for 
24 hours and the metabolic activity was measured. The Lipo-FAM™-siRNA-MSNs reduced 
the metabolic activity by 40 % compared to H2O treated controls, independent from the 
encapsulation parameters. The Lipo-nsRNA-MSNs decreased metabolic activity less. N=1, 
mean of triplicates. 
Furthermore, the influence of the Lipo encapsulation of siRNA-MSNs on cellular uptake was 
studied. HNSCCUM-02T cells were incubated with 10 µg/ mL Cy5-MSNs (ferrocene and NH2-
β-CD sealed MSNs according to the standard protocol), Lipo-FAM™-siRNA-MSNs, or Lipo-
MSNs for 24 and 96 hours, respectively. Then, the cells were stained for viability and were 
analyzed by flow cytometry. The incubation of MSNs with Lipo decreased the viability of Lipo-
FAM™-siRNA-MSN and Lipo-MSN treated cells after 24 hours by about 10 % compared to 
Cy5-MSN treated cells (Figure 49A). After 96 hours incubation, no difference in viability was 
observed between the different capped MSNs. The Cy5 signal of Lipo-FAM™-siRNA-MSNs 
and Lipo-MSNs was remarkably increased compared to Cy5-MSNs after 24 hours incubation 
(Figure 49B), so Lipo encapsulation enhanced the NP uptake tremendously. After 96 hours 
incubation, the Cy5-signal differed only a bit, but it was still better for Lipo-FAM™-siRNA-
MSNs and Lipo-MSNs. So, Lipo encapsulation greatly improved the NP uptake. However, the 
FAM™ signal was about the same for Lipo-FAM™-siRNA-MSNs and Lipo-MSNs after 
24 hours incubation (Figure 49C) probably caused by Lipo autofluorescence in the detection 
range. After 96 hours, the FAM™ signal was almost completely reduced to the level of the 
control cells (Cy5-MSNs, PBS). The experiment was only performed once (with triplicates), 
for that reason, the results must be evaluated with care. Taken together, the Lipo encapsula-
tion of MSNs decreased the viability only minimally while increasing the NP uptake massively. 
The FAM™ signal of Lipo-FAM™-siRNA-MSNs could not be distinguished from Lipo-MSNs, 
so no FAM™-siRNA presence in the cells could be proven. 
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Figure 49: Comparison of nanoparticle uptake in HNSCCUM-02T cells after 24 and 
96 hours incubation 
MSNs (SK-275) were sealed with ferrocene and NH2-β-CD (Cy5-MSNs) or Lipo (Lipo-MSNs). 
Also, MSNs were loaded with FAM™-siRNA and encapsulated with Lipo (Lipo-FAM™-siRNA-
MSNs). HNSCCUM-02T cells were incubated with 10 µg/ mL MSNs and analyzed by flow 
cytometry after 24 and 96 hours. The (A) viability was assessed by FVD780 staining. After 
24 hours, the viability of Lipo-sealed MSN treated cells was marginally decreased compared 
to PBS controls and Cy5-MSN treated cells, respectively. (B) Lipo sealing remarkably 
increased the Cy5 signal after 24 hours compared to Cy-MSNs. The difference was less 
after 96 hours of incubation. (C) The FAM™ signal of FAM™-siRNA was also analyzed. After 
24 hours incubation, the same FAM™ signal was detected in Lipo-FAM™-siRNA-MSN and 
Lipo-MSN treated cells. So, Lipo might exhibit autofluorescence in that range. The FAM™ 
signal was diminished after 96 hours of incubation. N=1, mean of triplicates. 
4.4.6 Higher concentrations of Lipo-eGFP-siRNA-MSNs do not reduce eGFP 
expression in HuH7-GFP cells 
Since a better uptake of Lipo-MSNs compared to Cy5-MSNs was observed, it was examined 
if higher concentrations of Lipo-eGFP-siRNA-MSNs could reduce eGFP expression in HuH7-
GFP cells. If more NPs were applied, more eGFP-siRNA should have been transported into 
HuH7-GFP cells. In one experiment, HuH7-GFP cells were incubated with 10 µg/ mL Lipo-
eGFP-siRNA-MSNs or Lipo-nsRNA-MSNs for 96 hours, respectively, and in a second exper-
iment, 25 µg/ mL Lipo-MSNs, Lipo-eGFP-siRNA-MSNs or Lipo-nsRNA-MSNs were applied 
for 96 hours. Also, the cells were transfected with eGFP-siRNA as a positive control and 
nsRNA as a negative control. The dead cells were stained, and the samples were analyzed 
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by flow cytometry for viability, Cy5-signal, and eGFP signal. When HuH7-cells were incubated 
with 10 µg/ mL Lipo-eGFP-siRNA-MSNs or Lipo-nsRNA-MSNs, respectively, no substantial 
reduction in viability was observed (Figure 50A). However, 25 µg/ mL Lipo-MSNs, Lipo-
nsRNA-MSNs, and Lipo-eGFP-siRNA-MSNs reduced the viability of HuH7-GFP cells by 
about 10 % compared to PBS treated controls (Figure 50B). The control transfections with 
eGFP-siRNA did not affect the cellular viability in both experiments. Besides, NP uptake was 
examined by means of the Cy5 mean fluorescence intensity (MFI) and a great difference be-
tween 10 µg/ mL (Figure 50C) and 25 µg/ mL (Figure 50D) Lipo-eGFP-siRNA-MSNs was 
observed. Although only 2.5 times more NPs were applied, the Cy5 signal for 25 µg/ mL Lipo-
eGFP-siRNA-MSNs was about 5.5 times higher than for 10 µg/ mL Lipo-eGFP-siRNA-MSNs. 
Still, the NPs were prepared for each experiment separately and the experiments were only 
performed once (with triplicates per treatment), so results must be evaluated carefully. More-
over, the eGFP MFI was determined to examine eGFP expression (Figure 50E and F). Both 
eGFP-siRNA control transfections reduced the eGFP expression of HuH7-GFP cells by about 
80 %. 10 µg/ mL Lipo-eGFP-siRNA-MSNs did not decrease the eGFP expression. Unfortu-
nately, no effect on eGFP expression was seen for 25 µg/ mL Lipo-eGFP-siRNA-MSNs com-
pared to Lipo-nsRNA-MSNs. 
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Figure 50: Treatment of HuH7-GFP cells with (A, C, E) 10 and (B, D, F) 25 µg/ mL Lipo-
eGFP-siRNA-MSNs for 96 hours analyzed by flow cytometry 
(A) 10 µg/ mL Lipo-eGFP-siRNA-MSNs and Lipo-nsRNA-MSNs did not reduce the viability 
compared to PBS treatment. (B) 25 µg/ mL Lipo-eGFP-siRNA-MSNs and Lipo-nsRNA-MSNs 
decreased the cellular viability by circa 15 % compared to PBS. (C) The Cy5-signal was 
comparable for 10 µg/ mL Lipo-eGFP-siRNA-MSNs and Lipo-nsRNA-MSNs. (D) When HuH7-
GFP cells were treated with 25 µg/ mL MSNs, the signal was greater than after 10 µg/ mL 
treatment but did not differ between Lipo-MSNs, Lipo-eGFP-siRNA-MSNs, and Lipo-nsRNA-
MSNs, respectively. (E) Cells transfected with eGFP-siRNA exhibited a reduction of the 
eGFP signal of about 80 % compared to nsRNA transfected cells. 10 µg/ mL Lipo-eGFP-
siRNA-MSNs did not decrease the eGFP signal. (F) The positive control (eGFP-siRNA 
transfection) showed a reduced eGFP signal, while 25 µg/ mL Lipo-eGFP-siRNA-MSNs did 
not diminish the eGFP signal. N=1, mean of triplicates. 
Furthermore, the eGFP mRNA expression was studied after treatment of HuH7-GFP cells 
with 10 µg/ mL and 25 µg/ mL Lipo-eGFP-siRNA-MSNs, respectively. A protocol for eGFP 
mRNA expression detection was established and relative eGFP mRNA expression (normal-
ized to calibrator) was greatly reduced after eGFP-siRNA transfection for 72 hours compared 
to nsRNA transfection (Figure 51A). Although 10 µg/ mL Lipo-eGFP-siRNA-MSNs decreased 
relative eGFP mRNA expression compared to Lipo-nsRNA-MSN treated cells (Figure 51B), 
the relative eGFP mRNA expression did not differ from PBS treated HuH7-GFP cells. When 
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25 µg/ mL Lipo-eGFP-siRNA-MSNs were applied, also no reduction in relative eGFP mRNA 
expression compared to PBS, Lipo-nsRNA-MSNs, and Lipo-MSNs was noticed. 
 
Figure 51: EGFP mRNA expression in HuH7-GFP cells after (A) eGFP transfection and 
(B) Lipo-eGFP-siRNA-MSN treatment for 72 hours 
(A) HuH7-GFP cells transfected with eGFP-siRNA had a greatly reduced eGFP mRNA 
expression compared to nsRNA transfection. (B) 10 µg/ mL Lipo-eGFP-siRNA-MSNs 
reduced the eGFP mRNA expression compared to Lipo-nsRNA-MSNs but not compared to 
PBS. The same effect was observed for 25 µg/ mL Lipo-eGFP-siRNA-MSNs. N=1. 
Overall, Lipo-eGFP-siRNA-MSNs neither decreased eGFP expression nor eGFP mRNA ex-
pression in HuH7-GFP cells independent from the applied concentration and incubation 
times. 
4.5 Active targeting of Cy5-MSNs in vitro 
Another approach to enhance NP uptake uses active targeting moieties that target cell sur-
face structures dominantly expressed on malignant cells. About 90 % of HNSCC cells highly 
express EGFR. Therefore, a monoclonal EGFR-antibody that binds the extracellular domain 
of the EGFR was utilized for targeting. First, EGFR expression in two different HNSCC cell 
lines, namely HNSCCUM-02T and RPMI2650, was analyzed. As depicted in Figure 52 by 
immunoblot analysis and immunofluorescence staining, HNSCCUM-02T cells highly ex-
pressed EGFR while RPMI2650 barely express EGFR. For this reason, both cell lines were 
used to validate EGFR-targeting success by EGFR-antibody conjugated MSNs. 
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Figure 52: EGFR expression in HNSCCUM-02T and RPMI2650 cells 
(A) Immunoblot analysis of EGFR expression in HNSCCUM-2T and RPMI2650 cells. 
HNSCCUM-02T cells highly express EGFR while RPMI2650 cells barely express EGFR. 
Immunofluorescence staining of EGFR with (B, C) anti-EGFR antibody (Thermo Fisher 
Scientific) or (D, E) anti-EGFR antibody (CST). Merged images with EGF receptors depicted 
in green, nuclei in blue and F-actin in red are presented. High EGFR expression of 
HNSCCUM-02T cells (B, D) was demonstrated with both antibodies. In accordance with 
immunoblot analysis was no EGFR expression identified in  RPMI2650 cells (C, E). 
Representative images are shown. Scale bar: 10 µm. 
4.5.1 Antibodies are successfully conjugated to MSNs 
The antibody conjugation to the MSNs was performed with a linker molecule. The linker con-
tained polyethylene glycol moieties for spacing and an N-hydroxysuccinimide ester for cou-
pling the amino groups of the NH2-β-CD with an amide bond. After antibodies were sulfhy-
drated with Traut’s reagent, (SH)x-antibodies were conjugated by a disulfide bond replacing a 
2-pyridyldithio group. As mentioned above, a monoclonal anti-EGFR mouse IgG2a antibody 
was used, so as unspecific control a mouse IgG2a control antibody was utilized. The Cou-
pling Factor (CF, see 3.2.2.5.1) was determined for each experiment to evaluate the coupling 
success. As presented in Figure 53A, the CF for EGFR-MSNs and IgG2a-MSNs was signifi-
cantly greater than for Cy5-MSNs. However, when the CF was normalized to Cy5-MSNs in 
the respective experiment, one experiment showed a greater coupling success than the other 
experiments (Figure 53B). Still, successful antibody conjugation was proven for each experi-
ment. 
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Figure 53: Coupling Factor and normalized Coupling Factor of antibody conjugation to 
MSNs 
The determination of the CF is described in detail in 3.2.2.5.1. (A) The CF is significantly 
higher for EGFR-MSNs and IgG2a-MSNs compared to Cy5-MSNs. N=4, mean ± S.D., one-
way ANOVA: P=0.0107; Dunnett’s Multiple Comparison Test: Cy5 -MSNs vs. EGFR-MSNs: 
P<0.05, Cy5-MSNs vs. IgG2a-MSNs: P<0.05. (B) When data were normalized to Cy5-MSNs, 
only one experiment showed a great coupling efficiency while the other experiments had 
similar coupling efficiencies. 
4.5.2 EGFR-MSNs are faster taken up by high EGFR expressing cells than 
IgG2a-MSNs 
As mentioned above, active targeting should improve cellular NP uptake. This hypothesis 
was tested by comparing the MSN association between a high EGFR expressing cell line, 
HNSCCUM-02T, and a low EGFR expressing cell line, RPMI2650, respectively. Moreover, 
different incubation times were analyzed, and the results are presented in Figure 54. Single 
cells were plotted in a dot plot dependent on viability and Cy5 signal, then were gated in four 
populations. 
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Figure 54: Uptake of 10 µg/ mL Cy5-MSNs, EGFR-MSNs and IgG2a-MSNs in (A, C) 
HNSCCUM-02T and (B, D) RPMI2650 cells after (A, B) 1 hour and (C, D) 24 hours incu-
bation analyzed by flow cytometry 
Single cells were gated for alive + Cy5, alive - Cy5, dead + Cy5, and dead - Cy5. Overall, no 
effect on viability was seen. (A) About 90 % of high EGFR expressing HNSCCUM-02T cells 
were alive with Cy5 signal after 1 hour incubation after EGFR-MSN treatment while IgG2a-
MSN treatment led to less MSN association. The lowest uptake was observed for Cy5-MSN 
treatment and no NPs were detected in PBS treated cells.  (B) In low EGFR expressing 
RPMI2650 cells, the MSN association was not enhanced by EGFR-targeting after 1 hour 
incubation, but high standard deviations between experiments occurred. After 24 hours 
incubation no difference between Cy5-MSN, EGFR-MSN and IgG2a-MSN treatment was 
noticed in (C) HNSCCUM-02T and (D) RPMI2650 cells. Almost all single and alive cells of 
both cell lines had taken up the MSNs and antibody-conjugated MSNs. N=3, mean + S.D. 
Overall, the viability was not affected by Cy5-MSN, EGFR-MSN and IgG2a-MSN treatment 
after one hour and 24 hours incubation in both cell lines, respectively. Also, no Cy5 positive 
population was identified after PBS treatment in both cell lines and after both time points. Af-
ter one hour EGFR-MSN incubation in HNSCCUM-02T cells (Figure 54A), about 85 % of the 
single cells were positive for Cy5 whereas about 70 % of all cells were positive for Cy5 after 
IgG2a-MSN treatment. Yet, incubation with Cy5-MSNs for one hour only led to 33 % Cy5 pos-
itive cells on average but with a high standard deviation. In contrast, no difference in the Cy5 
signal was observed after 24 hours incubation of the different NPs in HNSCCUM-02T cells 
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(Figure 54C). In RPMI2650 cells, great differences in the Cy5 signal between experiments 
were noticed in all MSN treatment groups after one hour incubation (Figure 54B). Besides, no 
substantial differences of alive and Cy5 positive cells were detected between Cy5-MSN and 
antibody-conjugated MSN treated cells. The amount of alive and Cy5 positive RPMI2650 
cells was smaller than the amount of corresponding HNSCCUM-02T cells one hour after 
treatment, and after 24 hours incubation time, all MSN treated RPMI2650 cells were Cy5 pos-
itive (Figure 54D). In conclusion, EGFR-targeting accelerated MSN uptake in high EGFR ex-
pressing HNSCCUM-02T cells compared to low EGFR expressing RPMI2650 cells while via-
bility was not impaired. 
4.5.3 Active targeting of eGFP-siRNA-MSNs does not reduce eGFP mRNA ex-
pression 
Active targeting against EGFR revealed an accelerated uptake of EGFR-MSNs. So, eGFP-
siRNA-MSNs were also conjugated with the EGFR-antibody and eGFP mRNA expression 
was analyzed in HuH7-GFP cells. HuH7 cells exhibit less EGFR expression than HNSCCUM-
02T cells, nevertheless, EGFR protein expression was still detectable (Figure 55A). First, 
MSNs were loaded with eGFP or nsRNA overnight, respectively, second, MSNs were sealed 
with ferrocene and NH2-β-CD, and third, EGFR-antibodies or IgG2a-antibodies were conju-
gated to the eGFP-siRNA-MSNs and nsRNA-MSNs, respectively. PBS treatment was used 
as a control. After 72 hours incubation with 10 µg/ mL of various MSNs, the RNA was isolat-
ed, transcribed to cDNA and a qPCR was conducted with eGFP as the target gene and 
RPLPO as the reference gene. The eGFP mRNA expression was normalized to untreated 
HuH7-GFP cells (calibrator samples) as presented in Figure 55B. No reduction in relative 
eGFP mRNA expression was observed for eGFP-siRNA-MSNs, EGFR-eGFP-siRNA-MSNs, 
and IgG2a-eGFP-siRNA-MSNs compared to the PBS control, indicated by the dotted line. At 
the same time, neither nsRNA-MSNs nor EGFR-nsRNA-MSNs nor IgG2a-nsRNA-MSNs de-
creased the relative eGFP mRNA expression. However, the experiment was only performed 
once, so results must be evaluated carefully. Taken together, active targeting did not facilitate 
eGFP-siRNA-MSN efficacy in HuH7-GFP cells. 
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Figure 55: (A) EGFR expression in HNSCCUM-02T and HuH7 cells and (B) relative 
eGFP mRNA expression in HuH7-GFP after 10 µg/ mL EGFR-eGFP-siRNA-MSN treat-
ment for 72 hours  
(A) Immunoblot analysis was performed with the assistance of Simone Mendler. HuH7 cells 
expressed less EGFR than HNSCCUM-02T but an EGFR expression was sti ll detectable. Β-
actin was used as control. (B) MSNs were first loaded with eGFP-siRNA or nsRNA, sealed 
with ferrocene and NH2-β-CD, and conjugated to EGFR or IgG2a antibodies, respectively. 
HuH7-GFP cells were treated with 10 µg/ mL of the stated MSN variants for 72 hours and 
then the RNA was isolated, transcribed to cDNA, and qPCR was performed. The dotted line 
indicates relative eGFP mRNA expression for PBS controls. Neither eGFP-siRNA-MSNs nor 
EGFR-eGFP-siRNA-MSNs nor IgG2a-eGFP-siRNA-MSNs reduced the relative eGFP mRNA 
expression in HuH7-GFP cells. All nsRNA-MSN controls also not affected relative eGFP 
mRNA expression. N=1. 
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5 Discussion 
The aim of this work was to evaluate MSNs as drug carriers for head and neck squamous cell 
carcinoma therapy in vitro. In general, drug carriers should meet certain criteria that qualify 
them for the use as drug delivery vehicles. First, the system must be classified as safe. Sec-
ond, efficient drug loading and release must be ensured and third, the delivery and efficacy of 
the loaded drug must be proven at the target site. The evaluation of these parameters regard-
ing the examined MSN drug carrier system will be discussed in the following subchapters. 
5.1 Characteristics and safety of the drug delivery system 
One major advantage of MSNs is the possibility to generate various shapes, particle and pore 
sizes dependent on the synthesis parameters such as time, stirring velocity, and the used 
surfactant. The here applied MSNs had a spherical shape and a hydrodynamic diameter be-
tween 140 and 200 nm after conjugation of the gatekeeper system dependent on the particle 
batch. In general, the MSNs exhibited a uniform size distribution and shape observed in TEM 
images and with DLS measurements. Gratton et al. discovered that the NP shape and size 
influence the cellular uptake of MSNs: On the one side, MSN rods are taken up the best 
compared to spheres, cylinders, and cubes for particle sizes greater than 100 nm [72]. On the 
other side, the smaller the NP size the higher the possibility that the NPs are taken up by 
chance by caveolae-dependent endocytosis or macropinocytosis, respectively [166]. In con-
trast, larger NPs (> 50 nm) must be usually incorporated by receptor-mediated endocytosis, 
so the uptake efficiency of untargeted NPs is also dependent on surface modifications. In this 
work, it was shown that the spherical MSNs with the gatekeeper system were present in en-
dosomes and lysosomes after six hours incubation time, so a general uptake occurred. How-
ever, incubation of the MSNs with Lipofectamine RNAiMAX, a cationic lipid formulation for 
experimental siRNA transfection, tremendously increased cellular uptake. Presumably, this 
effect was dependent on the membrane penetration capability of cationic lipids and the posi-
tive surface charge [69,100]. The cellular membrane is negatively charged and could interact 
with the positively charged Lipo-MSNs [69], hence the Lipo encapsulated MSNs could be 
taken up passively in a high number. Still, it is not known, and was not examined if the cellu-
lar uptake was mediated passively by electrostatic interaction or actively by endocytosis. 
Slowing et al. found that positively charged NPs are taken up faster by human cancer cells 
than neutral or negatively charged NPs [70]. Hence, not only the application of the cationic 
lipids but also the ferrocene/ β-CD gatekeeper system enhanced the uptake probability be-
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cause a positive charge was detected for the sealed MSNs. Still, the ζ-potential measure-
ments were not conducted in a physiological milieu, so the Cy5-MSNs did not have a protein 
corona during measurements. When NPs are incubated in a serum enriched medium, a pro-
tein corona develops and the characteristics of the NPs change. For example, the uptake of 
MSNs without a protein corona is better than the uptake of MSNs with a protein corona [167]. 
Yet, the extent of the protein corona of the here applied Cy5-MSNs was not analyzed, there-
fore, it can only be speculated that the positive surface charge enhanced NP uptake. In vivo, 
the nanoparticle uptake is also dependent on the evasion of the mononuclear phagocytic sys-
tem (MPS). On the one side, an MSN size of 100- 200 nm is favorable for MPS evasion [80] 
and on the other side, coating with PEG enhances blood circulation times [58,75]. For this 
reason, a modification of the NH2-β-CD with PEG should be considered to improve the in vivo 
compatibility. 
A major characteristic of the MSNs is their dendritic structure which generates pores that can 
be loaded with drugs. These pores must be sealed with a gatekeeper system to prevent un-
controlled drug release and a plethora of gatekeeper systems for MSNs are described in the 
literature (see 1.3.2.2). Usually, the pores should be opened inside the cancer cells or the 
extracellular environment of the tumor. Thus, these systems should react to internal or exter-
nal stimuli, e.g. acidic pH, reducing or oxidizing agents, light. Here, the examined drug deliv-
ery system had a capping system that reacted to intracellular stimuli. The redox- and pH-
sensitive gatekeeper system was constructed as follows: Ferrocenecarboxaldehyde was con-
jugated to the amino-functionalized MSNs via an imine bond that is cleaved by protonation in 
an acidic environment. So, when the MSNs were taken up by endocytosis, the imine bond 
could be cleaved in the endosomes and lysosomes (pH gradient from 6.2 to 4.6) [168]. Be-
sides, the ferrocene stalk is encircled by β-cyclodextrin via so-called host-guest interactions 
i.e. through hydrophobic interactions which are weakened upon oxidation of the iron [169]. 
Then, the pores are opened, and the cargo can be released. The functionality of this system 
was described by Xiao et al. and Khashab et al. who studied controlled release of Rhodamine 
B but did not examine the system in vitro and in vivo [64,170]. Intracellularly, oxidizing agents 
such as ROS, which are byproducts of the cellular oxidative metabolism and also include hy-
drogen peroxide [171], can oxidize the iron and thereby decrease the hydrophobic interaction 
with the β-CD [170]. However, no experiments were conducted to examine the ROS levels in 
the used cell lines in this work, and the effect of ROS on the Cy5-MSNs. 
In this work, the MSNs with the ferrocene/ β-CD gatekeeper system were analyzed for the 
first time in vitro and in vivo. The unloaded and sealed Cy5-MSNs exhibited good biocompat-
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ibility in various cancer cell lines, a mouse embryonic fibroblast cell line and in chicken em-
bryos. This is not surprising, considering that two of the main components, silica and β-CD, 
are recognized as safe by the FDA [53,172], and ferrocenecarboxaldehyde is categorized as 
not harmful by REACH [173]. In many cell culture studies MSNs did not exhibit toxicity up to 
100 µg/ mL [90,100,105,135], too, and sometimes even higher concentrations of 500 µg/ mL 
did not reduce the viability of the cells [91]. It should be noted that the in vitro and in vivo bio-
compatibility of the MSNs is dependent on the modifications of the MSNs, e.g. PEI coating 
reduced the metabolic activity after 100 µg/ mL MSN treatment [134]. Interestingly, the mouse 
embryonic fibroblast cell line NIH-3T3 exhibited reduced metabolic activity for 5 µg/ mL of 
Cy5-MSNs while concentrations from 10 µg/ mL to 50 µg/ mL showed stable metabolic activi-
ty. This effect was also observed by Salis et al. after 24 hours of MSN incubation but no ex-
planation was given [174]. In contrast, higher concentrations (≥ 50 µg/ mL) of Cy5-MSNs 
even increased the metabolic activity of a hepatocarcinoma cell line (HuH7). This phenome-
non was also observed in a human melanoma cell line for even higher concentrations of 
MSNs in the MTT assay, an assay which also evaluates the metabolic activity. Huang et al. 
even found increased tumor growth caused by MSNs in a nude mice xenograft model when 
tumor cells were pretreated with 0.2 mg/ mL MSNs before subcutaneous injection and claim 
that the effects are mediated by a decrease in endogenous ROS [175]. However, this was 
one murine study of many and in most in vivo studies no increased tumor growth by unloaded 
MSNs compared to the saline-treated controls was detected [88,114] which was also the 
case for the evaluated HNSCC cell lines (HNSCCUM-02T, RPMI2650, and Cal-33) in this 
work. Nonetheless, the promising biocompatibility data were reassessed in vivo, e.g. by Ta-
manoi et al. who determined a maximally tolerated dose of 50 mg/ kg spherical MSNs when 
the particles were applied intravenously in nude mice. Moreover, a long-term toxicity study 
revealed no unusual response after injection of 18 doses (50 mg/ kg) within two months [82]. 
Yet, the absence of an immune response is not surprising considering that the nude mice 
lacked a T-cell response and the MSNs were degraded to silicic acid or smaller particles and 
excreted via the kidneys [135]. It might seem contradictory that in this work, the biodistribution 
analysis in the CAM model revealed an accumulation of the MSNs in the glomeruli of the kid-
neys and the liver but the incubation time of 24 hours was too short for the NPs to degrade to 
smaller particles that could be excreted during that short time. Also, from an experimental 
point of view, degraded Cy5-MSNs could not be detected by CLSM because the degraded 
NPs would also dissociate from the fluorescent dye. Furthermore, the Cy5-MSN concentra-
tion in the chicken embryos blood circulation can only be estimated according to the data by 
C. Kind, who determined that the blood volume on day 12, the day the Cy5-MSNs were in-
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jected into the CAM, was 1.15 mL [176]. So, the initial concentration would have been 
43 µg/ mL or 21.5 µg/ mL of Cy5-MSNs in the embryo’s blood circulation, respectively, which 
was 4-fold or 2-fold higher than the concentration applied in most cell culture experiments 
(10 µg/ mL), respectively. Another characteristic of the CAM model is the immunodeficiency 
of the chicken embryo [177]. On the one side, this allows to establish xenograft tumor models 
on the CAM, on the other side, it cannot be evaluated if MSNs cause inflammatory effects at 
high accumulation sites such as the liver. Altogether, Cy5-MSNs were detected mainly in the 
blood vessels of the examined organs and no NPs were detected in the brain. Hence, the 
blood-brain-barrier retained the NPs. When the organs were removed, an increase of the kid-
ney size was noticed which could have been caused by an accumulation of the Cy5-MSNs in 
the glomeruli. The higher the particle concentration, the more pronounced was this effect. Of 
course, this is unfavorable and could cause an increase in blood pressure and organ failure if 
the MSNs are not degraded in time. Still, the chicken embryos survived the Cy5-MSN treat-
ment for 24 hours, but longer incubation times would be necessary to examine the NP accu-
mulation in more detail. 
A 3D tumor model consisting of hepatocarcinoma cells (HuH7 cell line) was established on 
the CAM to study whether Cy5-MSNs can extravasate the blood vessels. The EPR effect 
should enhance NP accumulation in the tumor but only a few Cy5-MSNs were detected in the 
tumor on the CAM. Yet, this is not surprising since the EPR effect only causes a 2-fold in-
crease in NP accumulation compared to critical normal organs (liver, spleen, kidneys) 
[32,178]. Furthermore, the Cy5-MSN uptake was examined by flow cytometry and CLSM to 
confirm that the NPs can be internalized by the cells, the pores can be opened, and the cargo 
released. It was noticed that the unloaded and sealed NPs were taken up time-dependently 
by endocytosis because after six hours incubation, more than half of the Cy5-MSNs, and after 
24 hours, almost all Cy5-MSNs were present in endosomes and lysosomes as shown by co-
localization analysis. Along the endolysosomal system, the pH decreases which facilitates 
pore opening by cleavage of the imine bond between ferrocene and the MSNs. Then, the 
cargo would be released but would also have to escape the endosomes and lysosomes be-
fore degradation. The endosomal escape could be modulated by the proton sponge effect 
which could be induced by the then free amino groups of the MSNs. Still, co-localization 
analysis by CLSM is not completely accurate and the analysis method can also influence the 
results [160]. A more accurate method to analyze the NP localization would have been TEM, 
e.g. J. Liu et all showed their hollow MSNs in endosomes and the cytoplasm of hepatocarci-
noma cells (HepG2 cell line) [114]. Moreover, no differences in NP uptake were observed 
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between methylated β-CD and amino-functionalized β-CD/ methylated β-CD capped MSNs. 
In later experiments, when MSNs were sealed only with NH2-β-CD, the Cy5-MSNs were still 
taken up comparably. The amino-functionalization of the β-CD enabled further modifications 
of the drug delivery system, e.g. with a targeting moiety or cell-penetrating peptides. Also, the 
NH2-β-CD could facilitate endosomal release, and targeting can improve cellular uptake and 
will be discussed later. After good biocompatibility and efficient Cy5-MSN uptake were estab-
lished in cancer cells, drug loading and release were studied, which will be discussed next. 
5.2 Drug loading and release of MSNs 
The aim of this work was to use MSNs for drug delivery. Especially, the transport of siRNA as 
therapeutic agent for protein expression regulation is challenging and requires modified 
nanocarriers. For this reason, it was examined if the MSNs with the ferrocene/ β-CD gate-
keeper are suited as siRNA delivery system. It was found that detecting the loading and re-
lease of siRNA is complex, and therefore, different model systems were exploited. On the 
one side, the small molecule drug Dox was used because of its characteristics, namely toxici-
ty in small concentrations and fluorescence, and on the other side, fluorescent dye-labeled 
siRNA was utilized. Also, a stable eGFP-expressing cell line (HuH7-GFP) was employed to 
test siRNA efficiency. 
The chemotherapeutic drug Dox is widely used as a model drug for testing innovative drug 
delivery systems and was also employed in this work. Dox exhibits fluorescence and there-
fore, the drug loading and efficiency of the gatekeeper could be observed. The MSNs which 
were used for Dox loading had an average pore size of 8.2 nm, which is relatively large com-
pared to other MSN systems. The most published MSNs with a similar diameter had pore 
sizes between 2 and 4 nm for loading of small molecule drugs [114,119,179]. After the Dox-
MSNs were loaded with Dox and sealed with the gatekeeper system, washing up to eight 
times to remove excess Dox was necessary. Then, the drug loading was determined by 
measuring the absorption and fluorescence of Dox in the supernatants. Mostly, the loading 
efficiency was between 20- 30 % of the initially loaded Dox amount and could be visually ob-
served by red staining of the NP pellet. The loading efficiency was higher than most de-
scribed by others (11 %) but mostly MSNs with smaller pores were used for Dox loading 
[91,114]. Of course, MSNs with larger pore sizes also have a higher drug loading capacity, 
e.g. Chen et al. synthesized MSNs (diameter 130 nm) with 4.7 nm pores and achieved a Dox 
loading efficiency of 58.3 % [180] with a different loading protocol and different protocol to 
determine the loading efficiency. Here, the MSNs had a greater pore size (8.2 nm) and it was 
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found that the loading efficiency was dependent on the used Dox concentration and not the 
total Dox mass. The Dox concentration was limited by the Dox solubility and 5 mg/ mL Dox in 
H2O was the highest possible concentration observed. Moreover, the incubation of Dox-
MSNs in different media for 24 and 96 hours revealed a Dox release of only small fractions of 
the loaded drug. Consequently, the gatekeeper system efficiently retained the drug under the 
examined conditions. In PBS, H2O, and DMEM less than 1 % of the loaded drug (equals less 
than 0.15 µM) were retrieved after four days incubation at 37 °C. Yet, DMEM with FCS exhib-
ited an increased Dox signal in the supernatants but also in the Cy5-MSN incubated control, 
even though the standard curve was prepared in the same medium. It was speculated that 
the present proteins might disturb the fluorescence measurement because the fluorescence 
value for the control was above the Dox-MSN value after 24 hours incubation. After four days 
of incubation, about 2.5 % of the Dox were retrieved in the supernatant of Dox-MSNs when 
the control value was deducted. Thus, FCS might facilitate a minimal Dox release in the me-
dium, but only low effects of Dox were expected by the released Dox. The toxic effect of Dox 
is time- and concentration-dependent as shown by the determination of the IC50 in two dif-
ferent HNSCC cell lines which also exhibited different sensitivity. When the base of tongue 
squamous cell carcinoma cells were incubated with 1 µM Dox, 10 µg/ mL Dox-MSNs, and 
control Cy5-MSNs in medium with and without FCS, the metabolic activity was decreased for 
cells incubated in medium without FCS after 24 hours. Still, the reduction of metabolic activity 
was also observed for the control groups, so the decrease was rather caused by the missing 
nutrients and growth factors. At the same time, a retarded release of Dox from Dox-MSNs 
was noticed. In the beginning, Dox-MSNs were loaded with a lower concentrated Dox solu-
tion, but the loading efficiency could not be determined because the whole Dox was detected 
in the supernatants. Yet, Dox-MSNs decreased the metabolic activity of two cell lines after 
incubation for 24 or 48 hours with the NPs and 72 or 48 hours without the NPs, respectively. 
Hence, it was assumed that the gatekeeper system dissociated inside the cells and released 
the Dox in a retarded manner. Then, the loading protocol was changed, and Dox-MSNs were 
loaded with a 2.5-fold higher concentrated Dox solution, but less total Dox which allowed 
quantification of the loading efficiency. Cancer cells were incubated with these Dox-MSNs 
and were analyzed by flow cytometry for viability, NP uptake, and Dox signal. The efficacy on 
the viability of Dox-MSNs corresponded to more than 1 µM Dox after 24 and 96 hours incuba-
tion. Still, after 24 hours of 1 µM Dox and Dox-MSN treatment, the viability was only slightly 
reduced compared to controls. On average, only half of all viable cells showed a Cy5 and 
Dox signal after 24 hours treatment with Dox-MSNs but almost all the rest of the viable cells 
were positive for Dox. So, Dox was released into the cells but probably also in the medium. 
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Yet, the concentration was too low to kill the cells within 24 hours. Almost all cells treated with 
1 µM Dox exhibited a Dox signal while the controls (PBS and Cy5-MSNs) were negative for 
Dox. Only 30 % of all viable cells were positive for Cy5, so the uptake of unloaded NPs was 
lower than the uptake of Dox-MSNs. After 96 hours of treatment with free Dox or Dox-MSNs, 
only a few cells survived while the controls consisted of more than 90 % viable cells. Higher 
concentrations of Dox-MSNs could have been applied to enhance the toxicity, but experi-
ments were performed with 10 µg/ mL NPs to be able to study the release kinetics in more 
detail. The retarded release of Dox was further analyzed in two cell lines by staining of 
γH2AX foci which indicate DNA damage. It was detected in both cell lines, that the γH2AX 
foci per nucleus increased from two to 24 hours incubation with Dox-MSNs. Also, after two 
hours incubation, MSNs were probably associated with the cellular membranes but only the 
nuclei were stained and not the cellular membranes for verification. Yet, experiments with 
unloaded MSNs revealed that the particles already associated with the cellular membrane 
after two hours incubation and were internalized and distributed around the nuclei after 
24 hours incubation. As expected, control NPs did not induce DNA damage. Overall, a re-
tarded release of Dox from Dox-MSNs was observed in two cancer cell lines, hence drug 
loading and release of a small molecule drug were possible in general. 
Next, siRNA loading and release in MSNs were tested using the MSN batch which was previ-
ously utilized for Dox loading and release. In the first experiment, MSNs were loaded with 
eGFP-targeting siRNA and stable eGFP-expressing cells (HuH7-GFP) were incubated with 
different particle concentrations and for different incubation times. The particle concentrations 
were even doubled compared to the experiments with Dox. Still, no reduction in eGFP ex-
pression was observed by flow cytometric analysis after eGFP-siRNA-MSN incubation. At the 
same time, transfection with Lipofectamine™ RNAiMAX transfection reagent and eGFP siR-
NA reduced the eGFP expression decently. Thus, the incorporated siRNA did not exhibit its 
effect on protein expression. Possible explanations were that the siRNA was degraded during 
loading and sealing (total preparation time 25 hours, incubated at 4 °C) or the NP concentra-
tion was too small, respectively. Yet, Hickerson et al. showed that siRNA could even be incu-
bated at 37 °C for 24 hours without degradation [181]. For that reason, the siRNA should be 
stable at the chosen incubation conditions. It was assumed that the pore size of the MSNs 
(8.2 nm) was too small for the siRNA which has a diameter of circa 2 nm and is about 7 nm 
long and therefore no adequate loading could be achieved. For this reason, a new batch of 
MSNs (SK275) with larger pores (11.7 nm diameter on average) was utilized for siRNA load-
ing. Another possibility for absent siRNA efficacy could have been, that the electrostatic inter-
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action between the negatively charged siRNA and the positively charged amino-
functionalized MSNs was too strong and the siRNA did not dissociate from the NPs inside the 
cells [182]. Thus, the MSNs were also pre-incubated with ferrocene before siRNA loading and 
afterward sealed with NH2-β-CD. These NPs were tested in HNSCCUM-02T cells and mRNA 
expression analysis after incubation with FAM™-siRNA-MSNs and hnRNP K-siRNA-MSNs. 
Also, the applied NP concentration was increased to 50 µg/ mL and the incubation time was 
reduced to 24 and 96 hours because a reduction in mRNA expression is detectable earlier 
than a reduction in protein expression. However, no decrease in mRNA expression was no-
ticed after NP treatment independent of the incubation time and target compared to nsRNA-
MSNs and PBS. This could have been provoked by different causes, namely, the loaded 
amount of siRNA was insufficient or was degraded in the endolysosomal system before it 
could exhibit its effect. On this account, the loading of siRNA to MSNs was examined more 
detailed and MSNs were pre-incubated with various smaller amounts of ferrocene compared 
to regular sealing before FAM™-siRNA loading. Yet, the ferrocene pre-incubation decreased 
the FAM™-siRNA loading, in other words, only minimal amounts of siRNA were loaded to the 
MSNs. Thus, it is not surprising that the mRNA expression was not reduced even by a high 
concentration of siRNA-MSNs. The siRNA loading efficiency could not be determined, alt-
hough RNA can be detected by UV/Vis measurement. The supernatants which were retrieved 
directly after loading were measured with a spectrophotometer, but the ferrocene and NH2-β-
CD interfered with the measurement. Thus, siRNA loading could only be evaluated qualita-
tively and not quantitatively. 
Another strategy for siRNA delivery via MSNs was applied by Durfee et al. who loaded siRNA 
and other drugs into MSNs and sealed the pores with a lipid bilayer mainly consisting of dif-
ferent lipids (e.g. DOPC, DPPC, DOPE, DPPE). Also, cholesterol and PEG were added for 
stabilization and shielding, respectively, and linker molecules were conjugated for further 
modifications [100]. Based on this approach, a new encapsulation strategy was examined to 
enable efficient siRNA transport and improve cellular NP uptake by using positively charged 
lipids [69]. After FAM™-siRNA loading, the MSNs were encapsulated by the common trans-
fection reagent Lipofectamine™ RNAiMax which also consists of different lipids (exact com-
position is not known), instead of the ferrocene/ NH2-β-CD system. Various incubation proto-
cols were tested, and FAM™-siRNA was successfully loaded to the MSNs independent of the 
incubation protocol. However, a disadvantage of the Lipo encapsulation was the cytotoxicity, 
thus the applied concentration must be carefully chosen. The Lipo encapsulation increased 
the MSN uptake tremendously compared to the ferrocene/ NH2-β-CD gatekeeper system. 
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Yet, FAM™-siRNA which was loaded to the MSNs could not be identified by flow cytometry 
because of Lipo autofluorescence. Still, this fluorescence vanished after 96 hours incubation 
(compared to 24 hours incubation), so the pores of the MSNs should have been opened by 
then and the siRNA was released. It can be assumed that the improved uptake is caused by 
the fact that the lipid shell (formed by Lipo) enables uptake via different routes of endocytosis 
e.g. macropinocytosis, caveolae- and clathrin-mediated endocytosis [183]. Next, Lipo-eGFP-
siRNA-MSNs were evaluated for eGFP-siRNA delivery to HuH7-GFP cells and eGFP protein 
and mRNA expression were analyzed. Only 25 µg/ mL NPs reduced the viability as observed 
by flow cytometry after four days of incubation. Still, no decrease in eGFP expression was 
noted although Lipo-eGFP-siRNA-MSNs were vastly taken up by the cells. Moreover, eGFP 
mRNA expression was also not affected by 25 µg/ mL Lipo-eGFP-siRNA-MSNs after three 
days of incubation. 
Taken together, siRNA could be loaded to the MSNs, but no siRNA release could be proven. 
The lack of siRNA release can be caused by several factors: First, only insufficient amounts 
of siRNA could be loaded to the MSNs, second, the electrostatic binding of the siRNA to the 
MSNs was too strong for a timely release, and third, the siRNA was degraded before it could 
reach the cytoplasm. This issue could be further addressed, e.g. by modifications of the drug 
delivery system with endosome bursting peptides or other reagents that can induce the pro-
ton sponge effect [129]. For example, Li et al. loaded magnetic MSNs with siRNA, sealed 
them with PEI, and added an endosome bursting peptide (KALA) via an SPDP linker to the 
drug delivery system. They showed that the NPs were taken up by the cells and the siRNA 
escaped the endolysosomal system. Also, they found a significant reduction in A549 tumor 
volume after five injections of their drug delivery system within 18 days in vivo [134]. The here 
evaluated siRNA delivery system was also modified to enhance cellular uptake by EGFR tar-
geting which will be discussed next. 
5.3 Further modifications of the MSNs 
For efficient drug delivery in vivo, the drug much reach the target site at high concentrations. 
This can be achieved by passive targeting based on the EPR effect, but angiogenesis is 
mostly slower than tumor growth, so active targeting is favorable. A site-directed delivery can 
be realized by conjugation of ligands that target especially receptors which are abnormally 
high expressed in malignant tissue. The EGFR receptor expression is upregulated in 70- 90 % 
of HNSCC and therefore suited as target structure [102,103]. Other prominent targets are the 
folate receptor by folic acid [61,90,184], CD20 by Rituximab [105], integrin αvβ3 by the RGD 
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motif [95]. In this work, an EGFR-antibody was chosen that bound the extracellular domain of 
EGFR, but would not inhibit EGF binding, and an antibody of the same subtype (mouse 
IgG2a) was used as control. The antibody was first tested in immunofluorescence staining 
and exhibited good specificity, but could not be applied in immunoblot analysis. So, the im-
munoblot analysis was conducted with a different EGFR-antibody that exhibited similar re-
sults in immunofluorescence staining: The cell line HNSSCUM-02T highly expressed EGFR 
while the cell line RPMI2650 weakly expressed EGFR and was used as control. The conjuga-
tion protocol was developed based on different protocols from Thermo Fisher Scientific and a 
linker with PEG-spacer was chosen to reduce steric hindrance and optimize the coupling effi-
ciency. For antibody conjugation, first, sulfhydryl groups were added to primary amines of the 
antibodies ((SH)x-Ab), e.g. on lysine side chains. Yet, it could not be controlled whether the 
sulfhydryl groups were added in the constant or the variable regions of the antibodies. There-
fore, conjugation within the variable regions was possible and could impair the binding to the 
EGFR. The applied reagent for sulfhydration was photosensitive and might have caused that 
the coupling efficiency decreased gradually during the experiments, but antibodies were still 
conjugated to the Cy5-MSNs. In the second step, MSNs were sealed with ferrocene and NH2-
β-CD and the linker was conjugated to the amino group. However, the number of attached 
linker molecules was not determined. Third, the (SH)x-antibodies were added to the linker-
modified Cy5-MSNs and incubated overnight at almost neutral (pH 7.2) conditions to ensure 
the stability of the antibodies and the NPs. Also, a protocol to verify successful antibody con-
jugation was developed, and the coupling efficiency was determined for every performed ex-
periment with a fluorescently labeled anti-mouse antibody. The fluorescence of the secondary 
antibody was normalized to the Cy5-signal of the NPs to compensate differences in MSN 
mass. A fluorescence background signal of unconjugated Cy5-MSNs was detected but was a 
lot smaller in one experiment than in the other experiments. Therefore, a great standard devi-
ation occurred for the normalized Coupling Factor. 
The cellular uptake of EGFR-MSNs, IgG2a-MSNs, and Cy5-MSNs was compared in two can-
cer cell lines with different EGFR expression, as mentioned above. In HNSCCUM-02T cells a 
higher EGFR-MSN association than IgG2a-MSN association with the cells was observed af-
ter one hour incubation, but no differences in NP uptake were noticed after 24 hours. The 
control cell line showed a great variance between experiments for NP association after one 
hour incubation, but overall the fraction of Cy5-positive cells was the same for all applied 
MSNs. So, the EGFR-targeting only accelerated MSN uptake but did not enhance overall 
MSN uptake. The uptake of EGFR-Ab conjugated MSNs is in accordance with a study per-
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formed by Durfee et al. who also found a fast uptake of the targeted MSNs within one hour 
[100]. The IgG2a-MSNs were also taken up better than the Cy5-MSNs. Thus, it can be 
speculated that the addition of proteins alone could improve NP uptake. In a final experiment, 
MSNs were loaded with eGFP-siRNA or nsRNA, sealed with ferrocene and NH2-β-CD, and 
EGFR-antibodies or IgG2a-antibodies were conjugated to the particles, respectively. Then, 
HuH7-GFP cells were incubated with the different NPs for 72 hours, and the eGFP mRNA 
expression was analyzed because the detection of mRNA expression is more sensitive than 
the detection of protein expression. Still, eGFP mRNA expression was only slightly reduced 
by eGFP-siRNA-MSNs but not by EGFR-eGFP-siRNA-MSNs compared to PBS treatment. 
Previous experiments detecting eGFP expression regulation by using Lipo as transfection 
reagent revealed a knockdown of about 90 % by eGFP siRNA compared to nsRNA. For this 
reason, great downregulation of eGFP by the eGFP-siRNA would be possible. On that ac-
count, siRNA release from untargeted and targeted siRNA-MSNs could not be proven. 
Overall, an EGFR-antibody was successfully conjugated to the Cy5-MSNs and accelerated 
NP uptake by high EGFR expressing cancer cells. Still, the experiments were performed in 
vitro under controlled settings, and further experiments in vivo would be necessary to confirm 
the targeting capability of the EGFR-MSNs. Also, active targeting did not induce the efficacy 
of siRNA-MSNs, and further improvement of the drug delivery system is necessary to achieve 
RNA interference. 
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6 Conclusion 
In this work, MSNs were evaluated as drug delivery vehicles for drug delivery to head and 
neck cancer cells. The MSNs were sealed with a pH- and redox-sensitive gatekeeper system 
and showed good biocompatibility in vitro and in vivo. Moreover, the Cy5-MSNs were injected 
in the CAM of chick embryos, and the NPs could be detected mainly in the liver and kidney 
but were also found in a tumor within the CAM. In vitro, MSNs were retrieved in the endolyso-
somal system and uptake could be accelerated by EGFR-targeting. Furthermore, drug load-
ing and release were examined by the incorporation of the drug doxorubicin. Effective Dox 
loading and retarded intracellular release were shown in two cancer cell lines by several as-
says. Furthermore, a larger drug for protein expression regulation, namely siRNA, was incor-
porated in MSNs. However, efficient siRNA loading was challenging, and several loading pro-
tocols were tested: The pore size of the MSNs was increased, and the MSNs were pre-
incubated with ferrocene to reduce electrostatic interactions. It was determined that siRNA 
could be loaded to the MSNs, but no effects on mRNA and protein expression were noticed 
although the applied NP concentrations were increased. Moreover, the gatekeeper system 
was replaced by the common transfection agent Lipofectamine RNAiMAX, which increased 
cellular NP uptake tremendously while exhibiting toxic effects. Still, no siRNA release was 
detected through a reduction in protein and mRNA expression. The siRNA-loaded MSNs 
were also targeted with an EGFR-antibody, which also did not induce a decrease in mRNA 
expression. Overall, the evaluated system exhibited promising characteristics in the begin-
ning, but a siRNA transport could not be achieved because either the siRNA was not re-
leased, or the siRNA was degraded before it could reach the cytoplasm and induce RNA in-
terference. For this reason, the here evaluated drug delivery system is not suited for large 
and charged molecules such as siRNA and further modifications are necessary to enable 
siRNA transport. Nonetheless, MSNs exhibited promising characteristics as drug carriers for 
small molecule drugs in head and neck cancer therapy. 
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8 Appendix 
8.1 Supplementary Results 
Table 38: Results of one-way ANOVA corresponding to Figure 25, HNSCCUM-02T 
One-way analysis of variance (HNSCCUM-02T) 
P value 0.7691 
 
P value summary ns 
Are means signif. differ-
ent? (P < 0.05) 
No 
Number of groups 6 
F 0.5023 
R square 0.1731 
ANOVA Table SS df MS 
 
Treatment (between 
columns) 
78.28 5 15.66 
Residual (within co-
lumns) 
374.0 12 31.17 
Total 452.3 17   
Dunnett's Multiple 
Comparison Test 
Mean Diff. q Significant? 
P < 0.05? 
Summary 95 % CI of diff. 
0 vs 5 -0.6667 0.1463 No ns -13.89 to 12.56 
0 vs 10 1.667 0.3656 No ns -11.56 to 14.89 
0 vs 25 -2.000 0.4388 No ns -15.22 to 11.22 
0 vs 50 -2.333 0.5119 No ns -15.56 to 10.89 
0 vs 100 -5.000 1.097 No ns -18.22 to 8.23 
 
Table 39: Results of one-way ANOVA corresponding to Figure 25, RPMI2650 
One-way analysis of variance (RPMI2650) 
P value 0.1635 
 
P value summary ns 
Are means signif. differ-
ent? (P < 0.05) 
No 
Number of groups 6 
F 1.925 
R square 0.4451 
ANOVA Table SS df MS 
 
Treatment (between 
columns) 
255.1 5 51.02 
Residual (within col-
umns) 
318.0 12 26.50 
Total 573.1 17   
Dunnett's Multiple 
Comparison Test 
Mean Diff. q Significant? 
P < 0.05? 
Summary 95 % CI of diff. 
0 vs 5 9.000 2.141 No ns -3.20 to 21.20 
0 vs 10 11.33 2.696 No ns -0.86 to 23.53 
0 vs 25 9.000 2.141 No ns -3.20 to 21.19 
0 vs 50 10.33 2.458 No ns -1.86 to 22.53 
0 vs 100 9.667 2.300 No ns -2.53 to 21.86 
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Table 40: Results of one-way ANOVA corresponding to Figure 25, Cal-33  
One-way analysis of variance (Cal-33) 
P value 0.8816 
 
P value summary ns 
Are means signif. differ-
ent? (P < 0.05) 
No 
Number of groups 6 
F 0.3359 
R square 0.1228 
ANOVA Table SS df MS 
 
Treatment (between 
columns) 
61.11 5 12.22 
Residual (within col-
umns) 
436.7 12 36.39 
Total 497.8 17   
Dunnett's Multiple 
Comparison Test 
Mean Diff. q Significant? 
P < 0.05? 
Summary 95% CI of diff. 
0 vs 5 -2.000 0.4061 No ns -16.29 to 12.29 
0 vs 10 -3.667 0.7444 No ns -17.96 to 10.62 
0 vs 25 -5.333 1.083 No ns -19.62 to 8.96 
0 vs 50 -4.667 0.9475 No ns -18.96 to 9.62 
0 vs 100 -1.667 0.3384 No ns -15.96 to 12.62 
 
Table 41: Results of one-way ANOVA corresponding to Figure 25, HuH7 
One-way analysis of variance (HuH7) 
P value 0.0223 
 
P value summary * 
Are means signif. differ-
ent? (P < 0.05) 
Yes 
Number of groups 6 
F 4.030 
R square 0.6268 
ANOVA Table SS df MS 
 
Treatment (between 
columns) 
2114 5 422.7 
Residual (within col-
umns) 
1259 12 104.9 
Total 3372 17   
Dunnett's Multiple 
Comparison Test 
Mean Diff. q Significant? 
P < 0.05? 
Summary 95 % CI of diff. 
0 vs 5 -7.000 0.8371 No ns -31.26 to 17.26 
0 vs 10 -7.333 0.8770 No ns -31.59 to 16.93 
0 vs 25 0.6667 0.07972 No ns -23.59 to 24.93 
0 vs 50 -21.33 2.551 No ns -45.59 to 2.93 
0 vs 100 -28.67 3.428 Yes * -52.93 to -4.41 
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Table 42: Results of one-way ANOVA corresponding to Figure 25, NIH-3T3 
One-way analysis of variance (NIH-3T3) 
P value 0.2741 
 
P value summary ns 
Are means signif. differ-
ent? (P < 0.05) 
No 
Number of groups 6 
F 1.392 
R square 0.2788 
ANOVA Table SS df MS 
 
Treatment (between 
columns) 
1597 5 319,5 
Residual (within co-
lumns) 
4132 18 229,6 
Total 5729 23   
Dunnett's Multiple 
Comparison Test 
Mean Diff. q Significant? 
P < 0.05? 
Summary 95 % CI of diff. 
0 vs 5 21.50 2.007 No ns -8.09 to 51.09 
0 vs 10 10.75 1.003 No ns -18.84 to 40.34 
0 vs 25 10.75 1.003 No ns -18.84 to 40.34 
0 vs 50 7.750 0.7234 No ns -21.84 to 37.34 
0 vs 100 -3.750 0.3500 No ns -33.34 to 25.84 
 
Table 43: Results of two-way ANOVA corresponding to Figure 26B 
Two-way ANOVA 
Source of Variation % of total variation P value 
 
Interaction 1.01 0.9148 
Time 23.94 0.0617 
Treatment 7.42 0.5357 
Source of Variation P value summary Significant? 
Interaction ns No 
Time ns No 
Treatment ns No 
Source of Variation Df Sum-of-squares Mean square F 
Interaction 2 0.02874 0.01437 0.08970 
Time 1 0.6806 0.6806 4.248 
Treatment 2 0.2108 0.1054 0.6579 
Residual 12 1.923 0.1602   
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Table 44: Results of two-way ANOVA corresponding to Figure 26D 
Two-way ANOVA 
Source of Variation % of total variation P value 
 
Interaction 4.14 0.3471 
Time 8.21 0.0535 
Treatment 66.17 0.0002 
Source of Variation P value summary Significant? 
Interaction ns No 
Time ns No 
Treatment *** Yes 
Source of Variation Df Sum-of-squares Mean square F 
Interaction 2 26.46 13.23 1.157 
Time 1 52.43 52.43 4.586 
Treatment 2 422.7 211.4 18.49 
Residual 12 137.2 11.43   
 
Table 45: Linear regression analysis corresponding to Figure 28 
Best-fit values 
Slope 0.06607 ± 0.006825 
Y-intercept when X=0.0 0.2370 ± 0.1722 
X-intercept when Y=0.0 -3.587 
1/slope 15.13 
95 % Confidence Intervals 
Slope 0.05160 to 0.08054 
Y-intercept when X=0.0 -0.1281 to 0.6021 
X-intercept when Y=0.0 -11.06 to 1.678 
Goodness of Fit 
R square 0.8542 
Sy.x 0.5020 
Is slope significantly non-zero? 
F 93.72 
DFn, DFd 1.000, 16.00 
P value < 0.0001 
Deviation from zero? Significant 
Data 
Number of X values 6 
Maximum number of Y replicates 3 
Total number of values 18 
Number of missing values 0 
 
 
 
 
 
Appendix  153 
Table 46: Results of two-way ANOVA corresponding to Figure 31 
Two-way ANOVA 
Source of Variation % of total variation P value 
 
Interaction 16,84 < 0,0001 
Marker 33,44 < 0,0001 
Time 43,49 < 0,0001 
Source of Variation P value summary Significant? 
Interaction **** Yes 
Marker **** Yes 
Time **** Yes 
Source of Variation Df Sum-of-squares Mean square F 
Interaction 5 5851 1170 13,00 
Marker 1 11619 11619 129,1 
Time 5 15110 3022 33,58 
Residual 24 2160 90,00   
 
Table 47: Results of one-way ANOVA corresponding to Figure 32 
One-way analysis of variance 
P value 0.5559   
P value summary ns 
Are means signif. differ-
ent? (P < 0.05) 
No 
Number of groups 3 
F 0.6271 
R square 0.1223 
ANOVA Table SS df MS   
Treatment (between 
columns) 
261.7 2 130.9 
Residual (within co-
lumns) 
1878 9 208.7 
Total 2140 11   
Dunnett's Multiple 
Comparison Test 
Mean Diff. q Significant? 
P < 0.05? 
Summary 95 % CI of diff. 
0 mg/mL vs 0.5 mg/mL 10.85 1.120 No ns -14.48 to 36.18 
0 mg/mL vs 1.0 mg/mL 4.600 0.4361 No ns -22.97 to 32.17 
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Table 48: Results of IC50 analysis of Dox in HNSCCUM-02T corresponding to Figure 
34A 
log c(Dox) vs. normalized response – 
Variable slope 
24 h  48 h  
Best-fit values 
LogIC50 0.1957 -0.7133 
HillSlope -0.9437 -1.442 
IC50 1.569 0.1935 
Std. Error  
LogIC50 0.06282 0.02531 
HillSlope 0.1203 0.1184 
95 % Confidence Intervals 
LogIC50 0.06545 to 0.3260 -0.7658 to -0.6608 
HillSlope -1.193 to -0.6942 -1.687 to -1.196 
IC50 1.163 to 2.119 0.1715 to 0.2184 
Goodness of Fit 
Degrees of Freedom 22 22 
R square 0.8899 0.9588 
Absolute Sum of Squares 2774 570,2 
Sy.x 11.23 5.091 
Number of points analyzed 24 24 
 
Table 49: Results of IC50 analysis of Dox in RPMI2650 corresponding to Figure 34B 
log c(Dox) vs. normalized response – 
Variable slope 
24 h 48 h 
Best-fit values  
LogIC50 -0.1252 -0.8816 
Hill Slope -0.6971 -1.399 
IC50 0.7496 0.1314 
Std. Error  
LogIC50 0.03646 0.02035 
Hill Slope 0.04282 0.08719 
95 % Confidence Intervals 
LogIC50 -0.2015 to -0.04886 -0.9242 to -0.8390 
Hill Slope -0.7867 to -0.6075 -1.582 to -1.217 
IC50 0.6288 to 0.8936 0.1191 to 0.1449 
Goodness of Fit 
Degrees of Freedom 19 19 
R square 0.9672 0.9772 
Absolute Sum of Squares 416.5 178.6 
Sy.x 4.682 3.066 
Number of points analyzed 21 21 
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Table 50: Results of two-way ANOVA corresponding to Figure 36A 
Two-way ANOVA 
Source of Variation % of total variation P value  
Interaction 9.17 0.0002 
Time 5.07 0.0002 
Medium 80.70 < 0.0001 
Source of Variation P value summary Significant? 
Interaction *** Yes 
Time *** Yes 
Medium **** Yes 
Source of Variation Df Sum-of-squares Mean square F 
Interaction 6 0.1624 0.02707 7.264 
Time 2 0.08983 0.04492 12.05 
Medium 3 1.429 0.4763 127.8 
Residual 24 0.08944 0.003727   
Number of missing values 1  
Bonferroni multiple comparisons: Number of comparisons 8  
96 h Dox-MSNs vs 24 h Dox-MSNs 
Medium 96 h Dox-MSNs 24 h Dox-MSNs Difference 95 % CI of diff. 
DMEM + 5 % FCS 0.7333 0.3543 -0.3790 -0.53 to -0.23 
DMEM 0.1217 0.06467 -0.0570 -0.21 to 0.092 
H2O 0.0330 0.0220 -0.0110 -0.16 to 0.14 
PBS 0.0600 0.0250 -0.0350 -0.18 to 0.11 
Medium Difference t P value Summary 
DMEM + 5 % FCS -0.3790 7.604 P < 0.0001 **** 
DMEM -0.0570 1.144 P > 0.05 ns 
H2O -0.0110 0.2207 P > 0.05 ns 
PBS -0.0350 0.7022 P > 0.05 ns 
96 h Dox-MSNs vs Cy5-MSNs 
Medium 96 h Dox-MSNs Cy5-MSNs Difference 95 % CI of diff. 
DMEM + 5 % FCS 0.7333 0.4537 -0.2797 -0.43 to -0.13 
DMEM 0.1217 0.07733 -0.04433 -0.19 to 0.11 
H2O 0.0330 0.09867 0.06567 -0.084 to 0.22 
PBS 0.0600 0.003667 -0.05633 -0.21 to 0.093 
Medium Difference t P value Summary 
DMEM + 5 % FCS -0.2797 5.611 P < 0.0001 **** 
DMEM -0.04433 0.8894 P > 0.05 ns 
H2O 0.06567 1.317 P > 0.05 ns 
PBS -0.05633 1.130 P > 0.05 ns 
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Table 51: Results of two-way ANOVA corresponding to Figure 36B 
Two-way ANOVA 
Source of Variation % of total variation P value  
Interaction 8.12 < 0.0001 
Time 5.71 < 0.0001 
Medium 84.28 < 0.0001 
Source of Variation P value summary Significant? 
Interaction **** Yes 
Time **** Yes 
Medium **** Yes 
Source of Variation Df Sum-of-squares Mean square F 
Interaction 6 7.536 1.256 17.74 
Time 2 5.296 2.648 37.41 
Medium 3 78.20 26.07 368.2 
Residual 23 1.628 0.07079   
Number of missing values 1  
Bonferroni multiple comparisons: Number of comparisons 5  
Cy5-MSNs vs 24 h Dox-MSNs 
Medium Cy5-MSNs 24 h Dox-MSNs Difference 95 % CI of diff. 
DMEM + 5 % FCS 3.280 2.587 -0.6933 -1.35 to -0.04 
DMEM 0.5533 0.4633 -0.0900 -0.74 to 0.56 
H2O 0.0250 0.1633 0.1383 -0.59 to 0.87 
PBS 0.02333 0.1800 0.1567 -0.50 to 0.81 
Medium Difference t P value Summary 
DMEM + 5 % FCS -0.6933 3.192 P < 0.05 * 
DMEM -0.0900 0.4143 P > 0.05 ns 
H2O 0.1383 0.5695 P > 0.05 ns 
PBS 0.1567 0.7212 P > 0.05 ns 
Cy5-MSNs vs 96 h Dox-MSNs 
Medium Cy5-MSNs 96 h Dox-MSNs Difference 95 % CI of diff. 
DMEM + 5 % FCS 3.280 5.340 2.060 1.41 to 2.71 
DMEM 0.5533 0.8733 0.3200 -0.33 to 0.97 
H2O 0.0250 0.2467 0.2217 -0.51 to 0.95 
PBS 0.02333 0.4233 0.4000 -0.25 to 1.05 
Medium Difference t P value Summary 
DMEM + 5 % FCS 2.060 9.483 P < 0.0001 **** 
DMEM 0.3200 1.473 P > 0.05 ns 
H2O 0.2217 0.9126 P > 0.05 ns 
PBS 0.4000 1.841 P > 0.05 ns 
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Table 52: Results of two-way ANOVA corresponding to Figure 37A (right) 
Two-way ANOVA 
Source of Variation % of total variation P value  
Interaction 27.31 < 0.0001 
Treatment 53.65 < 0.0001 
Time 13.33 < 0.0001 
Source of Variation P value summary Significant? 
Interaction **** Yes 
Treatment **** Yes 
Time **** Yes 
Source of Variation Df Sum-of-squares Mean square F 
Interaction 4 6692 1673 23.91 
Treatment 1 13146 13146 187.9 
Time 4 3267 816.7 11.67 
Residual 20 1399 69.97   
Bonferroni multiple comparisons: Number of comparisons 5  
Cy5-MSNs vs Dox-MSNs 
Time Cy5-MSNs Dox-MSNs Difference 95 % CI of diff. 
24 h 81.67 86.33 4.667 -14.77 to 24.10 
24 h + 72 h 88.67 29.33 -59.33 -78.77 to -39.90 
48 h 85.33 67.00 -18.33 -37.77 to 1.100 
48 h + 48 h 89.67 26.67 -63.00 -82.43 to -43.57 
96 h  98.00 24.67 -73.33 -92.77 to -53.90 
Time Difference t P value Summary 
24 h 4.667 0.6833 P > 0.05 ns 
24 h + 72 h -59.33 8.688 P < 0.0001 **** 
48 h -18.33 2.684 P > 0.05 ns 
48 h + 48 h -63.00 9.224 P < 0.0001 **** 
96 h  -73.33 10.74 P < 0.0001 **** 
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Table 53: Results of two-way ANOVA corresponding to Figure 37B (right) 
Two-way ANOVA 
Source of Variation % of total variation P value   
Interaction 9.16 0.0415 
Treatment 70.25 < 0.0001 
Time 5.52 0.1622 
Source of Variation P value summary Significant? 
Interaction * Yes 
Treatment **** Yes 
Time ns No 
Source of Variation Df Sum-of-squares Mean square F 
Interaction 4 2303 575.7 3.038 
Treatment 1 17666 17666 93.22 
Time 4 1389 347.2 1.832 
Residual 20 3790 189.5   
Bonferroni multiple comparisons: Number of comparisons 5  
Cy5-MSNs vs Dox-MSNs 
Time Cy5-MSNs Dox-MSNs Difference 95 % CI of diff. 
24 h 92.33 74.67 -17.67 -49.65 to 14.31 
24 h + 72 h 97.00 39.67 -57.33 -89.31 to -25.35 
48 h 96.67 54.67 -42.00 -73.98 to -10.02 
48 h + 48 h 99.00 31.00 -68.00 -99.98 to -36.02 
96 h  96.00 38.33 -57.67 -89.65 to -25.69 
Time Difference t P value Summary 
24 h -17.67 1.572 P > 0.05 ns 
24 h + 72 h -57.33 5.101 P < 0.001 *** 
48 h -42.00 3.737 P < 0.01 ** 
48 h + 48 h -68.00 6.050 P < 0.0001 **** 
96 h  -57.67 5.131 P < 0.001 *** 
 
Table 54: Results of two-way ANOVA corresponding to Figure 38A 
Two-way ANOVA 
Source of Variation % of total variation P value 
 
Interaction 27.88 < 0.0001 
Time 35.44 < 0.0001 
Treatment 36.16 < 0.0001 
Source of Variation P value summary Significant? 
Interaction **** Yes 
Time **** Yes 
Treatment **** Yes 
Source of Variation Df Sum-of-squares Mean square F 
Interaction 3 9809 3270 290.7 
Time 1 12467 12467 1109 
Treatment 3 12721 4240 377.0 
Residual 16 179.9 11.25   
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Table 55: Results of two-way ANOVA corresponding to Figure 38B 
Two-way ANOVA 
Source of Variation % of total variation P value   
Interaction 78.54 < 0.0001 
Population 17.42 < 0.0001 
Treatment 0.00 1.0000 
Source of Variation P value summary Significant? 
Interaction **** Yes 
Population **** Yes 
Treatment ns No 
Source of Variation Df Sum-of-squares Mean square F 
Interaction 9 46392 5155 69.13 
Population 3 10288 3429 45.99 
Treatment 3 1.676*10-7 5.585*10-8 7.490*10-10 
Residual 32 2386 74.57   
 
 
Figure 56: Single experiments corresponding to data in Figure 38B 
Cy5 positive and Dox positive (+Cy5 + Dox) and Cy5 negative and Dox positive ( -Cy5 + Dox) 
populations of HNSCCUM-02T cells treated with Dox-MSNs for 24 hours are depicted, 
respectively. In the first experiment, just about 20 % of all single cells were positive for Cy5 
and Dox, in the second and third experiment more than 60  % were positive for Cy5 and Dox. 
1: n=3; 2,3: n= 2, mean + S.D. 
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Table 56: Results of two-way ANOVA corresponding to Figure 41A 
Two-way ANOVA 
Source of Variation % of total variation P value 
 
Interaction 9.71 0.0160 
Time 8.31 0.0033 
Treatment 70.85 < 0.0001 
Source of Variation P value summary Significant? 
Interaction * Yes 
Time ** Yes 
Treatment **** Yes 
Source of Variation Df Sum-of-squares Mean square F 
Interaction 3 1917 639,0 4.654 
Time 1 1640 1640 11.95 
Treatment 3 13985 4662 33.95 
Residual 16 2197 137.3   
Bonferroni multiple comparisons: Number of comparisons 4  
2 h vs 24 h 
Treatment 2 h 24 h Difference 95 % CI of diff. 
PBS 0.7967 0.5633 -0.2333 -27.15 to 26.68 
1 µM Dox 44.21 69.25 25.04 -1.87 to 51.95 
Dox-MSNs 16.36 58.13 41.76 14.85 to 68.68 
Cy5-MSNs 0.9767 0.5400 -0.4367 -27.35 to 26.48 
Treatment Difference t P value Summary 
PBS -0.2333 0.02439 P > 0.05 ns 
1 µM Dox 25.04 2.617 P > 0.05 ns 
Dox-MSNs 41.76 4.365 P < 0.01 ** 
Cy5-MSNs -0.4367 0.04564 P > 0.05 ns 
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Table 57: Results of two-way ANOVA corresponding to Figure 41B 
Two-way ANOVA 
Source of Variation % of total variation P value 
 
Interaction 5.28 0.1162 
Time 2.40 0.0952 
Treatment 80.09 < 0.0001 
Source of Variation P value summary Significant? 
Interaction ns No 
Time ns No 
Treatment **** Yes 
Source of Variation Df Sum-of-squares Mean square F 
Interaction 3 624.8 208.3 2.301 
Time 1 284.7 284.7 3.145 
Treatment 3 9483 3161 34.92 
Residual 16 1448 90.53   
Bonferroni multiple comparisons: Number of comparisons 4  
2 h vs 24 h 
Treatment 2 h 24 h Difference 95 % CI of diff. 
PBS 0.2633 0.3000 0.03667 -21.82 to 21.89 
1 µM Dox 45.37 48.51 3.137 -18.72 to 24.99 
Dox-MSNs 16.85 41.27 24.42 2.57 to 46.28 
Cy5-MSNs 0.3600 0.3167 -0.04333 -21.90 to 21.81 
Treatment Difference t P value Summary 
PBS 0.03667 0.004720 P > 0.05 ns 
1 µM Dox 3.137 0.4038 P > 0.05 ns 
Dox-MSNs 24.42 3.144 P < 0.05 * 
Cy5-MSNs -0.04333 0.005578 P > 0.05 ns 
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Table 58: Results of two-way ANOVA corresponding to Figure 42A 
Two-way ANOVA 
Source of Variation % of total variation P value 
 
Interaction 16.85 < 0.0001 
Time 14.65 < 0.0001 
Treatment 67.44 < 0.0001 
Source of Variation P value summary Significant? 
Interaction **** Yes 
Time **** Yes 
Treatment **** Yes 
Source of Variation Df Sum-of-squares Mean square F 
Interaction 3 6199 2066 84.69 
Time 1 5388 5388 220.8 
Treatment 3 24812 8271 339.0 
Residual 16 390.4 24.40   
Bonferroni multiple comparisons: Number of comparisons 4  
24 h vs 96 h 
Treatment 24 h 96 h Difference 95 % CI of diff. 
PBS 100.0 100.0 0,0 -11.35 to 11.35 
2 µM Dox 44.07 0.7333 -43.33 -54.68 to -31.99 
Dox-MSNs 82.63 6.167 -76.47 -87.81 to -65.12 
Cy5-MSNs 90.97 90.90 -0.06667 -11.41 to 11.28 
Treatment Difference t P value Summary 
PBS 0,0 0.0 P > 0.05 ns 
2 µM Dox -43.33 10.74 P < 0.0001 **** 
Dox-MSNs -76.47 18.96 P < 0.0001 **** 
Cy5-MSNs -0.06667 0.01653 P > 0.05 ns 
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Table 59: Results of two-way ANOVA corresponding to Figure 42B 
Two-way ANOVA 
Source of Variation % of total variation P value 
 
Interaction 14.06 < 0.0001 
Time 7.07 < 0.0001 
Treatment 76.34 < 0.0001 
Source of Variation P value summary Significant? 
Interaction **** Yes 
Time **** Yes 
Treatment **** Yes 
Source of Variation Df Sum-of-squares Mean square F 
Interaction 3 4480 1493 29.63 
Time 1 2252 2252 44.68 
Treatment 3 24332 8111 160.9 
Residual 16 806,5 50.41   
Bonferroni multiple comparisons: Number of comparisons 4  
24 h vs 96 h 
Treatment 24 h 96 h Difference 95 % CI of diff. 
PBS 83.10 102.1 18.97 2.66 to 35.27 
2 µM Dox 33.23 0.3333 -32.90 -49.21 to -16.59 
Dox-MSNs 61.87 7.433 -54.43 -70.74 to -38.13 
Cy5-MSNs 87.50 78.37 -9.133 -25.44 to 7.17 
Treatment Difference t P value Summary 
PBS 18.97 3.272 P < 0.05 * 
2 µM Dox -32.90 5.675 P < 0.001 *** 
Dox-MSNs -54.43 9.390 P < 0.0001 **** 
Cy5-MSNs -9.133 1.576 P > 0.05 ns 
 
Table 60: Results of one-way ANOVA corresponding to Figure 53A 
One-way analysis of variance 
P value 0.0107 
 
P value summary * 
Are means signif. differ-
ent? (P < 0.05) 
Yes 
Number of groups 3 
F 7.826 
R square 0.6349 
ANOVA Table SS df MS 
 
Treatment (between 
columns) 
0.003919 2 0.001959 
Residual (within co-
lumns) 
0.002253 9 0.0002503 
Total 0.006172 11   
Dunnett's Multiple 
Comparison Test 
Mean Diff. q Significant? 
P < 0.05? 
Summary 95% CI of diff. 
Cy5-MSNs vs EGFR-
MSNs 
-0.03646 3.259 Yes * -0.06571 to -
0.007218 
Cy5-MSNs vs IgG2a-
MSNs 
-0.03996 3.572 Yes * -0.06921 to -
0.01072 
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Table 61: Results of two-way ANOVA corresponding to Figure 54A 
Two-way ANOVA (only alive cells) 
Source of Variati-
on 
% of total variation P value 
 
Interaction 90.28 < 0.0001 
Population 0.02 0.8668 
Treatment 0.00 1.0000 
Source of Variati-
on 
P value summary Significant? 
Interaction **** Yes 
Population ns No 
Treatment ns No 
Source of Variati-
on 
Df Sum-of-squares Mean square F 
Interaction 3 26878 8959 49.65 
Population 1 5.241 5.241 0.02904 
Treatment 3 0.2315 0.07718 0.0004277 
Residual 16 2887 180.5   
Bonferroni multiple comparisons: Number of comparisons 4  
alive - MSNs vs alive + MSNs 
Treatment alive - MSNs alive + MSNs Difference 95 % CI of diff. 
PBS 95.72 0.07108 -95.65 -126.5 to -64.79 
Cy5-MSNs 62.78 33.52 -29.26 -60.12 to 1.593 
EGFR-MSNs 9.214 86.77 77.55 46.70 to 108.4 
IgG2a-MSNs 26.29 69.91 43.62 12.77 to 74.48 
Treatment Difference t P value Summary 
PBS -95.65 8.720 P < 0.0001 **** 
Cy5-MSNs -29.26 2.668 P > 0.05 ns 
EGFR-MSNs 77.55 7.070 P < 0.0001 **** 
IgG2a-MSNs 43.62 3.977 P < 0.01 ** 
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Table 62: Results of two-way ANOVA corresponding to Figure 54B 
Two-way ANOVA 
Source of Variation % of total variation P value 
 
Interaction 30.97 0.0285 
Population 26.80 0.0057 
Treatment 0.01 1.0000 
Source of Variation P value summary Significant? 
Interaction * Yes 
Population ** Yes 
Treatment ns No 
Source of Variation Df Sum-of-squares Mean square F 
Interaction 3 8640 2880 3.911 
Population 1 7478 7478 10.16 
Treatment 3 1,453 0.4844 0.0006578 
Residual 16 11782 736.4   
Bonferroni multiple comparisons: Number of comparisons 4  
alive - MSNs vs alive + MSNs 
Treatment alive - MSNs alive + MSNs Difference 95 % CI of diff. 
PBS 93.29 0.1178 -93.17 -155.5 to -30.84 
Cy5-MSNs 66.62 27.74 -38.88 -101.2 to 23.45 
EGFR-MSNs 56.95 36.37 -20.58 -82.90 to 41.75 
IgG2a-MSNs 40.83 52.24 11.41 -50.92 to 73.74 
Treatment Difference t P value Summary 
PBS -93.17 4.205 P < 0.01 ** 
Cy5-MSNs -38.88 1.755 P > 0.05 ns 
EGFR-MSNs -20.58 0.9287 P > 0.05 ns 
IgG2a-MSNs 11.41 0.5150 P > 0.05 ns 
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